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Neonates with a family history of atopy are at higher risk for developing allergic 
disorders in early life. The inherent immunological responses at birth are emerging as 
an important participant in allergic disorders. 
Objectives  
This dissertation aims to:  
i)       study the early life demographic and clinical risk factors and the 
progression of allergic phenotypes in a 5 year follow-up from a birth 
cohort of high risk ( first degree relative with allergic disorder and allergen 
sensitization) for atopy infants. 
ii)      evaluate the influence of intrinsic immunologic responses in cord blood 
mononuclear cells on eczema and wheezing disorders and allergen 
sensitization at 2 years and 5 years  of age. 
Methods 
This study is centered in a cohort of 253 newborn infants who participated in a 
double-blind, placebo-controlled randomized clinical trial with a family history of 
allergic disease from the antenatal clinics at the National University Hospital, 
Singapore. Cord blood samples were collected from 195 eligible subjects. Soluble 
mediators from lipopolysaccharide (LPS) and phytohaemagglutinin (PHA) stimulated 
mononuclear cells were analyzed using the fluorescent activated cell sorting (FACS)-
array and Bio-Plex 200 instrument. These profiles were assessed in relation to the 
clinical outcomes of wheezing, eczema or allergen sensitization and healthy control at 





I) Clinical outcomes 
In this cohort, 63% of the wheeze and 85% of the eczema subjects developed 
symptoms in the first 2 years of life. Early onset is defined as clinical phenotype 
outcomes in the first 2 years of life. Early onset of eczema alone (adjusted OR, 5.00; 
95% CI 1.33-18.8) or early onset eczema and concomitant allergen sensitization 
(adjusted OR, 13.5; 95% CI 3.97-45.5) was associated to subsequent eczema at 5 
years. Early onset wheeze (OR, 4.34; 95%CI, 1.26-14.9) or early onset wheeze with 
concomitant early onset allergen sensitization (OR, 7.17; 95%CI, 1.51-34.2) or 
eczema, wheeze and allergen sensitization co-existing together (OR, 9.24; 95%CI, 
1.76-48.5) were associated with subsequent of wheeze at 5 years. 
II)  Cord blood cytokine responses 
Using factor analysis, wheeze in the first 2 years was significantly associated with 
enhanced combined LPS stimulated IL-1β, IL-6 and IL-12/IL-23p40 compared to 
healthy controls (OR=2.45; 95% CI=1.50–3.93, p=0.001). Wheeze had hyper-
responsive cytokine profiles with increased production of T-cell cytokines IL-2, IL-5, 
and IL-13. IL-5 was the strongest risk factor associated to the outcome of wheeze at 2 
years (adjusted OR, 35; 95% CI, and 5.0 – 246.7). Eczema was associated to hypo-
responsive LPS and PHA stimulated IL-8 (LPS: Adjusted OR, 0.7; 95% CI, 0.5 – 0.7) 
and (PHA: Adjusted OR, 0.6; 95% CI, 0.4 – 0.8) respectively.Reduced productions of 
chemokines were associated to the development of eczema and wheeze. In contrast, 







This study emphasizes the importance of early allergic clinical phenotypes as 
predictors of subsequent allergic disorders. The inherent aberrant immunological 
responses involving soluble mediators from cord blood mononuclear cells influence 
the development of early onset phenotypes. Future work is needed to provide a 
roadmap to gain more insights on the pathogenesis and identify novel signature 
biomarkers for prognosis or early diagnosis of allergic disorders in early childhood. 
xiv 
 
LIST OF TABLES 
TABLE 1-1 Summary of studies related to in vitro CBMC proliferative 
responses to subsequent development of atopic disorders 17 
TABLE 1-2 Summary of studies relating CBMC cytokine responses to a 
family history of atopic disorders 23 
TABLE 1-3 Summary of studies related to in vitro CBMC cytokine responses 
to the subsequent development of allergic disorders. Studies are in 
chronological order 26 
TABLE 1-4 CBMC cytokine profiles that deviate from Th1/Th2 paradigm in 
relation to allergic disorder development 31 
TABLE 3-1 Univariate analysis and clinical demographics of subjects in the 
cohort at 5 years of age 54 
TABLE 3-2 Sensitization characteristics of subjects at 1 year, 2 years and 5 
years of age 63 
TABLE 3-3 Summary data between allergen sensitization and allergic 
phenotypes at 2 and 5 years of age 65 
TABLE 3-4 Allergic phenotypes and allergen sensitization in association to 5 
year outcomes with unadjusted and adjusted *ORs and 95% CIs for current 
eczema, wheeze and rhinitis at age 5 years. 69 
TABLE 5-1 Definition of clinical outcomes at 2 and 5 years of age 102 
TABLE 5-2 Summary of factor analysis, including factor loadings from a 
model of cytokine responses in the LPS stimulated CBMCs of healthy control 
subjects 125 
TABLE 5-3 Summary of factor analysis; including factor loadings from a 
model of cytokine responses in the PHA stimulated CBMCs of healthy 
control subjects 127 
TABLE 6-1 Summary of both unistimulated and LPS stimulated chemokine 
and other soluble mediator profiles between the subjects with allergen 
sensitization and the healthy control group based on the Mann-Whitney U 
test 152 
TABLE 6-2 Summary of both unistimulated and LPS stimulated chemokine 
and other soluble mediator profiles between the subjects with eczema and the 
healthy control group based on the Mann-Whitney U test. 156 
TABLE 6-3 Summary of both unistimulated and LPS stimulated chemokine 
and other soluble mediator profiles between the subjects with wheeze and the 
healthy control group based on the Mann-Whitney U test 156 
xv 
 
TABLE 6-4 Summary of chemokines associated with the outcome of allergic 
disorders at 2 years of age 176 
xvi 
 
LIST OF FIGURES 
FIGURE1-1 Differentiation pathways of CD4+ Th cell subsets 21 
FIGURE 3-1 The prevalence of allergic disorders from year 1 to year 5 57 
FIGURE 3-2 Venn diagram of the co-existing allergic phenotypes at 5 years 
of age 58 
FIGURE 3-3 Phenotypes of ‘ever wheeze’ and ‘ever eczema’ up till 5 years of 
age 60 
FIGURE 3-4 The prevalence of allergen sensitization from year 1 to year 5 62 
FIGURE 3-5 Course of allergen sensitization, eczema and wheeze from to 2 
years to 5 years of age 67 
FIGURE 4-1 Individual CBMCs cultured in different cell culture media to 
study cytokine responses 84 
FIGURE 4-2 Kinetic and dosage response curves of lipopolysaccharide (LPS) 
stimulated cord blood mononuclear cells (CBMCs) 86 
FIGURE 4-3 Kinetic and dosage response curves of phytohaemagglutinin 
(PHA) stimulated cord blood mononuclear cells (CBMCs) 88 
FIGURE 4-4 Dosage response curves of cytokine responses from 
lipopolysaccharides (LPS) and phytohaemagglutinin (PHA) stimulated cord 
blood mononuclear cells (CBMCs) and peripheral blood mononuclear cells 
(PBMCs) 90 
FIGURE 4-5 Inhibition of LPS at 100ng/mL LPS and 1ug/mL LPS using 
polymyxin B ( 10ug/mL) or anti- TLR4 blocking antibody (10ug/mL) and 
cytokine production of IL-6 , TNF-α and IL-8 were measured from culture 
supernatants harvested at 24 hours 92 
FIGURE 5-1 Flow chart of study shows the collection of the cord blood 
samples and clinical phenotype outcomes at 2 years and 5 years of age 101 
FIGURE 5-2 Flow chart of cord blood mononuclear cell cytokine response 
study and its correlation to the clinical phenotypes at 2 years and 5 years of 
age 106 
FIGURE 5-3 A-H, CBMC innate pro-inflammatory cytokine profile of 
healthy (n=65), eczema (n=29) and wheeze (n=34) subjects at 2 years of age 
in response to 1ug/mL LPS (A-E) and 5ug/mL PHA (F-H) measured using the 
BD CBA Human Soluble Protein Flex Set assay 113 
FIGURE 5-4 CBMC cytokine profile of 1ug/mL LPS and 5ug/mL PHA 
stimulated IL-10 (A-B) and PHA stimulated IL-2, IL-5, IL-13 (C-F) and IFN-
xvii 
 
γ in healthy (n=65), eczema (n=29) and wheeze (n=34) subjects at 2 years of 
age measured using the BD CBA Human Soluble Protein Flex Set assay 115 
FIGURE 5-5 CBMC IL-6, IL-8 and TNF- α cytokine profile of healthy 
subjects with no allergen sensitization (NAS) n=65, healthy subjects with 
allergen sensitization AS n=32 subjects at 2 years of age in response to 
1ug/mL LPS (A-C) and 5ug/mL of PHA (D-F) measured using the BD CBA 
Human Soluble Protein Flex Set assay 117 
FIGURE 5-6 CBMC IL1-β and IL-12/23p40 cytokine profile of healthy 
subjects with no allergen sensitization (NAS) n=65, healthy subjects with 
allergen sensitization AS n=32 subjects at 2 years of age in response to 
1ug/mL LPS measured using the BD CBA Human Soluble Protein Flex Set 
assay 118 
FIGURE 5-7 CBMC cytokine profile of 1ug/mL LPS and 5ug/mL PHA 
stimulated IL-10 (A-B) and PHA stimulated IL-2, IL-5, IL-13 (C-F) and IFN-
γ in healthy CBMC cytokine profile of healthy subjects with no allergen 
sensitization (NAS) n=65, healthy subjects with allergen sensitization AS 
n=32 subjects at 2 years of age measured using the BD CBA Human Soluble 
Protein Flex Set assay 119 
FIGURE 5-8 Relationship between the outcome of eczema and wheeze at 2 
years of age with LPS and PHA stimulated cord blood cytokine profiles as 
well as clinical characteristics 123 
FIGURE 5-9 3D Scatter plot of the healthy control and wheeze group at 2 
years of age in respect to their correlation to the variables from the factor 
analysis 126 
FIGURE 5-10 CBMCs were cultured with 1 µg/mL LPS or 1ug/mL PHA for 
24 hours and stained for surface markers CD3, CD19, and CD14 followed by 
intracellular cytokine staining of IL-6 and IL-8. The IL-6 and IL-8 cytokine 
production from CD19+ ,CD3+ and CD14+ gated cells shown in the figures are 
from a single representative subject 130 
FIGURE 5-11 CBMC cytokine profile of healthy non-allergen sensitized (H) 
n=41,(E) n=8, wheeze (W) n=10 subjects at 5 years of age in response to 
1ug/mL LPS measured using the BD CBA Human Soluble Protein Flex Set 
assay 132 
Figure 5-12 A-H, CBMC cytokine profile of healthy (n=41), eczema (n=8) 
and wheeze (n=10) subjects at 5 years of age in response to 5ug/mL PHA 
measured using the BD CBA Human Soluble Protein Flex Set assay 133 
FIGURE 5-13 CBMC cytokine profile of healthy subjects with no allergen 
sensitization (NAS) n=41, healthy subjects with allergen sensitization AS n=9 
subjects at 5 years of age in response to 1ug/mL LPS measured using the BD 
CBA Human Soluble Protein Flex Set assay 134 
xviii 
 
FIGURE 5-14 CBMC cytokine profile of healthy subjects with no allergen 
sensitization (NAS) n=41, healthy subjects with allergen sensitization AS n=9 
subjects at 5 years of age in response to 5ug/mL PHA measured using the BD 
CBA Human Soluble Protein Flex Set assay 135 
FIGURE 6-1 Flow chart of cord blood mononuclear cell soluble mediator 
response study and its correlation to the clinical phenotypes at 2 years and 5 
years of age 147 
FIGURE 6-2 Chemokine profile of healthy non allergen sensitized (AS) 
(n=62) and healthy allergen sensitized (AS) (n=32) subjects from 
unstimulated (M) cord blood mononuclear cells (CBMCs) and in response to 
1ug/mL lipopolysaccharide (LPS) 153 
FIGURE 6-3 Soluble receptor, cytokine, growth factor, TIMP/MMP profile of 
healthy non- allergen sensitized (AS) (n=62) and healthy allergen sensitized 
(AS) (n=32) subjects from unstimulated (M) cord blood mononuclear cells 
(CBMCs) and in response to 1ug/mL lipopolysaccharide(LPS) 154 
FIGURE 6-4 Chemokine profile of healthy (n=62), eczema (n=29) and 
wheeze (n=31) subjects from unstimulated (M) cord blood mononuclear cells 
(CBMCs) and in response to 1ug/mL lipopolysaccharide (LPS) 157 
FIGURE 6-5 Soluble receptor, cytokine, growth factor, TIMP/MMP profile of 
healthy (n=62), eczema (n=29) and wheeze (n=31) subjects from unstimulated 
(M) cord blood mononuclear cells (CBMCs) and in response to 1ug/mL 
lipopolysaccharide (LPS) 159 
FIGURE 6-6 Chemokine profile of healthy (n=41), eczema (n=8) and wheeze 
(n=10) subjects from unstimulated (M) cord blood mononuclear cells 
(CBMCs) and in response to 1ug/mL lipopolysaccharide(LPS) 163 
FIGURE 6-7 Soluble receptor, cytokine, growth factor, TIMP/MMP profile of 
healthy (n=41), eczema (n=8) and wheeze (n=10) subjects from unstimulated 
(M) cord blood mononuclear cells (CBMCs) and in response to 1ug/mL 
lipopolysaccharide (LPS) 164 
FIGURE6-8 Chemokine profile of healthy non allergen sensitized (AS) 
(n=41) and healthy allergen sensitized (AS) (n=9) subjects from unstimulated 
(M) cord blood mononuclear cells (CBMCs) and in response to 1ug/mL 
lipopolysaccharide (LPS) 165 
FIGURE 6-9 Soluble receptor, cytokine, growth factor, TIMP/MMP   profile 
of healthy non- allergen sensitized (AS) (n=41) and healthy allergen sensitized 
(AS) (n=9) subjects from unstimulated (M) cord blood mononuclear cells 




LIST OF ABBREVIATIONS 
Ag                             Antigen 
AR                            Allergic rhinitis  
APC                          Antigen presenting cells 
CBMC                      Cord Blood mononuclear cells 
Derp                         Dermatophagoides pteronyssinus 
Bt                             Blomia tropicalis 
DMSO                      Dimethyl sulfoxide  
FCS                          Fetal calf serum 
Ig                              Immunoglobulin 
LPS                          Lipopolysaccharides 
LRIs                         Lower respiratory illness 
MMP                       Matrix metalloproteinases 
OR                            Odds ratio 
ORadj                       Adjusted odds ratio 
OVA                        Ovalbumin 
PBMC                      Peripheral blood mononuclear cells 
PHA                         Phytohaemagglutinin 
PPR                          Pattern Recognition Receptors 
RAST                       Radioallergosorbent 
RSV                         Respiratory syncytial virus 
RV                           Rhinovirus  
RSV                        Respiratory syncytial virus 
SPT                         Skin prick test 
SCORAD                Severity scoring of atopic dermatitis 
TIMP                      Tissue Inhibitor of Metalloproteinase 
TLR                         Toll Like Receptor  
Th                            T helper 
Th1                          Type 1 helper T cells 
xx 
 
Th2                          Type 2 helper T cells 
Tr1                           T regulatory type 1 cells 
Treg                         Regulatory T cells 





Chapter 1: Introduction and literature review 
 
1.1 Introduction  
Atopic disorders- asthma, wheeze, rhinitis, eczema and allergen sensitization are 
complex entities with an array of risk factors that may be categorized into genetic 
predisposition and environmental. A complex interaction between the genes and the 
environment occurs both pre- and postnatally (1). Epigenetic factors which are 
chemically stable, potentially reversible, can be modulated or induced by 
environmental factors can lead to inheritable changes in the gene expression 
expressing genes encoding protein involved in allergy (2). Furthermore, is it possible 
for the metabolomics of a healthy subject to be different in a subjects with allergic 
disease acknowledging its potential role in the diagnosis of allergy. to be different 
from an allergic subject (3). Atopic disorders are also classically characterized by 
chronic immune-mediated inflammation, initiated and perpetuated by CD4 + T helper 
(Th) cells (4) where Th2 responses predominate (5). The Th1 versus Th2 immune 
balance refers to immune responses with the production of Th-1 type cytokines to 
antigens in humans not predisposed to allergy, and a Th2 –type response involved in 
the induction and maintenance of IgE synthesis in humans predisposed to atopy (5).  
 
Cord blood biological assays have shown evidence of neonatal immune responses to 
antigens via in vitro cord blood mononuclear cell (CBMC) proliferation (6) and 
detection of allergen-specific IgE in cord blood (7). From the reported data, it has 
become evident that factors present during the antenatal development and the prenatal 
immune system in utero  may influence the risk of developing subsequent allergic 
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disorders (8). Since then there have been publications describing the responses of cord 
blood mononuclear cells and their association with subsequent allergic disorders.  
 
An at risk for atopy birth cohort like the one described in this thesis provides an 
optimal design to elucidate the influences of the immune responses at birth and the 
clinical outcomes from birth into early childhood that has been tracked prospectively. 
An at risk for atopy population was chosen in order to increase the likelihood of 
allergen sensitization and clinical manifestation of allergic outcomes. 
 
1.2  Atopy and allergic disorders 
1.2.1 Definitions 
1.2.1.1 Atopy  
Atopy is defined as a “personal or familial tendency to become sensitized and produce 
immunoglublulin (IgE) antibodies in response to normally innocuous environmental 
antigens (9). The term atopy cannot be used unless IgE sensitization has been 
documented with IgE antibodies in serum or by the results of a positive skin prick test 
(9).  
 
However, recent evidence has shown that allergen-specific IgE is demonstrable both 
systemically (e.g., positive skin tests) as well as local IgE that may be present in the 
end organ, for example allergic rhinitis (10). Rondon et al. has reported that persistent 
non-allergic rhinitis patients have nasal IgE production and a positive response to a 
nasal allergen provocation test despite no evidence of systemic atopy (11).  These 
evidence adds an additional layer of complexity that inheritance of atopic disorders 
may be end-organ specific—i.e. for the skin (eczema), nose (rhinitis) and airways 
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(asthma), and although inheritance of an exaggerated IgE response may underlie all 
these conditions, separate genes predispose to specific clinical manifestations of the 
allergic phenotype (10).  
1.2.1.2. Eczema  
Also known as atopic dermatitis, eczema is the preferred term for skin inflammation 
associated with itchiness and rash (12) according to the World Allergy Organization, 
because not all eczema is associated with immunoglobulin (Ig)E-mediated sensitivity 
to allergens (9). Due to the variety of the clinical presentations, the diagnosis of 
eczema has not been easy. The first diagnostic criteria was proposed in 1977 by 
Hanifin and Lobitz (13), and in 1980 by Hanifin and Rajka and modified by Seymour 
et al. for infants as a pruritic rash over the face and/or extensors with a chronic 
relapsing course (14). 
 
Schmid et al. suggested there are at least two forms of eczema, the allergic (extrinsic) 
form and a nonallergic (intrinsic) form (15). The allergic extrinsic form pertains to 
patients who have high serum IgE levels and positive skin prick test reactions to 
common environmental allergens such as food and aeroallergens. The non-IgE 
mediated/ non- allergic variant of eczema are characterized by patients who manifest 
identical skin lesions identical to the allergic form of eczema. However, the skin 
lesions are not associated with a specific sensitization, either in the skin tests or in 
radioallergosorbent test (RAST) to common environmental allergens (15). In 2004, 
the World Allergy Organization (WAO) committee suggested to call “atopic eczema” 
any inflammatory condition determined by an IgE reaction, otherwise it will be 
referred to as eczema (9). 
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Eczema has also been linked to filaggrin which has complex functions within the 
epidermis, constituting the structural and chemical barrier, and maintaining hydration 
and homeostasis. A Loss-of-function mutations in the ﬁlaggrin gene (FLG) have been 
identiﬁed as important for the development of atopic eczema, and between 14% and 
56% of individuals suffering from atopic eczema are carriers of at least one FLG 
mutation (16). 
 
Hanski et al. has reported that gammaproteobacteria, although representing only 3% 
of the sequences in the skin community may play a special role in the development 
and maintenance of the skin homeostasis and healthy barrier function, which points to 
the important of microbial diversity of the skin (17). This study links the rapidly 
declining biodiversity of microbiota as a contributing factor to the rising prevalence of 
allergic disease.  
 
1.2.1.3 Asthma and wheeze   
Asthma is a complex, heterogeneous disease which often manifests in early childhood 
with wheeze. Martinez et al. has suggested that these inherent alterations leading to 
heterogenous asthma phenotypes are more likely to occur during early life and even in 
utero than later during childhood (18).  Just like eczema,  both asthma and wheeze 
can be most commonly categorized as extrinsic wheeze/asthma ( atopic ) or intrinsic 




Wheeze is a lower respiratory tract illness (LRIs) that forms a heterogenous group. It 
is one of the most common reasons for seeking care during the first year of life, and is 
a major cause of hospitalization in infancy (20, 21). A number of clinical 
epidemiology studies have identified a strong association between rhinovirus (RV) 
wheezing illnesses (22) , respiratory syncytial virus (RSV) in infancy, and the 
development of asthma in later childhood (23, 24). HRV infection is also an important 
cause of infant bronchiolitis. Kusel et al. reported that among 263 infants with acute 
respiratory tract illness during the first year of life, half were associated with HRV, 
with HRV being the most common virus detected in children with upper and lower 
respiratory tract illnesses (25). Jackson et al. also demonstrated that in a large, high-
risk cohort, children had an increased risk of asthma at 6 years of age if they wheezed 
in the first 3 years of life with RSV (odds ratio [OR]: 2.6), HRV (OR: 9.8), or both 
HRV and RSV (OR: 10) (26). Kotaniemi et al. reported that children who were 
hospitalized with HRV wheezing illnesses during the first 2 years of life were at 
approximately four-fold increased risk of childhood asthma when compared to 
children hospitalized with wheezing associated with other viruses (27). The Tucson 
Children’s Respiratory Study that began in 1980 identified three main phenotypes in 
early childhood wheezing: transient wheeze, non-atopic persistent wheeze and atopic 
persistent wheezers (28). 
 
Wheezing in early childhood is an important respiratory disorder to focus research 
efforts. A considerable proportion of infants with wheezing might only have transient 
conditions associated with diminished airway function at birth that do not have 
increased risks of asthma or allergies later in life. Children with early transient 
wheezing can be symptom free before 6 years of age or later (24, 28). In a lesser 
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proportion of infants, however, wheezing episodes are probably related to a 
predisposition to asthma (21). Two prospective studies from Finland and Sweden 
have shown that former wheezers can become symptomatic again at adulthood (29, 
30), and may progress to develop allergic asthma later in life or continue to wheeze up 
to adolescence (19).  
1.2.1.4 Rhinitis  
Allergic rhinitis represents a global health problem affecting 10% to 20% of the 
population. Furthermore, allergic rhinitis patients have often comorbidities asthma 
being one of the most common. Up to 40% of patients with allergic rhinitis have 
asthma and at least as many as 80% of asthma patients experience symptoms of 
allergic rhinitis (31). It is diagnosed if the child has rhinorrhea, nasal obstruction, 
nasal itching and sneezing, accompanied by raised levels of allergen-specific IgE or a 
positive reaction to a skin prick test (SPT). These symptoms must be  reversible 
spontaneously or with treatment that is not due to a respiratory infection, as per 
recommendations from the World Health Organization (WHO) Allergic Rhinitis and 
its Impact on Asthma workshop (ARIA) (32). School performance or work 
productivity is reduced in patients with severe symptoms of allergic rhinitis. Non-
allergic rhinitis, which is another common problem, is a heterogeneous group of 
diseases less well understood (32).  
 
Rhinitis even in the absence of atopy has always been shown to be a strong predictor 
of adult asthma (33), and this link between the upper and lower airways is termed the 
“united airways” concept (34). Epidemiologic studies consistently show that asthma 
and rhinitis frequently co-exist in the same subjects (32, 35)  and their 
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pathophysiology is supported by commonalities in the inflammatory and structural 
elements of the airways, as well as similarities in the development and clinical 
manifestations (36). 
 
In view of the heterogeneity of eczema, wheeze and rhinitis phenotypes, 
prognostication may be difficult as not all wheezy infants are easily categorized into 
distinct clinical phenotypes based on their clinical features.  
 
1.2.2 The atopic march  
1.2.2.1 Birth cohort studies 
The concept of the atopic march was developed to describe the progression of atopic 
disorders from eczema in infants to allergic rhinitis and asthma in children during the 
first several years of life (37).  
 
Several prospective birth cohort studies have supported the outcome of the atopic 
march. Arshad et al. reported from the Isle of Wight birth cohort study that eczema at 
4 years of age was an independent risk factor for current wheeze at 10 years of age 
(38). Martinez et al. and The Tuscon Children’s Respiratory Study has shown that 
eczema during the first year of life was an independent risk factor for  persistent 
wheezing, and the presence of eczema by the age of 2 years in childhood was 
associated with chronic asthma (21, 39). Furthermore, atopy plays an important role 
as it was reported that eczema subjects with specific IgE antibodies to common 
environmental allergens (extrinsic AD), present by the age of 2 to 4 years, are at 
8 
 
higher risk for progressing in the atopic march to allergic rhinitis and asthma than 
those with eczema without IgE sensitization (intrinsic AD) (40, 41).   
 
In Asia, The Prospective Cohort of Thai Children (PCTC) evaluated the association 
between atopic dermatitis and wheeze symptoms in the first 12 months of life noted a 
significant increase in the risk of wheeze in infants with current atopic dermatitis but 
not in those with atopic dermatitis in remission (42).  
 
However, there are studies which also provide evidence that contradicts these 
findings. The German Multi Center Atopy Study (GMAS) has shown that those with 
early eczema showed no risk for the development of wheeze at 7 years, which 
indicates that eczema alone may not be the first most predictive phenotype in the 
atopic march (43). Klinnert et al. from the Childhood Asthma Prevention Study 
(CAPS) birth cohort reported no association between eczema in the first year of life 
and subsequent asthma (44).  
 
1.2.2.2 Role of atopy  
Underlying immunoglobulin E (IgE) antibody responses is considered to be critical in 
linking eczema, allergic rhinitis and asthma (37). The atopic march begins with food 
allergy and atopic dermatitis, with early and persistent sensitization to food allergens 
in the first years of life being predictors of subsequent sensitization to aeroallergens 




Early atopic events, either manifestation or allergen sensitization can be used as risk 
markers or even predictors of atopic disorders. The association of early allergen 
sensitization and the risk of developing allergic disorders have already been reported 
in many studies. The GINI (German Nutritional Intervention Study) has reported an 
increased risk for eczema, asthma and allergic rhinitis at 6 years in 12-month-old 
children sensitized to food and aeroallergens in particular (46). The GMAS study 
reported that food sensitization was a strong predictor of asthma and airway hyper-
responsiveness regardless of inhalant sensitization (43). Similarly, the Cincinnati 
Childhood Allergy and Air Pollution Study (CCAAPS) study reported that children 
who had positive SPT results for milk or egg allergen were at the highest risk for 
subsequent eczema development at ages 1, 2, and 3 years (47).  
 
Sensitization to indoor and outdoor aeroallergens alone has also been reported to be 
risk factors for both the development of asthma and rhinitis. The COAST cohort 
found associations of aeroallergen sensitization with the development of persistent 
wheezing (48). In this study, subjects sensitized to house dust mite, D. farina and D. 
pteronyssinus, were reported to be seven times more likely to be asthmatic than 
subjects not sensitized (48).  Additionally, Arshad et al. studied the association of 
allergen sensitization to asthma, rhinitis, and eczema in a birth cohort at the age of 4 
years. From this study, an independent effect of allergen sensitization on asthma was 
observed only with house dust mite with the highest independent risk 





1.2.3 Prenatal influence on atopic disorders  
The first evidence that early events during fetal life or in utero fetal programming 
may modulate susceptibility to atopic disorders have been demonstrated in several 
observational studies including in utero tobacco smoke exposure, in utero exposure to 
immunomodulatory microbial products and maternal diet.   
 
Overall, the association between maternal smoking and asthma has been well 
documented. Birth cohorts in Boston and the Isle of Wight have reported a strong 
association between wheezing and asthma with the exposure to in utero maternal 
smoke (50, 51).  It was also reported that children exposed to in utero cigarette smoke 
had a polymorphism in the IL-1R gene that was associated with a 4.5-fold increased 
risk of subsequent childhood asthma (51). Furthermore, there is evidence suggesting 
that the association between in-utero exposure to maternal smoking with wheeze 
and/or asthma in children is greater than that of postnatal exposure (52).  
 
In 1989, Strachan and Cook et al. proposed “The Hygiene Hypothesis “, a concept 
that is still debated. It proposes that protective factors versus allergy development are 
due to the effects of endotoxin and other microbial exposure via the innate immune 
system (53). The evidence that supports the hygiene hypothesis arrives from the lower 
prevalence of childhood allergic disorders in rural areas and non- affluent countries, 
suggesting that children from more affluent and more “hygienic” environments were 
more likely to develop allergic disorders. A study on famer’s children has reported 
that in-utero exposure to farming environments had protective effects on allergic 
phenotypes of asthma, hay fever and eczema (54).  Additionally, the Protection 
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against Allergy-Study in Rural Environments (PASTURE) birth cohort study has 
shown that maternal contact with farm animals and cats during pregnancy had a 
protective effect on atopic dermatitis in the first 2 years of life which was also 
associated higher gene expressions of innate immune receptors TLR5 and TLR9 in 
cord blood (55). 
 
There have been a number of studies on maternal diet in pregnancy and the outcomes 
of allergic disorders. These studies have focused mainly the dietary intake of   
antioxidants. The most recent study conducted in Australia has shown how 
antioxidant intake in pregnancy may influence fetal immune programming and the 
risk of allergic disease. This study has shown that higher maternal dietary copper 
intake was associated with reduced risk of wheeze and development of any early 
allergic disease in infants at high risk due to family allergy history. Furthermore, 
maternal dietary vitamin C intake in pregnancy was shown to protect against the 
development of wheeze in the first year of life (56). Similar results were obtained 
with a study in Boston  where maternal total intake of antioxidants vitamin E and zinc 
were found to be  inversely associated with any wheezing at 2 y of age (57). 
Furthermore, low vitamin D intake during pregnancy is also believed to be associated 







1.3 Innate immunity 
Innate immunity serves as a first line of defense against infectious agents including 
viral and bacterial components, it is also highly important in regulating the acquired 
immune responses. In an acquired immune response, cells are able to generate a set of 
allergen–specific receptor molecules by gene rearrangement and somatic 
hypermutation (60). When recognition of a microbial non-self ligand by antigen–
presenting cells (APC) is followed by uptake, it proceeds to surface presentation in 
conjunction with MHC class I and II molecules. The same microbial stimuli will 
induce enhanced expression of co-stimulatory molecules through the same or different 
receptors, and this will enable the APC to activate the adaptive immune response. 
Furthermore, these cells then retain immunologic memory of the original allergen 
exposure, and upon allergen re-exposure the cells mount a memory immune response 
against the allergen (60). The innate immune system also functions at the interface 
between the mucosal and skin barriers as well as the environment to non-specifically 
eliminate allergens (61). However, it is important to note that the innate immune 
system in the airways, skin and gastrointestinal tract can communicate across organ 
systems and within tissues as it is highly integrated within the acquired immune 
system. The first line of defense of the innate immune system is formed based on 
germline-coded receptors expressed by macrophages, dendritic cells (DCs), 
monocytes, neutrophils, natural killer (NK) cells, and others known as the pattern 






1.3.1 Toll- Like-Receptors. 
Receptors termed pattern recognition receptors (PPRs) on innate immune cells can 
broadly recognize a variety of molecular patterns from microbes, allergens and self-
antigens which are also termed the ‘pathogen-associated molecular patterns’ or 
PAMPs. These PPRs comprise 10 members of the Toll-like receptor (TLR) family 
which have been identified in humans. The engagement of a microbial product to the 
TLRs of the innate immune system instructs APCs to activate and secrete a pattern of 
cytokines in order to polarize naive T cells towards an appropriate effector phenotype. 
Cell-surface TLRs recognize conserved microbial patterns known as PAMPs ,such as 
lipopolysaccharide (LPS) of Gram-negative bacteria (TLR4), lipoteichoic acids of 
Gram-positive bacteria and bacterial lipoproteins (TLR1/TLR2 and TLR2/TLR6), and 
flagellin (TLR5). PRR activation results in the production of cytokines, chemokines 
and antimicrobial peptide’s, as well as the activation and recruitment of immune cells 
(immature DCs,  NK cells, and neutrophils) (62). As transmembrane proteins, TLRs 
share a basic structure with an extracellular domain (ECD) that consists up to 25 
leucine-rich repeats (LRRs) and a cytoplasmic Toll/IL-1 receptor (TIR) domain. The 
LRRs of the ECD define the ligand-binding site of the TLR and mediate recognition 
of PAMPs (63). Binding of a ligand with its specific TLR results in dimerization of 
TLRs as a homodimer (TLR4), or heterodimer (TLR2 with either TLR1 or TLR6), or 
a conformational change in the pre-existing dimer (TLR3). Ligand binding and 
dimerization induces a conformational change required for the activation of the 
intracellular signaling cascade which is initiated through the TIR domain leading to a 
major signaling pathway. This starts off with a liberation of the nuclear-transcription 
factor NF-κB from its protein inhibitor IκB which leads to the subsequent 
translocation from the cytoplasm into the nucleus and further induces gene 
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transcription and production of pro-inflammatory cytokines like IL-1 , IL-6 and TNF-
α (64). One of the major signaling pathways of TLRs utilizes the adaptor protein 
MyDD88 and IL-1R-associated kinases (IRAK)s , furthermore this pathway is 
activated by all the TLRs except TLR3. The TLR4 has not been shown to bind 
directly to their ligands such as LPS, or their complexes with LPS binding protein 
(LBP). Instead, they bind to CD14 and initiate a downstream signaling response and 
NF-kB activation, these accessory molecules help to increase the strength of ligand 
binding and probably to optimize and direct a more specific downstream signaling 
(62). 
 
1.3.1.1 Bridging the innate and adaptive immunity with Toll-Like-Receptors 
Although many factors influence the decision of becoming Th1 or Th2 cells, 
cytokines IL-12 and IL-4, acting through signal transducer and activator of 
transcription 4 (STAT4) and STAT6, respectively, are key determinants of the 
outcome. The interaction of PAMPs with TLRs results in the release of cytokines, and 
the production of IL-12 promote the development of the naive Th cell into a Th1 
effector cell. This is due to the interaction of this cytokine with the IL-12 receptor (IL-
12R) which results in the activation of the signal transducer and activator of 
transcription (STAT)-4 followed by the activation of another transcription factor, the 
protein T-box expressed in T cells (T-bet). T-bet then binds to the promoter of the 
IFN-γ gene and induces the production of this cytokine which contributes to Th1 
polarization (65). The principal function of the Th1 cells is to elicit phagocyte-
mediated defense against infections, and IFN-γ production stimulates the production 
of IgG antibodies as well as activate macrophages enhancing their microcidal action 
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(66). On the other hand, IL-4 during an innate immune response is able to promote a 
Th2 cell development and the IL-4/IL-4R interaction on the naive Th cell results in a 
cascade of different transcription factors, the most important being STAT6, c-maf, 
and GATA-3. C-maf is critical for high levels of IL-4 production and skewing toward 
the Th2-cell development. GATA-3 not only increases the transactivation of the IL-4 
promoter, but also directly regulates IL-5 and IL-13 expression (65). Additionally, IL-
4 is also a major inducer of B-cell switching to IgE production (66). While IL-4 
inhibits the development of Th1 cells, IFN-γ inhibits the development of Th2 cells, 
while GATA-3, which allows the differentiation of Th2 cells, inhibits Th1 
development and the expression of T-bet inhibits Th2 development. 
 
1.4 Cord blood mononuclear cells (CBMCs) responses and atopic disorders. 
In line with observations that early allergen sensitization are risk factors for the 
subsequent development of allergic disorders, and that in utero fetal programming 
may modulate susceptibility to atopic disorders, evidence  has also suggested that 
‘priming’ of neonatal T-cells against allergens might occur in utero (67). 
Additionally, if the phenomenon of fetal programming influences the susceptibility to 
atopic disorders, it would do so via the developing fetal immune system (67-69). 
 Cord blood is the earliest and most useful hematological sample for studying 
immunological developments in early life. It is now evident that immune 
dysregulation at birth may be an intrinsic feature of a newborn child (70) that 




1.4.1 Fetal responses to allergens 
Allergens can be maternally transferred to the fetus or neonate. The first evidence of 
the capacity to recognize antigen-like stimuli developed in utero to common 
environmental antigens within the developing immune system is observable around 
22 weeks of gestation. Peripheral blood mononuclear cells (PBMCs) were obtained 
from fetuses and premature babies (15-34 weeks gestation) and stimulated with birch 
pollen allergen. The positive proliferative responses suggested that in utero fetal 
exposure to an allergen from around 22 weeks gestation may result in primary 
sensitization to that allergen (72). Additionally, Prescott et al. has reported low level 
lymphoproliferative responses when CBMC was cultured in vitro with common 
allergens such as β-lactoglobulin and ovalbumin (OVA). This further supports that 
initial priming of allergen-specific T cell responses can occur before birth (67) and 
this has led to the notion that human T-cells are capable of expressing allergen 
specific immune responsiveness to stimuli.  
 
1.4.2 CBMC proliferative responses and atopic disorders 
Evidence gathered has shown us that the neonatal immune response is primed by the 
environment in utero and the gestational environment is of particular importance for 
shaping fetal immune responses. in vitro proliferative responses of CBMC from 
neonates who subsequently develop atopic disorders show that significantly increased 
lymphoproliferative CBMC responses were associated with the onset of atopic 
eczema associated to positive allergy skin-prick tests to cows' milk and egg allergens 
at 1 year of age (73). Similarly, Prescott et al. also observed increased 
lymphoproliferation in PHA stimulated CBMCs in children who developed atopy 
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(atopic dermatitis (AD), asthma-like disease and food or upper-airway allergy) by age 
1, but not in allergen specific stimulated CBMC with cow’s milk, egg white and 
house dust mite extract (6) . 
  
These 2 reports uniformly demonstrate that increased CBMC proliferative responses 
are associated with an increased likelihood of childhood atopic disorders. However 
another 2 studies, both using allergen specific stimuli failed to show any association 
between CBMC proliferation and allergy at 2 years of age (74, 75) (Table 1-1).   
 
Table 1-1: Summary of studies related to in vitro CBMC proliferative responses to 






OVA ovalbumin, BLG β-lactoglobulin , HDM house dust mite, PHA 
Phytohaemagglutinin, TT tetanus toxoid, CM cow’s milk. Lymphoproliferation 





1.4.3 Cord blood IgE in allergic disorders  
IgE being central to the pathophysiology of allergic disorders was reported to be a 
good predictor allergy during infancy, also as a measure of atopic propensity in the 
newborn (76). However, these studies have shown that cord blood IgE alone is not 
sufficient to predict ‘high allergic risk newborns’. Raised cord blood IgE 
concentration is specific but not sensitive in the prediction of the development of 
allergic disorders (77). 
 
 An early study in 1982 reported that high IgE concentrations and a family history of 
allergy were associated with the development of atopic disease in 73% of infants. 
However, high IgE concentrations were also seen in infants showing no signs of 
atopic disease (78). A more recent study by Hansen et al. reported that a greater 
number of children with elevated cord blood IgE levels was seen to be statistically 
associated with the development of allergic disorders before 5 years of age. These 
authors also reported that cord blood IgE levels had low sensitivity as a predictor of 
atopic disease with a positive predictive value of only 26% and sensitivity of 33% 
(77). Another recent study has reported no association between total nor specific cord-
blood IgE (cIgE) levels with family history of atopy and the incidence of allergy (76). 
Furthermore, Bønnelykke et al. showed that approximately half of cord blood samples 
with increased IgE levels result from maternofetal transfer. There was a strong 
association between maternal IgE and cord blood IgE. The data contradicts the value 




1.4.4. Cord blood mononuclear cell (CBMC) cytokine responses  
1.4.4.1 Network of cytokines determines CD4+ T-cell fates 
Aside from the limitation of the Th1/Th2 paradigm, another limitation to the 
interpretation of results from most cord blood studies is that the statistical analysis of 
CBMC responses has been limited to the use of non-parametric methods to study one 
cytokine at a time. Because cytokines act in complex networks, other statistical tests 
can be employed to combine cytokine responses that are closely intercorrelated to 
simulate a cascade type of cytokine activity. 
 
CD4+ naive cord blood T cells can differentiate into at least 4 major lineages Th1, 
Th2, Th9 and Th17. This differentiation depends on the adjuvanicity of the innate 
immune response stimulating substances co-exposed with the antigen, and the 
cytokines in the microenvironment (80). Networks of cytokines are critical for 
determining CD4+ T-cell fates and effector cytokine production. Furthermore, for 
each Th lineage differentiation more than one cytokine is involved (81) ( Figure 1-1).  
Cytokine IFN-γ as well as IL-12 is important for the differentiation of IFN-γ 
producing Th1 cells (82). The Th1 cells which predominantly produce IFN-γ Th1 
cells are involved in cell mediated defense against intracellular microorganisms and in 
promotion of memory IgG responses. The differentiation of naïve T cells into Th2 
cells produces Th2-type cytokines including IL- 4, IL- 5, and IL- 13, associated with 
the promotion of IgE and eosinophilic responses in atopy (83). For the differentiation 
of Th2 cells, the presence of IL-4 alone is not sufficient in the absence of STAT5 




The 2 more recent subsets identified to be involved in allergy and asthma are Th9 and 
Th17 (80). Overall, IL-9 has been reported to play important roles in airway 
remodeling with mucus production in the epithelium and asthmatic inflammation 
(84). Cytokine TGF-β in the presence of IL-4 reprograms Th2 cell differentiation that 
leads to the development of Th9 cells and the production of IL-9 and IL-10 (85). The 
Th17 cells have been reported in the involvement of atopic dermatitis and allergic 
airway inflammation through their production of IL-17a, IL-17f, and IL-22.  
 
Collectively, the main cytokines that have been described as essential for human Th17 
cell development and expansion encompass a combination of cytokines IL-1β, IL-6 
and IL-23 (86). The role for IL-23 which is mainly produced by phagocytic cells, 
macrophages, and activated DCs is proposed for the terminal differentiation and final 
phenotype of Th17 cells (86). Other pro-inflammatory cytokines such as IL-1β, TNF-
α (87), IL-6 and IL-8 (88) which are innate cytokines produced at early stages of most 
immune responses are important cytokines to focus on as well as they play an 
important role in their effects on the Th1, Th2 and even Th17 differentiation.  
 
In summary, naive CD4+ T cells have multiple fates that they may acquire when 
stimulated and the fate decision is regulated by the network of cytokines expressed in 
the activated cells. Furthermore, a particular cytokine may have different function 




 So far, only one publication has reported the study of higher production of combined 
LPS stimulated cord blood cytokines IL-6 and IL-8 in association to infants 
hospitalized for RSV infection compared to outpatient infants of healthy controls (89). 
Thus, it is important for more cord blood studies to study combined cytokine 
responses that are closely intercorrelated to understand how it might relate to an 








Figure 1-1: Differentiation pathways of CD4+ Th cell subsets. Depending on the 
cytokines in the microenvironment, naïve CD4+ T cell subsets can differentiate into 
Th1, Th2, Th9, Th17 and Th22 helper cells. The different T-cell subsets can then 
promote different types of inflammatory responses based on their respective cytokine 







1.4.4.2 Cord blood mononuclear cell (CBMCs) cytokine profiles in infants at risk 
for atopy.  
Overall, an increased in vitro CBMC proliferative responses is associated with 
subsequent atopic disorders, a number of studies have attempted to investigate family 
history of atopic disorders as determinants of CBMC cytokine responses ( Table 1-2) . 
The criteria for high-risk was defined as at least a first-degree relative with an atopic 
disorder (90).  The earlier studies compared CBMC cytokine profiles between the 
high risk and low risk for atopy groups without subsequent follow-up of clinical 
outcomes.  
 
Gabrielsson et al. investigated if the atopic status of the mother influences the cord 
blood immune responses. A Th2 skewed cytokine profile with higher IL-4 as well as 
higher IL-4/IFN-γ producing cells was found in the biparental atopic heredity 
(paternal and maternal atopy) group compared to the no atopic heredity group. When 
CBMCs were stimulated with birch and cat allergen, the highest production of IL-12 
was seen in the non- atopic group, followed by the biparental atopic heredity group, 
and lastly the maternal atopy group. These results indicate a strong genetic influence 
on the cytokine pattern in CBMCs (91).  
 
CBMCs have also been activated with a combination of bacterial products  like 
lipopolysaccharide (LPS) and staphylococcal enterotoxin E (SEE) which induced 
stronger IFN-γ responses in CBMC of neonates at low risk for atopy (92). Moreover , 
Liao et al. has shown that the CD4 + T cells of the high-risk group produced lower 
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levels of IFN-γ but higher levels of  pro-inflammatory cytokine IL-6 (93). In contrast 
to the study by Gabrielsson et al. (91), the production of Th2 cytokine IL-4 could not 
be detected in their study (93). However, an equal number of studies have failed to 
demonstrate any significant association. Piastra et al. showed no differences in the 
CBMC secreted IL-2 or IL-4 (94), and Martinez et al. found no differences in the 
production of IFN-γ (95). 
Table 1-2: Summary of studies relating CBMC cytokine responses to a family history 









PMA Phorbol-12-myristate-13-acetate, PHA Phytohaemagglutinin , PPD Purified 
protein derivative , LPS Lipopolysaccharide , SEE staphylococcal enterotoxin E , Con 





1.4.4.3 Cord blood mononuclear cell (CBMC) cytokine profiles at birth and 
subsequent allergic disorders 
As it was not sufficient to predict the outcome of allergic disorders based solely on a 
‘high-risk for atopy’ background, numerous studies have sought to evaluate cytokine 
responses of cord blood mononuclear cells as predictors of subsequent childhood 
disorders (Table 1-3).  
 
In follow-up studies with clinical outcomes, the most consistent association between 
cytokine production at birth and the subsequent development of allergic disorders was 
found in the context of decreased IFN-γ. IFN-γ produced mainly by T cells and 
natural killer cells is a central player in immune system. It promotes differentiation of 
T cells in a Th1 direction, activates phagocytic, cytotoxic functions in inflammatory 
cells, and regulates the determination of antibody class in B cells away from IgE 
synthesis. Furthermore, it assists in the resolution of inflammation including induction 
of apoptosis in eosinophils and lymphocytes (96).  
 
One of the earliest studies on the correlation of IFN-γ levels and the development of 
allergic disorders was in 1994. Tang et al. reported that infants who developed either 
symptoms of atopic disease (eczema or asthma) or had a positive IgE-mediated skin 
prick test at 12 months of age produced significantly less IFN-γ compared with those 
who did not. Results from this study suggest that defective IFN-γ secretion is an 
intrinsic feature of the atopic individual that predisposes an infant to the development 
of atopy (97). Kondo et al. has also reported that cord blood IFN-γ levels induced by 
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stimulation with ovalbumin (OVA) or bovine serum albumin (BSA) were 
significantly lower in infants who developed allergic disorders by 6 years of age (98). 
In a study by Herberth et al., reduced frequencies of Th1 cytokine IFN-γ producing 
CD4+T cells were at higher risk for atopic dermatitis within the first 2 years of 
life(68). Similarly Nilsson et al. reported decreased IFN-γ production in association to 
atopic dermatitis in the first 24 months of life (99).  
 
Aside from the IFN- γ responses, studies on the cord blood mononuclear cells started 
exploring Th2 responses in relation to allergic disorders. Herberth et al. reported 
increased percentage of  Th2 cytokine IL-4 producing CD4+T cells were at higher risk 
for atopic dermatitis within the first 2 years of life (100). Th2 cytokine IL-13 has also 
been mentioned in studies related to cord blood to be associated with atopic diseases. 
PHA and house dust mite Derp 1 stimulated CBMCs of children who developed 
atopic dermatitis by the age of 3 years had a higher production of IL-13 compared to 
those who did not develop atopic dermatitis (101). This indicates that not only an 
impaired Th1 response but rather a Th1/Th2 dysbalance at birth may influence the 
risk for later development of atopic dermatitis.  
 
Innate pro-inflammatory cytokines were also studied by Prescott et al. in CBMC 
responses to TLR ligands. It was reported that TNF-α and IL-6 responses to TLR2, 
TLR4, and TLR5 activation were significantly higher in newborns who subsequently 
had allergic disorders. These allergic subjects consisted of infants who developed 
atopic dermatitis, IgE-mediated food allergy, and sensitization to inhalant or dietary 
extracts at 12 months of age (102) 
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Table 1-3: Summary of studies related to in vitro CBMC cytokine responses to the subsequent development of allergic disorders. Studies are 





Table 1-3: Summary of studies related to in vitro CBMC cytokine responses to the subsequent development of allergic disorders. Studies are in 




Prescott (a) Prescott et al. 2008  PHA Phytohaemagglutinin Ova Ovalbumin, BLG β-lactoglobulin, Derp1 House dust mite allergen TLR Toll-Like-Receptor LPS Lipopolysaccharide 
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1.4.4.4 Inconsistencies in cord blood studies and Th1/Th2 cytokines 
In summary of the cord blood studies presented in Table 1-2 and Table 1-3, I believe 
that the discrepancies between reported data could be due to the nature of the mitogen 
used, the degree of disease severity and/or chronicity, the classifications of the clinical 
outcome of interest, the differences in the subject population (eg: low risk versus high 
risk), the length of follow-up and the mode of cytokine measurement. The conflicting 
results might arise in main part from the diversity of the study settings, some study 
measure cytokines from un-stimulated cord blood cells, some from stimulated cord 
blood cells and other studies measure the cytokine from the serum/plasma of the cord 
blood samples. Furthermore, while some studies used enzyme linked immunosorbent 
assay (ELISA), other used ELISpot, sandwich type time-resolved fluorometry or used 
intracellular staining methods followed by analysis by flow cytometry. In most studies 
where cord blood mononuclear cells were stimulated before the cytokine 
measurement, different stimulatory reagents were used such as PHA, LPS, 
PMA/Ionomycin or allergens, eg: house dust mite or dietary allergens like OVA 
which might account to the heterogeneous results. The main reason for the 
controversial results in the literature could be due to the study of overlapping clinical 
phenotype outcomes. To study a specific clinical phenotype outcome on its own 
might be the better way to approach the question about possible specific cytokine 
profiles being associated to specific clinical outcome groups, and how there might be 





 In effort to better understand and identify immunological markers to predict atopic 
disorders, much attention has been focused over the previous years on the Th1 versus 
Th2 immune balance and how in atopic disorders the Th2 responses predominate.  
The Th1 and Th2 lymphocytes were thought to be a differentiated population of naïve 
CD4+ T helper cells defined by the cytokines they produce. Th1 phenotypes are 
characterized by the secretion of   cytokines IL-2, IFN-γ, and TNF-β without IL-4, IL-
5, IL-9, and IL-13 production. By contrast, Th2 phenotypes are characterized by the 
prevalent production of cytokines IL-4, IL-5, IL-9, and IL-13 in the absence of IFN-γ 
and TNF-β production (Figure 1-1) (4, 5). Accordingly, allergy results from an 
imbalance in favor of a Th2 response, and is negatively regulated by Th1 cells. Indeed 
studies have shown the association between atopic phenotypes and the increased in 
Th2 cytokines (103, 104) (Table 1-3). 
 
On the whole it appears that there is an underlying association between CBMC 
responses and the development of atopic disorders. Despite the overall trend of 
decreased Th1 responses associated with allergic outcomes and increased Th2 
responses, there are clear inconsistencies between studies (Table 1-4). A study by 
Prescott et al. has shown that allergic outcomes do not always have to be associated 
with an accentuated Th2 bias. Instead it can be associated with a parallel reduction in 
Th2 cytokines when reduced neonatal Th2 responses from IL-4 , IL-6 , IL-10 and IL-
13  was found to be risk factors for atopy outcomes at 2 years of age (6). Neaville et 
al. compared PHA-stimulated CBMC cytokine-response profiles (IL-5, IL-10, IL-13, 
and IFN-γ) in children who subsequently developed atopic dermatitis or food allergy 
at age 1 year to those who did not develop atopic dermatitis or those with no food 
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allergy, and there were no statistically significant differences between the cord blood 
cytokine responses in the 2 groups studied (105).  
 
Furthermore, despite the consistency of observations across a variety of studies on 
IFN-γ deficiency in disease pathogenesis, Rowe et al. was the first to show that 
increased IFN- γ  by CD8+ T cells is concurrent with increased Th2 cytokine IL-13 in 
PHA stimulated CBMC of high-risk  children with allergen sensitization at 2 years, 
while no correlations were observed between allergen-specific CBMC responses and 
atopic outcomes (hay fever, atopic dermatitis and asthma) (106).  Moreover, a study 
by Macaubus et al. found an association between higher cord-blood concentrations of  
Th1 cytokine IFN-γ and TNF-α, including Th2 cytokine IL-4 with a lower risk of 
asthma and atopy outcomes at age 6 years which does not agree with the initial 
proposal of the Th1/Th2 paradigm in allergic disorders (107).  
 
 These studies show us that the immune responses involved in infants who 
subsequently develop allergic disorders are likely to be more complex, and cannot be 





















Prescott (b) Prescott et al .2008  PHA Phytohaemagglutinin Ova Ovalbumin, HDM House dust mite  Feld1 Cat allergen TT Tetanus toxoid SEB staphylococcal enterotoxin B  
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1.5 Chemokines in the role of allergic disorders 
1.5.1 Chemokines in the innate immunity 
Chemokines are a superfamily of proteins involved in the immune cell chemotaxis by 
recruiting cells to the site of infection and are divided into functionally distinct 
groups; three groups of small basic proteins termed the C, CC and CXC chemokines 
and the fourth will be the CX3C chemokines. The series of cytokine and chemokines 
released during an inflammatory reaction will result in a distinct microenvironment 
(103).  
1.5.2 Chemokines in the pathogenesis of eczema 
In eczema, the predominant Th2 cytokines IL-4, IL-13 and IL-5 are involved in the 
pathogenesis where IL-4 and IL-13 are implicated in the initial phase of inflammation 
which mediates an isotype switching to IgE synthesis and upregulation of the 
expression of adhesion molecules on endothelial cells (103). Chemokines released 
play an important role in the pathogenesis of eczema as well when great amounts of 
chemokines like MIP-4/CCL18, TARC/CCL17, PARC/CCL18 and MDC/CCL22 and 
CCL1 are involved in the development of acute and chronic lesions, while MCP-4, 
RANTES and eotaxin contribute to the infiltration of macrophages, eosinophils and 
T-cells into skin lesions. The thymic stromal lymphopoietin (TSLP) which is 
expressed primarily by epithelial cells is able to activate cutanoues DCs and prime T 
helper cells to produce pro-allergic cytokines IL-4, IL-5, IL-13 and TNF-α  which are 
further associated with the activation and migration of DC within the dermis, and is 




1.5.3 Chemokines in the pathogenesis of asthma 
Both cytokines and chemokines may be involved in primary host response to RSV 
infection, recurrent allergic wheezing and asthma. Chemokines play a role as possible 
critical mediators induced during a viral infection by attracting various cell types and 
inducing inflammation and immune regulation. For example, CCL11/eotaxin plays a 
significant role in inducing chemotaxis and activating eosinophils and RSV infection 
increased levels of CCL11 in the lungs of allergic mice  therefore stimulate 
eosinophilic airway inflammation (108). Chemokine CCL5/RANTES has also been 
shown to have eosinophil chemoattractant properties and a role in regulating allergic 
airway responses. Furthermore, an inhibition of CCL5 during RSV infection reduced 
subsequent allergic airway inflammation to cockroach allergen (CRA) challenge 
associated with a reduction in T cell recruitment into the bronchoalveolar space, 
leukotriene release and chemokine generation (109).  
 
1.5.4  Chemokines and other soluble mediators in the role of allergic disorders 
Aside from cytokines, other soluble mediators have been measured in cord blood. 
Fueled by the “ Hygiene hypothesis” earlier studies have focused on CD14, an LPS 
receptor in amniotic fluid or breast milk  to study soluble receptors connected to 
bacterial immune defense in association for a putative protective effect on the 
development of allergic disorders. Jones et al. reported that soluble CD14 levels in 
breast milk were significantly lower in children with eczema at 6 months of age 
irrespective of whether they were atopic (110),while Snijders et al. concluded in their 
study that there is no evidence between sCD14 in breast milk and atopic outcomes in 
infants at 2 years of age (111).  A study by Boyle et al. study shown that a low 
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expression of CD14 on cord blood mononuclear cells and a reduced percentage of 
CD14+  cord blood monocyte’s are associated with family history of allergic disorders 
(112). While another study has shown that soluble CD14 levels were highest in 
children with atopic mothers but there were no significant associations seen between 
the development of atopic disease at 2 years of age and soluble CD14 levels (113). 
According to the “hygiene hypothesis” lower levels of sCD14 should reflect a reduced 
capacity to respond to microbial signals or decreased exposure to microbial signals 
thus higher susceptibility to allergic disorders, but with the conflicting results 
published a final association between sCD14 and atopic disease could not be 
affirmed. 
 
Other than the role of cytokines in allergy, chemokines are known to be involved in 
the mediation of inflammatory cells such as T cells, dendritic cells, mast cells, 
eosinophils and neutrophils. Additionally, not only are chemokines involved in 
recruitment of these cells, they also play a role in activation and differentiation of 
inflammatory cells, by selectively activating Th1 or Th2 cells, or by effects on 
epithelial or endothelial cells (114). Chemokines can also be produced in substantial 
amounts by structural cells like epithelial cells, fibroblasts, and endothelial cells. 
These structural cells are able to selectively produce particular chemokines, not only 
in reaction to their immunological environment, also in direct response to microbial 




 Only recently chemokines measured from the serum of cord blood have been studied 
in the development of allergic disorders. Cord blood chemokines CCL17 and CCL22 
levels, and increased CCL22/CXCL10 and CCL17/CXCL10 ratios were associated 
with allergy development at 6 years of age which included the development of 
allergen sensitization and asthma (116). In another study, allergic sensitization was 
found to be preceded by elevated levels of Th2-associated chemokine CCL22 and 
reduced levels of Th-1 associated chemokine CXCL11 at birth, while CCL17 was 
elevated in infants developing recurrent wheeze and  a high (CCL22/CXCL10) ratio 
at birth was  associated with both sensitization and eczema development at 2 years of 
age (117). Cord blood serum CCL22 was also reported to be significantly associated 
with the outcome of wheeze in infants aged 12-15 months old, however the other 
chemokines measured CCL17,CCL11,CCL22 and CXCL10 were not found to be 
associated to total IgE levels, a positive family history for atopic disease or the 
development of atopic disorders (118). So far the cord blood studies on chemokines 
have shown consistent results with mainly CCL22 and CCL17 which are Th2 -
associated chemokines to be positively associated to the outcome of allergic disorders.  
Aside from these studies, soluble cytokine and immunoglublulin receptors like 
sCD30, sCD23 and sIL4-receptor have also been measured in cord blood before but 
were not found to be associated with the development of atopic disorders. CD30 and 
CD23 level in serum of cord blood  were not associated to subjects who subsequently 
developed allergic sensitization and atopic dermatitis before the age of 3 (119). 
Another study, measured serum levels IL-4 ,sCD23 and IFN-γ  in cord blood but only 
found significantly higher levels of IL-4 to be are associated with allergic disorders in 




Sigurs et al. has reported that RSV bronchiolitis in infancy severe enough to cause 
hospitalization was highly associated with the development of allergic sensitization up 
to age 7 (23). Similarly, Schauer et al. has shown that RSV bronchiolitis was an 
important risk factor for allergic sensitisation when they reported that a positive test 
for IgE antibodies was noted in 14 of 42 (33%) RSV children compared to only 2 of 
84 (2.3%) children from the control group (121). However, evidence has now shown 
that allergic disorders, especially those that develop in early life are not always 
association with sensitization and are not always IgE mediated (21, 41). Wheezing in 
infants are generally associated with viral infections (122), and studies have suggested 
the association of chemokines in viral respiratory tract infection. For instance, serum 
levels of CCL5 were found to be higher in RSV-infected children but not in influenza 
virus-infected patients (123). CCL3 has been identified to be implicated in airway 
hyper-reactivity and an important mediator of virus-induced inflammation in vivo 
(124).  Furthermore, in chronic inflammatory skin disorders like atopic dermatitis, 
trafficking of dendritic cells is regulated by chemokines released into the 
microenvironment that play an important role in regulating and  maintaining atopic 
skin inflammation In a study by Gunther et al. ,  serum CCL18 secreted by monocytes 
and dendritic cells was found at higher levels in patients with atopic dermatitis (125).  
 
1.6 Rationale of study  
Many birth cohort studies designed to study allergic disorders have been conducted in 
both European countries and the United States. Almost all these studies aim to 
evaluate the environmental contributions to allergic disorders. Similarly, birth cohort 
studies in Asia have also focused mainly on the environmental and lifestyle 
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contribution to allergic disorders. The main reported findings from Japans Osaka 
Maternal and Child Health Study (OMCHS) was the lack of significant association 
between breastfeeding and symptoms of wheeze (126) and atopic eczema (127). 
Additionally, this group has also reported that the exposure to high levels of house 
dust mite allergen levels during pregnancy may increase the risk for infantile atopic 
eczema (128). Furthermore, paternal allergic history was identified as a risk factor for 
childhood allergy in both the Japan (127) and Taiwan (129) birth cohorts.  
 
This is the largest and first published prospective study on Singaporean children at 
high-risk for atopy. This study is aimed at providing information on the natural 
history, progression of allergic disorders as well as allow us evaluate the early life risk 
factors affecting the subsequent development of allergic disorders with a follow-up of 
clinical outcomes up till 5 years of age.  
 
Additionally, the prospective design of this study enabled the study of immunological 
responses at birth from cord blood mononuclear cells and associates the findings with 
subsequent development of allergic outcomes. Aside from the extensively published 
literature on cord blood cytokines, Th1 and Th2 cytokines in particular, the published 
literature still lacks in the study of innate immune cytokines released by cells such as 
monocytes, macrophages and dendritic cells by studying CBMC responses to Toll-
Like-Receptor agonists. So far, only 2 studies have managed to show an association 
between cord blood lipopolysaccharide (LPS) stimulated IL-6 (102) and IL-8 (89) 
with the association of allergic phenotype outcomes. Furthermore, many previous 
studies have chosen to study the association of CBMC cytokine responses with 
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combined outcomes of allergic phenotypes (97, 98, 102) instead of studying each 
allergic outcome separately (Table 1-3). 
 
Furthermore, the review on other cord blood soluble mediators associated to allergic 
disorders (Section 1.4.3) provide evidence that many more chemokines can be 
studied. The secretion of chemokines from cord blood mononuclear cells presents an 
opportunity to identify immune dysregulations associated to allergic disorders on top 
of the study of cytokines. Additionally, there are no publications so far that have 
studied chemokine responses from cord blood mononuclear cells. All the previous 
studies have measured chemokines from cord blood serum. Thus, there is a need to 
further contribute to the current data on cord blood studies and provide new 
information on the potential of using cord blood mononuclear cells soluble mediator 




1.7 Study hypothesis and aims of study 
This study aims to add new information on the cord blood immunological responses 
in association to the outcome of allergic disorders in an Asian birth cohort of high risk 
for atopy infants.  
 
Study hypothesis:  
• The potential immune dysregulation of pro-inflammtory cytokines and T-cell 
cytokines at birth detected via cord blood mononuclear cells (CBMCs) 
secretion of soluble mediators such as cytokines, chemokines or soluble 
receptors are associated with the risk of developing allergic disorders such as 
eczema, wheeze and allergen sensitization in early childhood.  
• Each clinical phenotype will be evaluated separately and the immune response 




I    Clinical studies   
To study the early life demographic and clinical risk factors and the progression 
of allergic phenotypes in a 5 year follow-up from a birth cohort of high risk         
( first degree relative with allergic disorder and allergen sensitization) for atopy 
infants.   
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i)       To evaluate allergen sensitization with the manifestation of eczema, 
wheeze and rhinitis in the first 2 years of life and at the 5 year time point. 
ii)       To evaluate the progression of eczema, wheeze and allergen sensitization 
in the first 2 years of life followed up to 5 years of age. 
iii)      To evaluate allergen sensitization and/or clinical phenotypes in the first 2 
years of life with the outcome of allergic disorders at 5 years of age.  
 
II   Cord blood immune response studies  
1. To optimize in vitro cell culture experiments with cord blood mononuclear 
cells in AIM-V serum-free medium. 
i) To compare cytokine responses with lipopolysaccharide (LPS) and 
phytohaemagglutinin (PHA) stimulated CBMC in different culture 
conditions ( AIM-V serum free medium , RPMI medium supplemented 
with fetal calf serum (FCS) and RPMI medium supplemented with 
fetal calf serum (FCS) with recombinant IFN-γ pre-priming). 
ii) To conduct kinetic and dosage studies with LPS and PHA stimulated 
CBMCs in AIM-V serum free media. 
iii) To compare cytokine responses from LPS and PHA stimulated CBMC 
and PBMC in Aim-V serum free media. 
 
2. To investigate the association between CBMC responses and the outcome 
of eczema, wheeze and allergen sensitization at 2 years and 5 years of age 
and compare these cytokine profiles with a control group of healthy 
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subjects (no symptoms of allergic disorders and skin prick test negative to 
allergen panel).  
i)      To evaluate cytokine, chemokine and other soluble mediator (soluble 
receptors and growth factors) profiles in relation to distinct clinical 
outcomes of eczema, wheeze and allergen sensitization while 
distinguishing between atopic and non-atopic eczema and wheeze. Eczema 
and wheeze overlaps will be excluded in our analysis. 
ii)      To evaluate cytokine responses from LPS and PHA stimulated CBMC in 
relation to subjects who develop eczema, wheeze and allergen sensitization 
groups with healthy controls using non-parametric statistical analysis. 
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Chapter 2: Materials and Methods 
 
2.1 Subject recruitment and cord blood collection  
Cord blood samples were collected from newborns participating in a prospective 
randomized double-blind placebo-controlled PROMPT (PRObiotic in Milk for the 
Prevention of aTopy trial) study (ClinicalTrials.gov Identifier: NCT00318695). 
Altogether, 253 families with a history of allergic disease were recruited from the 
antenatal clinics at the National University Hospital, Singapore, between May 2004 to 
June 2006 (130). Cord blood samples were collected to investigate the immunological 
responses of the cord blood mononuclear cells and its potential to predict risk of 
allergic disease. Written informed consents were obtained from all families. The study 
was approved by the National University Hospital’s ethics review committee (DSRB 
Ref Code: B/00/322). 
 
2.2 Details of inclusion/exclusion criteria  
2.2.1 Inclusion criteria  
2.2.1.1 Pre-delivery evaluation  
• Either parent or sibling (first-degree relative) with a history of physician-diagnosed 
asthma, rhinitis or eczema and a positive skin prick test to the dust mites, 
Dermatophagoides pteronyssinus and/or Blomia tropicalis, which are the most 
common cause of inhalant allergen sensitization in our atopic population (131). 
• Parents agreed to the subject’s participation in the study as indicated by parent’s 
signature on the informed consent form.  
• The parents were willing to comply with procedures and were able to keep to 




2.2.1.2 Post-delivery evaluation  
(Refer to Screening Form, Appendix A)  
• The subject was born at more than 35 weeks gestation and weighed more than 2 
kilograms.  
• The subject did not have major congenital malformations or major illness as judged 
by the doctor.  
• The subject was in otherwise good, stable health on the basis of medical history, 
physical examination, and the family appeared to be able to successfully complete this 
trial on the basis of an interview.  
 
2.2.2 Exclusion criteria  
• The subject was excluded when the parent was assessed to be mentally or legally 
incapable of informed consent.  
• The parents were unable or unwilling to comply with procedures.  
• Parents who chose to breast-feed exclusively were not considered for the study.  
 
2.3 Background on study 
A prospective randomized double-blind placebo-controlled study (ClinicalTrials. 
govIdentifier: NCT00318695), was conducted to assess the effect of probiotic 
supplementation in the first 6 months of life on the incidence of allergic diseases in 
Asian infants at risk of allergic disease with a two year follow-up. The primary aim of 
the study was to assess the effect of bifidobacteria and lactobacillus on the incidence 
of allergic sensitization, eczema, asthma and rhinitis. Soh et al. reported that 60mL of 
cow’s milk formula with probiotic supplementation Bifidobacterium longum (BL999) 
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and Lactobacillus rhamnosus (LPR) fed to infants in this study for the first 6 months 
of life showed no effect on the prevention of eczema or allergen sensitization in the 
first year of life (130). However, the probiotic supplementation in the first 6 months 
of life could improve Hepatitis B (HepB) antibody responses in subjects receiving 
monovalent doses of HepB vaccine at 0, 1 month and a hexavalent diphtheria–
tetanus–acellular pertussis (DTPa–HepB) combination vaccine at 6 months (132). 
Additionally, Phase II of the study continued a clinical follow-up for a further 3 years 
till 5 years of age. The conclusion was that this study did not detect any statistically 
significant difference in incidences of allergic diseases in the 3-year follow-up period 
from 3 to 5 years of age, including asthma, eczema, allergic rhinitis and food allergy, 
between two groups of subjects fed (probiotic group) and not fed (placebo group) 
with probiotics in the first 6 months of life. 
 
2.4 Processing and storage of cord blood mononuclear cells from cord blood 
samples collected. 
Umbilical cord blood (about 100mL) was drawn from the placenta at birth and 
collected into blood bags (Terumo, Somerset, USA) containing heparin and RPMI 
medium 1640 (Gibco Life Technology, Grand Island, NY, USA). The collected cord 
blood was processed within 12 hours from time of collection. The blood sample was 
first centrifuged for 10 minutes to collect the plasma to be stored in the -80°C freezer. 
The blood was then transferred to 15mL or 50mL centrifuge tubes and diluted with 
equal volume of Hanks balanced salt solution (HBSS) HyClone (Logan, UT, USA). 
The diluted blood was then carefully overlayed on top of the Ficoll-Hypaque solution 
(GE Healthcare, Uppsala, Sweden) without allowing the blood to mix with the Ficoll-
Hypaque layer before centrifuging for 20 minutes with no brake. After gradient 
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centrifugation, the interphase layer of mononuclear cells was collected using a sterile 
pipette and transferred into a new centrifuge tube. The cells were then washed by 
adding excess HBSS (approximately 3 times the volume of the mononuclear cell 
layer). The cells were then resuspended in AIM-V media before the recovery and the 
viability of the cells were determined using the tryphan blue (0.4%) (Sigma, Munich 
,Germany ) exclusion method with a hemocytometer ( Fisher Scientific , New 
Hampshire ,USA)  and the inverted microscope (Olympus, MA,USA). After the 
numbers of cells were determined, the cells were centrifuged to remove the excess 
AIM-V media. The cells were then first resuspended in cold fetal calf serum (FCS) 
(HyClone (Logan, UT, USA) followed by a similar volume of cold freezing medium 
prepared with 15% (Dimethyl sulfoxide) DMSO (Sigma, Munich, Germany) in fetal 
calf serum. The volume of FCS and freezing media added depended on the number of 
cells to be frozen. The freezing media was added slowly and drop by drop into the 
cells. During this step, the cells were mixed gently while kept on ice. The cells were 
then transferred to cryovials (Thermo Scientific, Rochester, NY) and placed into “Mr 
Frosty” (Thermo Scientific) containing 200 ml of isopropanol (Sigma) previously 
equilibrated to 4°C and Mr. Frosty was then transferred to a -80°C freezer (Thermo 
Scientific) for 1 day, and the very next day the cryovials were transferred into liquid 
nitrogen (-150°C) for storage until required for further analysis. 
 
2.5 Clinical assessment  
The children in the cohort have been followed up prospectively. The primary clinical 
outcome measure in this study was the incidence of eczema, and the secondary 
outcome measures were wheeze, allergic rhinitis and allergen sensitization. Infants 
were evaluated by a pediatrician at 1, 3, 6, 12, 24, 36, and 48 and 60 months of age, 
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which involved a detailed history, recording of anthropometric data and clinical 
examination, including looking for the presence of allergic disorders. Questionnaires 
(not validated) were also administered by the candidate and research nurses at these 
visits to record clinical disease and environmental exposures, including day care, 
sibship, use of antibiotics, smoking and pets (refer to Follow-up Form, Appendix B). 
Biweekly phone calls were performed for the first 6 months after which monthly 
phone contacts were done to collect data on the health status of the children 
(Appendix C).  Eczema was defined as a pruritic rash over the face and/or extensors 
with a chronic relapsing course, as described by Hanifin and Rajka and modified by 
Seymour et al. for infants (133), while the SCORAD (SCORing Atopic Dermatitis) 
index was used to objectively score the severity of atopic dermatitis (134) which were 
carried out by the pediatricians ( refer to Appendix D). Frequent wheeze/asthma will 
be diagnosed if the child had three episodes of nocturnal cough with sleep 
disturbances or wheezing symptoms, separated by at least seven days, in a setting 
where asthma was likely and conditions other than allergy have been excluded (135). 
The subject will be diagnosed with rhinitis if the child had rhinorrhea, nasal 
obstruction, nasal itching and sneezing which were reversible spontaneously or with 
treatment that was not due to a respiratory infection as per recommendations from the 
World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma 
workshop (ARIA) (136). 
 
2.6 Skin prick test and serum collection 
2.6.1 Skin prick test 
Skin prick test was performed by the trained candidate and research nurses at 12 
months , 24 months and 5 years of age using standardized technique with common 
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allergen extracts, including soy (Alyostal, Stallergenes Laboratoires, France), milk, 
egg yolk, egg white, dust mite allergens - Dermatophagoides pteronyssinus (Greer 
Laboratories, Lenoir, NC) and Blomia tropicalis (manufactured in-house) (137). 
Peanut and shrimp allergens (Greer Laboratories, Lenoir, NC) were added to the panel 
at 24 months of age while fish allergen and house dust mite allergen from 
Dermatophagoides farina (Greer Laboratories, Lenoir, NC) were added to the panel 
at 5 years of age. Histamine dihydrochloride solution (10mg/ml) was used as a 
positive control and solvent (50% Cocas 50% Gly) as a negative control. A wheal 
greater than 3mm in diameter above the negative control was considered positive 
(138). 
 
2.6.2 Serum collection and IgE measurement  
Serum was collected at 12 months of age and stored at -80°C before assayed for total 
IgE using the fluoroenzymeimmunoassay method (UniCAPs Phadiatop, Pharmacia 
Diagnostics, Uppsala, Sweden) with a detection limit of 0.35 kU/L. 
 
2.7 Selecting cord blood samples for further studies  
The cord blood samples were first selected for further immunological studies based on 
their 12 month and 24 month clinical outcomes in 2008. Cord blood samples from 
both the placebo and probiotic group of the intervention study were included in the 
study, and the cord blood mononuclear cells thawed out for experiments were selected 




Chapter 3: Development of allergic phenotypes in an at risk for atopy Singapore 




Although eczema, wheeze and rhinitis are considered allergic disorders, their onset in 
early childhood may occur in the absence of allergy or allergic sensitization (21, 41, 
139). Moreover, wheezing in infancy and early childhood is often viral rather than 
allergen triggered (25). However, atopy or the presence of allergen sensitization in 
infancy and early childhood which has an important role in the development of 
allergic asthma is also augmented by viral respiratory illnesses in early life (140). 
While it is well known that children with atopic disease often exhibit sensitization, the 
usefulness of sensitization in early childhood to predict the subsequent development 
of atopic disease is less clear. Furthermore, there is considerable heterogeneity in the 
allergic phenotypes in children (21). Thus, there has been considerable interest in 
understanding the relationship between early-life sensitization and the subsequent 
outcomes of eczema, wheeze and rhinitis in children.  
 
Our birth cohort comprises of children who are at risk for atopy with a first degree 
relative with atopic disorder. This is an ideal study group to address risk factors for 
sensitization and allergic disorders. The aim was to examine the progression of 
allergic phenotypes and allergen sensitization in the first 2 years of life, and evaluate 
the role of these early risk factors in the clinical outcomes of eczema, wheeze and 




3.2 Methods  
3.2.1 Subject recruitment, clinical assessment and skin prick test 
Details were described in 2.1, Section 2.2, Section 2.5 and Section 2.6, page 33, 36 
and 37. The early manifestation of eczema and wheeze was defined as the onset of 
these allergic disorders within the first 2 years of life. 
 
3.2.2 Statistical analysis 
Statistical analysis was performed using the SPSS software version 17.0 for windows 
(SPSS, Inc. Chicago III, and USA). Due to the non-normality of the data, Mann 
Whitney U test was performed to assess differences in the continuous variables (eg:  
birth height, birth weight). The Mann Whitney U test is the nonparametric equivalent 
of the Student’s T test, and therefore compares medians instead of means, and normal 
distribution of data is not necessary for use of the Mann Whitney U test (141). When 
differences in the demographic data were evaluated, the Mann-Whitney U was used 
for numerical data, and the χ2 tests for categorical data. Comparison between two 
clinical outcomes groups at year 5 (i.e. Eczema versus no eczema) was made using 
Pearson Chi-square (χ2) test or Fisher’s Exact test to determine if there were 
statistically significant relationships between prevalence’s and  the categorical 
variables (142). 
 
We wanted to investigate the association between the allergic phenotypes and allergen 
sensitization in the first 2 years of life with the clinical outcomes of eczema, wheeze 




A 2-level variable was created using eczema and allergen sensitization outcomes at 2 
years to examine its association to the outcome of eczema and rhinitis at 5 years: 
• No eczema and no allergen sensitization ( Reference group)  
•  Allergen sensitization without eczema ( Sensitization only) 
•  Eczema without allergen sensitization ( Eczema only)  
• Eczema with allergen sensitization (Both eczema and allergen sensitization).  
Multiple logistic regression models were fitted to examine the associations between 
this 2-level variable and the outcome of eczema, or rhinitis at 5 years of age while 
adjusting for confounders.  
 
A 3-level variable was created using eczema, wheeze and allergen sensitization 
outcomes at 2 years to examine its association to the outcome of wheeze at 5 years: 
• No wheeze, no eczema or no allergen sensitization (Reference group)  
• Eczema without wheeze or allergen sensitization (Eczema only)  
• Wheeze without eczema or allergen sensitization (Wheeze only)  
• Allergen sensitization without eczema or wheeze ( Allergen sensitization only) 
• Eczema and wheeze without sensitization ( Eczema and wheeze only) 
• Eczema and allergen sensitization without wheeze ( Eczema and allergen 
sensitization only)  
• Wheeze and allergen sensitization only without eczema (Wheeze and allergen 
sensitization only)  




A multiple logistic regression model was fitted to examine the associations between 
this 3-level categorical variable and the wheeze at 5 years of age while adjusting for 
confounders. 
 
A conservative strategy was chosen for confounder adjustment including only a 
limited choice of co-variates to avoid overfitting of the statistical models. A more 
stringent cut off was used for statistical significance (p value < 0.1) when selecting 
variables from the univariate analysis of baseline demographics to include into the 
multiple logistic regression in order to determine the independent effect of these 
variables on the allergic phenotype outcomes. 
 
 The binary logistic regression is a generalized linear model which is used when the 
dependents (i.e. allergic phenotypes) are dichotomous and the independents (i.e. 
covariates) are continuous or categorical variables. Logistic regression determines the 
odds ratio (OR), the associated 95% confidence interval (CI) and adjusts for relevant 
covariates of the categorical dichotomous outcomes (i.e. Eczema versus no eczema). 
The 95% confidence interval for the odds ratio is obtained as 1.96 standard errors on 
either side of the estimate. The change in value of the independent variable is not 
associated in change in the odds of the dependent variable if the 95% confidence 
interval around the odds ratio includes the value of 1.0 (143). Values of p ≤ 0.05 were 








3.3.1 Demographic data of the allergic phenotypes at 5 years of age. 
Table 3-1 shows the demographic data of the subjects stratified by those who 
developed eczema, wheeze and allergic rhinitis versus those who did not.  A 
significantly higher percentage of subjects who developed eczema by 5 years of age 
had early life eczema by 2 years of age (69% versus 21%, p value=0.001). Eczema at 
5 years was also significantly associated to allergen sensitization to any food or 
inhalant allergens by 2 years and at 5 years of age [2 years: 58% versus 32%, p 
value=0.009 5 years: 73% versus 48%, p value=0.017]. Furthermore, a family history 
of sibling allergic rhinitis was significantly associated with the development of 
eczema at 5 years (27% versus 10%, p value=0.016). Notably, there was a lower 
percentage of probiotic supplementation in subjects with eczema compared to subjects 
without eczema (35% versus 53%) but this difference did not reach statistical 
significance (p=0.073).  
 
A significantly higher percentage of subjects who developed wheeze by 5 years of age 
had early life wheeze by 2 years of age compared to those who did not develop 
wheeze at age 5 (45% versus 14%, p value=0.001). Unlike eczema, wheeze at 5 years 
was significantly associated to allergen sensitization only at 5 years of age (79% 
versus 46%, p value=0.001). Interestingly, subjects with wheeze had higher total IgE 
levels measured from peripheral blood at year compared to subjects without wheeze 





More than half of the subjects who developed allergic rhinitis at 5 years had early 
eczema by age 2 years compared to those who did not have allergic rhinitis (55% 
versus 22%, p value=0.001). Allergic rhinitis at 5 years was significantly associated 
with allergen sensitization at 5 years compared to those without allergic rhinitis (88% 
versus 45%, p value=0.001). Overall, there are more Chinese (70%) but less Malays 
(21%) and Indians (0.9%) who developed allergic rhinitis compared to those who did 
not ( p value=0.013). Subjects who developed allergic rhinitis also had more of a 
paternal history of allergic rhinitis (48% versus 25%, p value= 0.007), plus they were 

















*Eczema  No eczema p value  # Wheeze  No Wheeze  p value  **Allergic rhinitis  No allergic rhinitis  p value  
n=26 n=193 ( n=33) (n=186) (n=33) (n=186) 
Allergic disorder by   < 2 years (%) 
Eczema  18(69) 40(21) *0.001 13(39) 45(24) 0.068 18(55) 40(22) *0.001 
Wheeze 7(27) 34(18) 0.253 15(45) 26(14) *0.001 7(21) 34(18) 0.619 
Allergen sensitization by  < 2 years (%) 15(58) 61(32) *0.009 14(42) 62(33) 0.312 13(39) 63(34) 0.539 
Allergen sensitization at 5 years (%) 19(73) 93(48) *0.017 26(79) 86(46) *0.001 29(88) 83(45) *0.001 
12months sensitization (Any) (%) 8(31) 41(21) 0.274 9(27) 40(22) 0.464 4(12) 45(24) 0.125 
Food sensitization 4(15) 7(4) 4(12) 8(4) 1(3) 11(6) 
Sensitization against aeroallergens 5(19) 37(19) 6(18) 35(19) 3(9) 38(20) 
24months sensitization (Any) (%) 13(50) 28(15) *0.001 9(27) 32(17) 0.172 11(33) 30(16) *0.02 
Food sensitization 4(15) 5(3) 1(3) 8(4) 4(12) 5(3) 
Sensitization against aeroallergens 12(46) 25(13) 9(27) 28(15) 8(24) 29(16) 
Feeding history – birth to month 6 (%) 0.217 0.553 0.905 
Near total breastfeeding with at least 60mL of  
formula for 6 months 2(7.7) 4(2) 0(0) 6(3) 1(3) 5(3) 
Any breastfeeding 16(61) 137(71) 23(70) 130(70) 24(73) 129(69) 
Total formula  8(31) 52(27) 10(30) 50(27) 8(24) 52(28) 
Probiotic supplementation (%) 9(35) 103(53) 0.073 16(48) 96(52) 0.74 14(42) 98(53) 0.277 
Infant sex , no (%) 0.289 0.068 0.756 
Male 15(58) 90(47) 11(33) 94(51) 15(45) 90(48) 
Ehtnic group (%) 0.621 0.417 *0.013 
Chinese 14(54) 84(44) 18(55) 80(43) 23(70) 75(40) 
Malay 11(42) 88(46) 14(42) 85(46) 7(21) 92(49) 
Indian 1(4) 19(10) 1(3) 19(10) 3(9) 19(10) 
Others 0(0) 2(1) 0(0) 2(1) 0(0) 2(1) 
Mode of delivery , no.(%) 0.715 0.265 0.142 
Lower segment caesarean section¶ 6(23) 51(26) 6(18) 51(27) 12(36) 45(24) 
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*Eczema No eczema p value # Wheeze No Wheeze p value **Allergic rhinitis No allergic rhinitis p value 
n=26 n=193 ( n=33) (n=186) (n=33) (n=186)
Any smoker's in the house (%) 10(38) 78(40) 0.849 11(33) 77(41) 0.384 9(27) 79(42) 0.101
Mother's who smoked during pergnancy (%) 1(4) 9(47) 0.851 3(9) 7(4) 0.177 1(3) 9(5) 0.647
Birth order (%) 0.367 0.82 0.823
1 9(35) 77(39) 15(45) 71(38) 16(48) 70(38)
2 6(23) 54(28) 11(33) 49(26) 10(30) 50(27)
>3 11(42) 62(32) 7(21) 66(35) 7(21) 66(35)
Type of housing (%) 0.528 0.921 0.271
Public housing 24(92) 164(85) 29(88) 159(85) 28(85) 160(86)
Private housing ( Condominium) 1(4) 21(11) 3(9) 19(10) 5(15) 17(9)
Landed property 1(4) 8(4) 1(3) 8(4) 0(0) 9(5)
Keep pets ( %) 4(15) 46(24) 0.335 8(24) 42(23) 0.834 9(27) 41(22) 0.51
Family history of allergic disease (%)
Paternal asthma 5(19) 22(11) 0.254 6(18) 21(11) 0.267 5(15) 22(12) 0.593
Paternal allergic rhinitis 8(31) 55(28) 0.81 12(36) 51(27) 0.269 16(48) 47(25) *0.007
Paternal eczema 3(12) 21(11) 0.92 3(9) 21(11) 0.709 6(18) 18(9) 0.149
Maternal asthma 7(27) 43(22) 0.59 4(12) 46(25) 0.112 4(12) 46(25) 0.112
Maternal allergic rhinitis 13(50) 87(45) 0.636 17(51) 83(45) 0.464 12(36) 88(47) 0.245
Paternal eczema 1(4) 27(14) 0.146 3(9) 25(13) 0.49 3(9) 25(13) 0.49
Sibling asthma 5(19) 21(11) 0.217 6(18) 20(11) 0.224 2(6) 24(13) 0.263
Sibling allergic rhinitis 7(27) 20(10) *0.016 3(9) 24(13) 0.539 3(9) 24(13) 0.539
Sibling eczema 6(23) 25(13) 0.164 2(6) 29(16) 0.148 6(18) 25(13) 0.472
Maternal atopy 17(65) 120(62) 0.751 22(67) 115(62) 0.597 16(48) 121(65) 0.07
Gestational age in weeks mean (SE) 38.7(0.32) 38.5(0.09) 0.522 38.5(0.24) 38.5(0.10) 0.839 38.7(0.24) 38.5(0.1) 0.514
Head circumference at birth mean (SE) 33.3(0.32) 33.4(0.13) 0.771 33.3(0.21) 33.4(0.14) 0.92 33.8(0.2) 33.3(0.14) 0.119
Birth height mean (SE) 49.3(0.61) 49.8(0.18) 0.27 50.4(0.40) 49.7(0.19) 0.134 51.1(0.46) 49.6(0.19) *0.003
Birth weight mean (SE) 3.05(0.11) 3.17(0.031) 0.21 3.23(0.08) 3.14(0.03) 0.307 3.34(0.08) 3.12(0.03) *0.011
IgE measurements ( Geometric mean)
Cord blood IgE (kU/l) ¶ 1.395 1.404 0.852 1.021 1.469 0.455 1.13 1.444 0.61
1 year peripheral blood IgE ( KU/l) 31.167 20.067 0.264 28.571 19.906 0.066 22.357 20.796 0.512
SCORAD index mean + SD (Range) 16.5 + 6.7 ( 7.2-30.4)
*The p value was calculated based on the difference between the subjects who developed eczema and those who did not 
#The p value was calculated based on the difference between the subjects who developed wheeze and those who did not 
** The p value was calculated based on the difference between the subject who develoed allergic rhinitis and those who did not
¶ Cord blood not collected from 30 subjects
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3.3.2 Manifestations of allergic disorders up to 5 years of age. 
Information on the prevalence of allergic disorders was available for 97% (245/253) 
of the subjects at year 1 with the number of subjects dropping to 87% (219/253) by 
year 5 due to a total of 34 dropouts. Figure 3-1 shows the profile of different allergic 
phenotypes, and the point prevalence of the clinical phenotypes from 1 years to 5 
years of age is presented as percentage and their 95% confidence intervals. By year 1 
eczema was the most common phenotype, with 22% (53/245) developing eczema 
compared to those who developed wheeze [9% (22/245)] or rhinitis [0.8% (2/245)]. 
The prevalence of eczema at year 2 was almost similar to year 1 at 25% (57/231). At 
year 3 there was a decrease in prevalence for eczema to 8% (19/226) and the 
prevalence remained low at year 4 [11% (25/225)]. By year 5, the percentage of 
eczema has declined to only 12% (26/219) which was almost half of its initial 
prevalence at year 1 and year 2.   
 
The prevalence of wheeze increased slightly to 12% (27/231) at year 2 compared to 
year 1.  At year 3 there was a decrease in prevalence for wheeze to 8% (19/226). At 
year 4 the prevalence for wheeze remained low at 10% 24/225. The prevalence of 
wheeze increased at year 5 to 15% (33/219) which marks the highest prevalence of 
wheeze at year 5.  
 
The prevalence of rhinitis remained low at year 1 [[0.8% (2/245)] and year 2 [1.3 %   
(3/231)]. Rhinitis developed later in life with the number of subjects gradually 
increasing starting from year 3 to year 5 with percentages starting from 3% (7/226) at 




















Figure 3-1: The prevalence of allergic disorders from year 1 to year 5. Prevalence 
of eczema, wheeze and rhinitis from 1 year to 5 years of age. All data was expressed 
as percentage with 95% confidence intervals with tables of the descriptive data 
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3.3.3 Co-existent of allergic phenotypes at year 5  
Figure 3-2 shows us that even by age 5 years, only 4.1% of all these allergic 
phenotypes co-exist, with only 1.4% of eczema and wheeze and 8.2% of eczema and 










Figure 3-2: Venn diagram of the co-existing allergic phenotypes at 5 years of age.  
 
3.3.4 Phenotypes of eczema and wheeze  
Figure 3-3 shows us how the allergic phenotypes of eczema and wheeze can be 
divided into different subgroups based on age and persistence of symptoms. Wheeze 
and eczema were defined as 6 phenotypes (never, ever, early-onset, late-onset, early-
transient and early-persistent). Early-onset described the onset of these allergic 
disorders at the age of 2 years or earlier. Late-onset were those who developed the 
allergic phenotype after the age of 2 years. The early-transient and early-persistent 
phenotypes were  further divided according to those who developed these allergic 
disorders in the first 2 years of life and who’s symptoms remit by 5 years of age, or 




The cumulative prevalence of eczema and wheeze phenotypes in the cohort was quite 
similar: “ever eczema” with a percentage of 31 % (68/219), and “ever wheeze” with a 
percentage of 30% (65/219). Both allergic phenotypes tend to manifest in the first 2 
years of life with 63% (41/65) of subjects developing early-onset wheeze and 85 % 
(58/68) of subjects developing early-onset of eczema. Overall a higher percentage of 
these early onset phenotypes are transient (wheeze: 63%, eczema 69%), with 
symptoms that remit by 5 years of age. 
 
Furthermore, of the early transient and early persistent wheeze phenotypes, only about 
20% of both phenotypes are categorized as frequent wheeze (wheeze >3 times) 





























Figure 3-3: Phenotypes of ‘ever wheeze’ and ‘ever eczema’ up till 5 years of age 
(A) The phenotypes of ‘ever wheeze’ were divided into ‘early and late wheeze’ 
and the ‘early wheeze’ were further divided into ‘persistent wheeze/frequent 
wheeze’ or ‘transient wheeze/transient frequent wheeze’. The subjects who were 
classified as ‘frequent wheeze’ were those who had 3 or more times episode of 
wheeze. (B) The phenotypes of ‘ever eczema’ were divided into ‘early and late 







































































3.3.5 Allergic disorders and allergen sensitization  
 In our cohort, the prevalence of allergic phenotypes associated to allergen 
sensitization was low in early life especially in subjects with eczema and wheeze, 
with only 32% of both the eczema (17/53) and wheeze (7/22) subjects at year 1 being 
sensitized to either dietary or inhalant allergens. Of the 2 subjects who developed 
rhinitis, allergen sensitization was present in only one subject (Figure 3-4). The 
percentage of allergen sensitization in all phenotypes remained almost the same at 
year 2 but increased significantly (p<0.05) at year 5 to 73% (19/26) for eczema, 79% 
(26/33) for wheeze and to 88% (29/33) for rhinitis (Figure 3-4). 
 
Table 3-2 shows the sensitization characteristics of the subjects in this cohort. By 1 
year, 22% (53/245) of the subjects had at least a positive skin prick test response to at 
least one allergen (dietary or inhalant) (Table 3-2). This decreased slightly to 19% 
(43/231) by year 2 and increased up to 2.7 times by year 5 to 51% (112/219). The 
highest sensitization rate to dietary allergens occurred at 1 year with subjects being 
sensitized mainly to egg white 5% (12/245) and egg yolk 3 % (3/245). Sensitization to 
these allergens decreased at year 2, with only 2% (5/231) of subjects sensitized to egg 
white and 0.4% (1/231) subjects sensitized to egg yolk. There were only 0.4% (1/231) 
of subjects sensitized to cow’s milk and soy, and 1.3 %( 3/231) who were also 
sensitized to peanut and shrimp allergens. At year 1 and year 2, house dust mite 
(HDM) allergen sensitization was the most common, with subjects at both years being 
nearly equally sensitized to HDM Dermatophagoides pteronyssinus at 15% (37/245)  
and 16% (37/231) at year 1 or 2 respectively. The prevalence of sensitization 
increased to 44% (97/219) at year 5. Subjects were least sensitized to house dust mite 
Blomia tropicalis at year 2 , and sensitization increased to 37% (81/219) at year 5 
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compared to [15% (37/245)] and [4.8% (11/231)] at year 1 and year 2 respectively. 
Overall, the sensitization data at 2 years and 5 years showed more subjects sensitized 
to house dust mite Dermatophagoides pteronyssinus compared to Blomia tropicalis 
[At 2 years, 16% (37/231)  versus 4.8%(11/231), and at 5 years 44% (97/219) versus 
37% (81/219) respectively ] . Skin prick tests for Dermatophagoides farinae were 
only done at year 5 and 42% (92/219) subjects were sensitized to this allergen (Table 
3-2). From here, we summarize that our cohort has higher sensitization to house dust 












*Comparison between the allergic disorders and sensitization at year 1 and year 5 ( p 
value < 0.05)  
# Comparison between the allergic disorders and sensitization at year 2 and year 5 ( p 
value < 0.05) 
 
Figure 3-4: The prevalence of allergen sensitization from year 1 to year 5. 
Prevalence of subjects who developed eczema, wheeze and rhinitis that are skin prick 
test positive to any dietary or inhalant allergen. All data was expressed as percentage 
with 95% confidence intervals with tables of the descriptive data presented below the 
graphs. 
Prevelance of sensitization 1 Year 2 Year 5 Year
95%(CI)
Eczema 32.1(0.21-0.45) 36.8(0.25-0.49) 73.1(0.54-0.86)
Wheeze 31.8(9.16-0.53) 25.9(0.13-0.45) 78.8(0.62-0.89)
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*One subject in year one was not assessed for dietary allergens 
and SPT was not done for one subject at 1 year. 
  
**SPT was not done for 2 subjects at 2 years due to refusal.   
*** SPT for egg white, fish was performed on only 2 subjects at 5 years. 
#SPT for egg yolk, soy and shrimp was performed on only 1 subject at 5 years. 
† SPT for peanut was performed on only 3 subjects at 5 years. 
 
3.3.6 Association of allergen sensitization to allergic phenotypes at 2 and 5 years 
of age 
 Table 3-3 presents the odds ratio and 95% CI of the univariate and multivariate 
analysis showing the association of allergen sensitization with the manifestation of 
allergic phenotypes at the first 2 years of life and at 5 years. The variable of interest 
which is allergen sensitization has been adjusted with other co-variates at 2 years 
1 year old *  2 year old ** 5 year old *** # †
n=245 n=231 n=219
Allergen sensitization (%)
Positive skin prick test ( any) 53(22%) 43(19%) 112(51%)
Dermatophagoides pteronyssinus 37(15%) 37(16%) 97(44%)
Blomia tropicalis 37(15%) 11(4.8%) 81(37%)
Dermatophagoides farinae Not done Not done 92(42%)
Cow's milk 0 1(0.4%) Not Done
Egg white 12(5%) 5(2%) 1(0.5%)
Egg Yolk 8(3%) 1(0.4%) 0
Soy 0 1(0.4%) 1(0.5%)
Peanut Not done 3(1.3%) 1(0.5%)
Shrimp Not done 3(1.3%) 1(0.5%)
Fish Not done Not done 1(0.5%)
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(data not shown) and at 5 years (Table 3-1) selected based on a p value of less than 
0.1.  Only eczema was associated to allergen sensitization in the first 2 years of life 
after adjustment for potential confounding factors (adjusted OR, 1.94; 95% CI 1.03-
3.62), but not wheeze (Table 3-3). The number of subjects with early manifestation of 
allergic rhinitis were too few (n=5) to carry out any statistical analysis.  
 
However, at year 5 all the allergic phenotypes were significantly associated to 
allergen sensitization in the unadjusted analysis (Table 3-3). However only wheeze 
(adjusted OR, 3.39; 95% CI, 1.33-8.64) and rhinitis (adjusted OR, 8.95; 95% CI, 2.84-
28.2) maintained significant associations after adjustments were made in the 
multivariate logistic regression analysis but not eczema (Table 3-3). From the skin 
prick test results in Table 3-2, we can conclude that the association seen between 
allergen sensitization to the allergic phenotypes at both year 2 and 5 are mainly due a 




Table 3-3:  Summary data between allergen sensitization and allergic phenotypes at 2 









Only the variables of interest (allergen sensitization) are presented in Table 3-2 
*Variables included into the logistic regression were gestational age, total IgE in one 
year and paternal eczema 
** Variables included into the logistic regression model were probiotic 
supplementation , sibling allergic rhinitis  
#Wheeze was not associated to sensitization in the univariate analysis therefore 
further adjustment in the logistic regression was not made. 
## Variables included into the logistic regression were gender, total IgE at 1 year  
^ Variables included into the logistic regression were paternal allergic rhinitis, 




3.3.7 Progression of early allergic phenotypes up to 5 years of age 
3.3.7.1. Progression of early allergic phenotypes  
The progression of early manifestation of allergen sensitization, eczema and wheeze 
in the first 2 years of life up to 5 years of age was shown in Figure 3-5 (A-C). Up till 
year 5, 76 subjects developed allergen sensitization at age of 1 and 2 years and 60.8% 
of these subjects remained allergen sensitized at 5 years of age. Subsequently, of 
subjects with no allergen sensitization in the first 2 years of life, 53.8% developed late 
onset allergen sensitization only at 5 years of age (Figure 3-5A). There were 
35/76(46%) subjects with allergen sensitization but with no concomitant clinical 
manifestation of allergic phenotypes. 
 
The eczema phenotype in this cohort developed mainly in the first 2 years of life [85 
% (58/68)] (Figure 3-5B).  Following the course of eczema from age of < 2 years, 60 
% (35/58) were in complete remission after 2 years while only 21 %( 12/58) 
persisting up to 5 years of age. An intermittent pattern of eczema up to age 5 was 
observed of 19% of the subjects with early eczema (Figure 3-5B). 
 
Similar to eczema, wheeze phenotypes that mainly developed in the first 2 years of 
life [63 %( 41/65)] also tend to be transit with half 51 %( 21/41) of the subjects in 
complete remission after the age of 2. Only 17 %( 7/41) had symptoms that persisted 


















Figure 3-5 (A-C): Course of allergen sensitization, eczema and wheeze from to 2 
years to 5 years of age. Each symbol represents one subject from the cohort with 
early eczema (n = 58), wheeze (n = 41) or allergen sensitization (n = 76) and the 
natural course of each subject was traced vertically. Black squares represent subjects 
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3.3.7.2 Association of risk factors at 2 years and clinical phenotype outcomes at 5 
years. 
We wanted to study how early eczema and wheeze phenotypes in the first 2 years of 
life and the presence of allergen sensitization  relate to the outcome of the subsequent 
allergic phenotypes at 5 years ( as described in section 3.2.2,page 40).  
 
To study the association of allergen sensitization and eczema in the first 2 years of life 
to eczema at age 5 years, a 2-level variable was formed using these 2 risk factors to 
categorize the risk groups of interest into 4 groups (Table 3-4).  From here, we found 
that early onset allergen sensitization alone was not found to be a significant risk 
factor for eczema at 5 years of age. Instead, early eczema alone (adjusted OR, 5.00; 
95% CI 1.33-18.8) or subjects with early eczema and concomitant allergen 
sensitization (adjusted OR, 13.5; 95% CI 3.97-45.5) were more likely to have eczema 
at 5 years of age (Table 3-4). 
 
Table 3-4 presents the risk for wheeze at 5 years of age after using a 3-level variable 
to categorize the risk groups of interest into 8 groups according to the phenotypes of 
eczema, wheeze and allergen sensitization in the first 2 years of life. The multivariate 
analysis of the different sub-groups of phenotypes show us that neither early eczema 
nor early sensitization per se constituted an increased risk to subsequent wheeze at 5 
years. Instead early onset wheeze (adjusted OR, 4.34; 95%CI, 1.26-14.9) or early 
onset wheeze with concomitant early onset allergen sensitization (adjusted OR, 7.17; 
95%CI, 1.51-34.2) or eczema, wheeze and allergen sensitization co-existing together 
(adjusted OR, 9.24; 95%CI, 1.76-48.5) were associated with subsequent of wheeze at 
5 years of age. Additionally, subjects with early eczema only (adjusted OR, 4.00; 95% 
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CI, 1.20-13.1) were associated to subsequent risk for rhinitis at 5 years of age (Table 
3-4). 
Interestingly, the effect of eczema and wheeze alone as a risk factor to subsequent 
development of these allergic disorders at 5 years of age were independent of 
concurrent allergen sensitization.  
 
Table 3-4: Allergic phenotypes and allergen sensitization in association to 5 year 
outcomes with unadjusted and adjusted *ORs and 95% CIs for current eczema, 









Only the variables of interest allergic phenotypes and allergen sensitization in the first 
2 years of life were presented in Table 3-3 above with statistically significant 
variables ( p < 0.05) highlighted in bold. 
*Adjusted for the other variables in the table that were selected based on the 
univariate analysis and a  p value <0.1.  
** Variables included into the logistic regression model were probiotic 
supplementation, sibling allergic rhinitis  
# Variables included into the logistic regression were gender, total IgE at 1 year  
^ Variables included into the logistic regression were paternal allergic rhinitis, 





In this at risk for atopy birth cohort, we studied the manifestations and progression of 
atopic disorders (eczema and wheeze) and allergen sensitization till 5 years of age. 
Our definition of early onset eczema or wheeze was based on onset within the first 2 
years of life. This is a frequently used time span for the definition of early 
manifestation of allergic disorders in other studies (144-146), and comprises the age 
group with the peak prevalence of eczema and wheeze in Singapore (147).  
 
In this birth cohort, eczema cases were mostly diagnosed in the first 2 years of life 
and were associated with low prevalence of allergen sensitization. Furthermore, 85% 
of the subjects with early onset eczema outgrew their symptoms by 3 years of age. 
The Danish Allergy Research Centre (DARC) cohort reported that the prevalence of 
eczema cases in their cohort peaked at an early age of 10 months and the prevalence 
decreased at 36 and 76 months to slightly below 7% (148), which was similar to what 
was observed in our study cohort . The Prevention of Atopy among Children in 
Trondheim (PACT) study in Norway has also shown that the point prevalence of 
eczema in their cohort peaked at 2 years of age with a percentage of 16.5% (144), and 
this percentage subsequently decreased with age (149). Furthermore, the German 
Multicenter Atopy Study (MAS) reported that the peak prevalence of atopic 
dermatitis in their cohort was at 2 years of age at 21.5%, and only 20% of these had 
persistent eczema up to age 7 years. They have also found that the association of 
atopic sensitization and atopic dermatitis was strongest in early life at the first year of 
life (145). This observation also agrees with our study which has shown that despite 
the low prevalence of eczema with allergen sensitization at 2 years compared to 5 
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years of age, the logistic regression revealed that eczema was more strongly 
associated with allergen sensitization at 2 years rather than at 5 years of age (Table 
3.3). 
 
The early phenotypes of wheeze in our cohort started as transient wheeze with only 
about 20% of these wheezers being frequent wheezers. However, by 5 years of age, 
all the subjects who were persistent wheeze had frequent wheeze. At year 3, 63% of 
early wheezers have outgrown their symptoms. The prevalence of asthma symptoms 
such as frequent wheeze is more likely to increase with age. As reported by a Swedish 
cohort, 33% of the children in their birth  cohort developed asthma before the age of 
1.5 years but 50% developed asthma later on in life by age 3 years (146). 
Furthermore, a proportion of early wheeze in the first 2 years of life is transient and 
not found to be associated with sensitization or with asthma or allergies later in life, 
but instead with reduced airway size or viral infections in infancy (21) .  
 
We have also shown the progression of allergen sensitization in this cohort with age. 
The prevalence of allergic sensitization to at least one of the dietary or inhalant 
allergens increased from 22% at 1 year to 51% at 5 years. This increase was mainly in 
inhalant allergens. In our cohort, sensitization to dietary allergens especially egg 
white and egg yolk were present at 1 year but waned by 5 years of age. Whereas 
sensitization to aeroallergens Dermatophagoides pteronyssinus and Blomia tropicalis 
increased from year 1(15% respectively) to year 5 (44% and 37% respectively). This 
observation is out of keeping with a classical” atopic march’ as our earliest skin 
testing at age 1 year has already identified predominance of aeroallergen over food 
sensitization. The pattern of allergen sensitization reported by the Multicenter Allergy 
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Study (MAS) birth cohort shows an annual decrease in incidence rates of sensitization 
to food allergens from 10% at 1 year of age to 3% at the 6 years of age, but an 
increased sensitization to inhalant allergens with age (from 1.5% at 1 year to 8% at 6 
years) (150). Furthermore, a study by Rhodes et al. based on a birth cohort in England 
reported that sensitization to food allergens started as early as 6 months, and the 
numbers with food sensitization decreased by 2 years while sensitization to 
aeroallergens began at 1 year of age (151).  
 
We found that sensitization alone in the first 2 years of life was not a significant risk 
factor for eczema at 5 years, but instead was associated with early onset of eczema, 
and early eczema together with early sensitization. We might not have been able to 
show that sensitization alone precedes the development of eczema, but we cannot rule 
out that sensitization still has a role to play if it is present concomitantly with eczema. 
Due to the low sensitization rate to dietary allergens in this study, we can conclude 
that subjects sensitized in this cohort were mainly contributed by the sensitization to 
house dust mites allergens. A study based in Singapore has reported that indeed  
patients with eczema were more sensitized to a panel of common dust mite allergens 
Dermatophagoides pteronyssinus (Der p) and Blomia tropicalis (Blo t) (152) . In 
support of our observations was a study by Harris et al . who reported  no clear linear 
associations between early exposure to house dust mite or cat allergens to the 
subsequent risk of eczema at 8 years of age (153).Furthermore, the Study of 
Prevention of Allergy in Children in Europe has failed to show any associations 
between the house dust mite exposure in children with the development of eczema by 
24 months (57).  Interestingly, The German Infant Nutritional Intervention (GINI) 
study reports that aeroallergen sensitization alone  in the first year of life without 
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eczema in the first year of life was not a risk factor for later eczema at 6 years (154).  
This observation is similar to our study and points to the fact that the early eczema 
phenotype plays an important role along with allergen sensitization as a co-factor for 
the risk of subsequent eczema.  
 
Other studies have reported a strong association between early sensitization to foods 
and development of allergic disorders. The Multicenter Allergy Study (MAS) 
reported that children sensitized to hen’s egg at 1 year developed atopic eczema more 
frequently than those without (39.7% versus 10.8% respectively) (155). While another 
study has reported that milk and peanut allergy by age 1 year was associated with a 
greater risk of asthma development by 7 years of age (156). We did not see a similar 
association in this study, possibly due to the small numbers from the low sensitization 
to dietary allergens in our study at <5% at 1 year and 2 years of age.  
 
Early eczema alone in the first 2 years of life was also significantly associated to the 
outcome of rhinitis at 5 years of age but not wheeze. Typically, early eczema precedes 
the development of aeroallergen mediated airway disorders rhinitis and asthma in 
progression of allergic disorders termed the “atopic march” (37). In our study, we did 
not see the association of early eczema nor early sensitization alone with wheeze at 5 
years. The progression of the development of eczema and wheeze in our cohort as 
well the multivariate analysis showed us that childhood wheeze began concurrently 
with eczema in the first 2 years of life rather than as a sequel.  
 
 The multivariate regression analysis showed us that wheeze alone, or eczema and 
wheeze as well as wheeze and allergen sensitization present concomitantly at 2 years 
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leads to subsequent wheeze at 5 years. Interestingly, house dust mite sensitization at 2 
years did not seem to be a main risk factor for the outcome of wheeze in our study 
unlike other reported studies (157, 158). Early wheeze in the first 2 years of life was 
associated with subsequent wheeze at 5 years which is not surprising as  it has been 
shown that a proportion of those who develop wheeze in early life are more likely to 
continue wheezing later on in life (159). Yet, we cannot rule out the role of early 
sensitization, as the phenotype of wheeze together with allergen sensitization still 
contributes to the risk for wheeze at 5 years.  
 
Our results however, were very similar to the German Multicenter Atopy Study 
(MAS). This cohort has reported that eczema alone without any co-factors is not a 
risk factor for wheeze. Instead, early wheeze and allergen sensitization at 2 years were 
the main risk factors that contributed to the outcome of wheeze at 7 years of age. In 
further agreement with our study was their report that children with early eczema and 
concomitant wheeze contributed to higher risk for subsequent wheeze (145).  
 
The German MAS birth cohort has also reported that eczema before the age of 2 years 
was found to be a significant risk factor for the development of seasonal allergic 
rhinitis by 7 years of age (160). This report agrees with the observation in our study of 
eczema at 2 years being a risk factor for subsequent rhinitis at 5 years of age.  
 
Given the multifactorial etiology of both eczema and wheeze, it is likely that 
environmental and genetic factors play a prominent role on the outcome of these 
allergic phenotypes aside from allergen sensitization. Most children are infected by 
respiratory syncytial virus (RSV) before age of 2 years and develop non-atopic 
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wheezing which are  transient wheezing phenotypes that disappear by the age of 3 
years (21). The early wheezers in this cohort are most likely triggered by viral 
infection and lose their symptoms by 5 years of age and are hence independent of pre-
existent allergen sensitization at 2 years. Genetic factors such as a common loss of 
function mutations within the filaggrin gene are independent risk factors for the 
development eczema. Interestingly, a study by Weidinger et al. has found that the 
association of filaggrin mutations with asthma was restricted to asthma occurring in 
the context of eczema (161), which further supports the study by Illi et al.  indicating 
co-manifestation of early eczema and wheeze rather than a progressive atopic march 
(145). 
 
In conclusion, eczema was associated to allergen sensitization at 2 years of age but 
not wheeze. At 5 years of age, wheeze was significantly associated to allergen 
sensitization but not in eczema subjects. However, allergen sensitization per se at 2 
years does not contribute to the risk of allergic disorders; instead it is important for 
early allergen sensitization to be present concomitantly with its allergic phenotypes as 
co-factors. From here, the findings from this study conclude that early allergic 
phenotypes of eczema and wheeze precede the development of allergen sensitization 





Chapter 4: Optimizing in vitro cell culture experiments with cord blood 
mononuclear cells in serum-free medium. 
 
4.1 Introduction  
 Serum supplementation using fetal calf serum (FCS) in cell culture medium has been 
a main choice for many cord blood studies (97, 102, 162, 163).  Fewer studies have 
chosen to work with serum-free AIM-V medium in cell cultures with peripheral blood 
mononuclear cells (PBMCs) (164) or with cord blood mononuclear cells (CBMCs) 
(165). AIM-V serum free medium has been deemed a poor choice for detecting 
cytokine production in mononuclear cells especially with LPS as a stimulus due to the 
lack of carriers like soluble CD14 and LPS binding protein that are normally present 
in serum (166) . Cells tend to be unresponsive to low LPS concentrations using the 
AIM-V serum free medium and by contrast there is a sensitivity threshold of 0.1-1.0 
ug/mL in the culture containing serum-supplemented media (164). 
 
AIM-V medium has human serum albumin as an additive in its media formulation 
unlike RPMI-1640 which avoids the need for further supplementation of fetal calf 
serum into the media (167). The use of human serum is still recommended over serum 
from other species, as human T cells may have unexpected reactivity with xeno-
proteins present in fetal calf serum (167). It was also reported that between RPMI and 
AIM-V media, PBMCs isolated freshly from healthy donors and stimulated in AIM-V 
serum-free medium yielded higher (2·4-fold) antigen-specific signals in IFN-γ 
ELISPOTS upon challenge with low-dose HLA-A2-restricted viral peptides, 




Furthermore, including fetal calf serum into cell culture medium can lead to 
variability and suboptimal assay performance. It is known that batches of serum from 
the same manufacturer can differ widely in performance due to non-specific 
activation of T cells or suppression of antigen –specific responses. This batch to batch 
variation can lead to inconsistent assay results (169). Serum-free media eliminates 
much of this variability as they are highly standardized, and contain identical 
components in every lot, furthermore they do not share mitogenic or suppressive 
factors which can potentially be found in fetal calf serum (169).  
 
Due to problems arising with the use of serum supplemented culture media, 
preliminary experiments were carried out in serum-free AIM-V medium in the 
presence of  stimuli lipopolysaccharide (LPS) (89, 102) and 
phytohaemagglutinin(PHA) (162, 170) in order to determine its feasibility for 
subsequent use in the evaluation of CBMC immune responses in the birth cohort 
described in this thesis. 
 
Numerous studies have probed the importance of TLR4 signaling in allergic 
inflammation (171-173) where it functions as a receptor of the innate immune system 
involving the ligand   lipopolysaccharide (LPS) (62). Stimulation of  professional 
antigen presenting cell Toll-like receptors (TLRs) by microbial products such as LPS 
lead to the activation of signaling pathways that result in the induction of 
inflammatory cytokines as well as chemokines (62). The LPS stimulus will be used in 
future experiments to target specifically cells such as the monocytes , macrophages, 
dendritic cells and B cells – the professional antigen presenting cells (174) . 
Phytohaemagglutinin (PHA) which is used as  a potent mitogen for mononuclear cells 
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is capable of inducing the production of cytokines from monocytes as well as naive T 
cells in cord blood mononuclear cells (175). 
 
Using LPS and PHA as stimuli for CBMCs, experiments were conducted in serum-
free AIM-V medium to study cytokine responses and to establish the optimal cell 
culture conditions for future studies. 
 
4.2 Materials and methods  
4.2.1 Preparation and storage of cord blood mononuclear cells (CBMCs) and 
peripheral blood mononuclear cells (PBMC).  
Preliminary experiments were carried out to establish specific cell culture conditions 
to study immune responses of the cord blood mononuclear cells. Umbilical cord blood 
was harvested into blood bags (Terumo, Somerset, USA) containing heparin and 
RPMI medium 1640 (Gibco Life Technology, Grand Island, NY, USA) and processed 
within 12 hours from time of harvesting. Peripheral blood was drawn from adults 
using a BD Vacutainer® Glass tube containing sodium heparin (BD Diagnostics, 
Franklin Lakes, NJ, and USA). The method of processing and storage of PBMCs was 
similar to that of CBMCs (Methods described in Section 2.4, page35). 
 
4.2.2 Stimulation of cord blood cells with lipopolysaccharide (LPS) and 
phytohaemagglutinin (PHA) for dosage and kinetic studies 
After thawing, CBMCs or PBMCs were plated in 96-well BD Falcon™ U-Bottom 
Plates (BD Diagnostics ) in triplicates at 2 × 105 viable cells/well in 200 μl serum-free  
AIM-V medium (Gibco Life Technology). Cells were cultured with LPS (Escherichia 
coli LPS 0111:B4, Sigma ,St. Louis, MO) from a concentration of 0- 100,000ng/mL 
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,or phytohaemagglutinin (PHA) purchased from Sigma (St. Louis, MO,USA)  from a 
concentration of 0 – 5µg/mL for 24 hours or 48 hours  at 37°C in 5% CO2.  The 
culture supernatants were harvested and stored at -80˚C.  
 
4.2.3 Cytokine protein detection  
4.2.3.1 Fluorescence activated cell sorter (FACS) –Array (Becton Dickinson) 
The BD Cytometric Bead Array (CBA) Human Soluble Protein Flex Set (BD 
Biosciences, San Jose, CA, USA) assay was used instead of the conventional 
Enzyme-linked immunosorbent assay (ELISA).  This assay system allows for 
multiplexed analysis of multiple proteins from a single sample using less time and 
less amount of sample. The human flex set standards were first prepared by pooling 
lyophilized standards from each BD CBA Human Soluble Protein Flex Set into a 
15mL centrifuge tube. The standards were then reconstituted with 2mL of Assay 
Diluent provided. The reconstituted standards were allowed to equilibrate for at least 
15 minutes at room temperature. A 10 time’s serial dilution was then performed to 
prepare standards from a concentration ranging from 0pg/mL-5000pg/mL. Next, the 
total volume of Capture Beads needed for the experiment was prepared according the 
manufacturer’s instructions. The cell culture supernatants to be assayed were 
transferred to appropriate assay tubes containing Capture Beads and incubated for one 
hour. Lastly, the PE Detection reagent was prepared according to the manufacturer’s 
instructions and added into the assay tubes containing the Capture Beads and 
supernatant samples and incubated for 2 hours. The assay tubes were then washed 
with the wash buffer provided, and finally 300µL of wash buffer was added into the 
assay tubes before the samples were acquired using the fluorescence activated cell 
sorter (FACS) –Array. Cytokine profiles of cytokines IFN-γ , IL-12p70 , IL-1β, IL-
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10, IL-2 ,IL-5 , IL-13, IL-6,IL-8 and TNF-α were analyzed by fluorescence activated 
cell sorter (FACS) –Array (BD Biosciences) After the samples were acquired, the BD 
FCAP Array software was used to analyze the data. The detection limit for each 
cytokine in this study was at 10pg/mL.  
 
4.2.4 Comparison of cell culture conditions 
Heaton et al. has reported that mononuclear cells tend to be unresponsive to certain 
concentrations of LPS in the serum-free AIM-V culture system (164). Experiments 
were conducted to compare the cytokine responses of LPS stimulated CBMCs in 3 
different and most commonly used cell culture conditions in cord blood studies. This 
was done to determine the threshold concentration of LPS at which CBMCs begin to 
respond in the serum-free AIM-V condition. This was compared with those of other 
serum supplemented media conditions. Cytokines IL-6, IL-8 and TNF-α were 
measured from 3 individual CBMCs. 
 
4.2.4.1 Cell culture of CBMC in serum-free AIM-V medium 
2 x 105 cells were cultured in 200μl serum-free AIM-V medium in the presence of 
lipopolysaccharide (LPS) at concentrations ranging from 0-1000ng/mL for 24 hours 
in a 5% CO2 atmosphere incubator (HERAcell, Thermo Scientific, MA, USA). 
 
4.2.4.2. Cell culture of CBMC in RPMI media supplemented with fetal calf 
serum (FCS) 
2 x 105 cells were cultured in 200μl complete RPMI 1640 medium with 10% FCS, in 
the presence of lipopolysachharide (LPS) at concentrations ranging from 0-




4.2.4.3 Cell culture of CBMC with the recombinant IFN-γ ( rIFN-γ) priming  
2 x 105 cells were cultured in 10ng/mL rIFN-gamma (BD Pharmigen, San Diego, CA, 
USA) for 3 hours to prime cells before the addition of lipopolysachharide (LPS) at 
concentrations ranging from 0-1000ng/mL in  200μl complete RPMI  medium (RP10) 
+ 10% FCS for 24 hours in a 5% CO2 atmosphere incubator.  
 
4.2.5 Polymyxin B and TLR4 blocking experiment 
Heaton et al. reported that mononuclear cells have poor responses to LPS due to the 
lack of carriers like soluble CD14 and LPS binding protein that are normally present 
in serum (164). However, the mononuclear cells should still be able to respond to LPS 
that bind directly to the cell surface TLR4 (173). For assessing the role of TLR4 in 
inducing cytokine production from LPS stimulated CBMCs, biochemical and 
immunologic approaches were used. Firstly, 2 x 10 5 cells were incubated with 
100ng/mL or 1µg/mL of LPS with or without polymyxin B (10µg/mL) (Sigma, St. 
Louis, MO, USA), for 24 hours as a negative control in a total of 200 µl AIM-V. 
Secondly, to assess the effects of blocking the co-receptor for LPS  which is Toll-
Like-Receptor (TLR)4 (Clone HTA 125) (eBioscience, San Diego, CA, USA) ,          
2 x 105 cells were incubated for 15 minutes with or without  monoclonal antibody 
against TLR4  (10µg/mL) before stimulation with 100ngmL or 1µg/mL LPS in a total 
of 200µl AIM-V . Cytokine production of IL-6, IL-8 and TNF-α were analyzed by 






4.2.6 Statistical analysis 
The Mann-Whitney U test was used to calculate the significant difference between 
culture conditions  using the SPSS software version 16.0 for windows (SPSS, Inc. 
Chicago III, and USA). P Values of p ≤ 0.05 were considered statistically significant. 
 
4.3 Results  
4.3.1 Lipopolysaccharide (LPS) stimulated CBMC cytokine response in serum 
free AIM-V medium compared to RPMI-serum supplemented media. 
Before undertaking the main study, potential effects of different culture conditions 
that are normally used in the study of CBMCs on the levels of cytokine production 
were assessed using 3 individual cord blood collected from full-term neonates of 
representative subjects. Individual CBMC samples were cultured for 24 hours in the 
presence of increasing  concentrations of LPS (0– 1000ng/mL) in serum-free AIM-V 
medium, RPMI medium supplemented with 10% fetal calf serum or RPMI medium 
supplemented with 10% fetal calf serum with cells pre-primed with rIFN-γ . The 
levels of IL-6, IL-8 and TNF-α were the cytokine readouts from this set of 
experiments (Figure 4-1). 
 
It was noted that in serum-free AIM-V medium the CBMCs are generally insensitive 
to LPS concentrations below 100 ng/mL, seen by the very low or nearly no 
production of cytokines. By contrast, cultures containing FCS-supplemented medium 
and cultures that were pre-primed with rIFN-γ responded to LPS concentrations as 
low as 0.1ng/mL. Overall, it was noted that there was a greater magnitude of cytokine 
concentration levels induced in the FCS-supplemented medium as well as cultures 
pre-primed with rIFN-γ and supplemented with serum compared to the serum-free 
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condition (Figure 4-1). However, in the serum-free AIM-V medium, the cells started 
to respond in a dose dependent manner from a concentration of 10ng/mL as seen with 
the IL-8 production. Due to the known disadvantages of using serum in cell culture 
medium, it was decided that the most suitable culture conditions for CBMC studies in 
this thesis was serum- free AIM-V culture medium. The higher concentration of LPS 
used in serum-free medium conditions as cord blood studies have conducted their cell 
cultures using concentrations of at least 10ng/mL (102) or 100ng/mL even in serum-
supplemented conditions (89). 
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Figure 4-1: Individual CBMCs cultured in different cell culture media to study
cytokine responses. Individual CBMC samples were cultured for 24 hours in the
presence of varying concentrations of LPS, in serum-free AIM-V medium , in RPMI
medium supplemented with 10% fetal calf serum or RPMI with 10% fetal calf serum
and cells that were pre-primed with recombinant IFN-γ. Results were presented as
mean + and standard deviation of triplicate measurements.
rIFN-γ pre-priming
in RPMI and 10%
FCS




















































































































































































4.3.2 Kinetic and dosage response of lipopolysaccharide (LPS) stimulated 
cytokine production from cord blood mononuclear cells in the serum-free AIM-
V medium 
To further evaluate the kinetic responses, a titration curve was performed using a 
wider concentration range of LPS concentrations (0-100,000 ng/mL).  A wider panel 
of cytokine responses (IL-1β, IL-6, and TNF-α, IL-10, IL-2, IL-5, IL-13, IFN-γ and 
IL-12p70) was also studied to determine the optimum concentration and time point 
for supernatant harvesting (Figure 4-2). Measurable amounts of cytokine were 
secreted starting from a concentration of 100ng/mL of LPS for cytokines IL-1β, IL-6, 
and TNF-α and IL-10. 
 
Lower concentrations of LPS only elicited baseline levels of cytokine production. 
There was a clear dose dependent effect seen for cytokine IL1-β at both 24 hours and 
48 hours of culture. The TNF-α production at 24 hours peaked at 100ng/mL and 
gradually dropped until the concentration of 10,000ng/mL before increasing again at 
100,000ng/mL. The levels of IL-6 seemed to have reached a plateau at 100ng/mL, and 
increasing doses of LPS did not further increase the amount of IL-6 secreted at both 
24 hours and 48 hours of culture. The IL-10 production gradually increased from 
100ng/mL to peak at 10,000ng/mL before dropping at 100,000ng/mL. The TNF-α 
level was significantly higher at 24 hours compared to the 48 hour time point at LPS 
concentrations 100 -10,000 ng/mL. Similarly, IL-1β and IL-10 levels were 
significantly higher at the 24 hour time point at concentrations 100-1000ng/mL and 




Overall, the optimum concentration for future in vitro cultures was set at 1000ng/mL 
and cell culture time point at 24 hours. Cytokines IL-12p70, including T-cell 
cytokines IL-2, IL-5, IL-13 and IFN-γ were secreted at very low levels when 











Figure 4-2: Kinetic and dosage response curves of lipopolysaccharide (LPS) 
stimulated cord blood mononuclear cells (CBMCs). CBMCs were plated in 96-
well round-bottom cell-culture plates in triplicates at 2 × 105 viable cells/well in 200 
μl of serum-free AIM-V medium. LPS stimulation was done at concentrations ranging 
from 0 to 100,000 ng/mL. Culture supernatants were harvested at 24 and 48 hours and 
cytokines IL-1β, TNF-α, IL-6 and IL-10 were measured. Data is expressed as mean ± 
standard deviation of triplicate measurements, black boxes indicate the 24 time point 
and white boxes the 48 hour time point. An asterisk indicates a P value of <0.05 of 
the differences between the 24 hour and 48 hour time point.  
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4.3.3 Kinetics and dosage responses of phytohaemagglutinin (PHA) stimulated 
cytokine production from cord blood mononuclear cells in the serum-free     
AIM-V medium 
Next the cytokine production of IL-2, IL-5, IL-6, IL-8, IL-10, IL-13, IFN-γ, and TNF-
α from CBMCs stimulated with various concentrations of PHA in serum-free AIM-V 
medium was studied. This was done to determine the optimal PHA dosage and time 
point to harvest supernatants for the following experiments in this study. All the 
cytokine levels were significantly higher at a time point of 48 hours as compared to 
24 hours at the PHA concentration of 5 µg/mL except for IL-8 (Figure 4-3). The 
production of IL-8 appears to be more sensitive to the PHA stimulation thus eliciting 
a plateau response at 24 hours at high PHA concentrations of 2.5 µg/mL and 5 
µg/mL. The cytokine readouts in Figure 4-3 at 48 hours show that a PHA 
concentration of 5 µg/mL induced the highest levels of cytokine responses for all 
cytokines measured in this cohort except for IL-10 where the cytokine concentrations 
peak at 2.5 µg/mL.   
 
In summary, based on these findings AIM-V serum-free medium with  a PHA 
concentration of 5 µg/mL and a time point of 48 hours for supernatant harvesting was 
















Figure 4-3: Kinetic and dosage response curves of phytohaemagglutinin (PHA) 
stimulated cord blood mononuclear cells (CBMCs). CBMCs were plated in 96-
well round-bottom cell-culture plates in triplicates at 2 × 105 viable cells/well in 200 
μl of AIM-V medium and PHA stimulation was done at concentrations ranging from 
0 to 5 μg/mL (0, 0.1, 0.5, 1, 2.5 and 5 μg/mL). Culture supernatants were harvested at 
24 and 48 hours and cytokines IL-2, IL-5, IL-6, IL-8, IL-10, IL-13, IFN-γ and TNF-α 
were measured. Data are expressed as mean ± standard deviation of triplicate 
measurements, black boxes indicate the 24 time point and white boxes the 48 hour 
time point. An asterisk indicates a P value of <0.05 of the differences between the 24 
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4.3.4 Comparison of cytokine secretion profiles between cord blood mononuclear 
cells (CBMCs) and peripheral blood mononuclear cells (PBMCs) in the AIM-V 
serum free medium. 
The literature reports that overall, PBMC is able to respond better than cord blood 
mononuclear cells to stimuli in terms of T-cell cytokine production (176) . In some 
cases CBMCs are able to respond as well as PBMCs in the secretion of innate pro-
inflammatory cytokines (177). Figure 4.4 shows a comparison of the cytokine 
production capacity for CBMCs and PBMCs stimulated with LPS at 24 hours and 
PHA at 48 hours in AIM-V serum free cell culture media. At a concentration of 100-
10,000ng/mL of LPS, CBMCs have shown an overall capacity to produce higher 
levels of TNF-α and IL-6 compared to PBMCs. PBMCs produced more IL-10 than 
CBMCs at a concentration of 100ng/mL onwards while at these concentrations 
CBMCs showed similar capacity to PBMCs in producing cytokine IL-1β. Overall, the 
cytokines IL-2, IL-5, TNF-α and IL-6 stimulated by phytohaemagglutnin (PHA) 
showed higher cytokine productions from the PBMCs compared to the CBMCs with 
significant differences for all cytokines at PHA concentrations of 5ug/mL. 
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Figure 4-4: Dosage response curves of cytokine responses from
lipopolysaccharides (LPS) and phytohaemagglutinin (PHA) stimulated cord
blood mononuclear cells (CBMCs) and peripheral blood mononuclear cells
(PBMCs). Data are expressed as mean ± standard deviation of triplicate
measurements, black boxes indicate PBMC and white boxes indicate CBMC. An
asterisk indicates a P value of <0.05 of the differences between the CBMC and the
PBMC cytokine responses.
Peripheral blood mononuclear cells (PBMC)














































































































4.3.5. Inhibition of lipopolysaccharide (LPS) stimulated cytokine production by 
polymyxin B and anti-TLR4 antibody.  
It has been reported that serum or at least recombinant soluble CD14 is needed in 
serum-free media to mediate an LPS induced secretion of cytokines (166). 
Experiments were conducted to show that even though AIM-V medium is free of 
carriers such as sCD14 and LPS-binding protein which are present in serum (164) , 
the cells can rely on the interaction between LPS and the TLR4 on the cell surface to 
activate an inflammatory response directly through TLR4 (178). Figure 4-5 shows the 
results of LPS cytokine responses after incubation with TLR-4 blocking antibody. 
This was done by blocking the TLR4 dependent LPS responses with a TLR-4 
blocking antibody. Anti-TLR4 (10ug/mL) antibody inhibited LPS stimulated 
cytokines IL-6, TNF-α and IL-8 at 100ng/mL LPS by 92%, 84% and 100% 
respectively while cytokines stimulated at 1ug/mL LPS were nearly abolished when 
















Figure 4-5 : Inhibition of LPS  at 100ng/mL LPS and 1ug/mL LPS using 
polymyxin B ( 10ug/mL) or anti- TLR4 blocking antibody ( 10ug/mL) and 
cytokine production of IL-6 , TNF-α and IL-8 were measured from culture 
supernatants harvested at 24 hours.  Data are expressed as mean ± standard 
deviation of triplicate measurements were measured using the FACS Array. Data are 
expressed as mean ± standard deviation of three representative CBMC samples from 
each group. An asterisk indicates a P value of <0.05 of the differences between the 
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4.4 Discussion  
Based on the results of kinetic and dose response studies of LPS stimulated CBMCs, 
the concentration of 1ug/mL and a time point at 24 hours were shown to be the 
optimal conditions for evaluating cytokine responses. Previous cord blood studies 
using LPS as a stimulus have used concentrations varying from 10ng/mL (102), 
100ng/mL (89) to 1ug/mL (179). Despite the varying concentrations of LPS used, the 
cell culture supernatant harvested for cytokine assay have been uniform at 24 hours. 
In the serum-free culture condition, no T-cell cytokine (IL-2, IL-5, IL-13, and IFN-γ) 
nor cytokine IL-12p70 was produced via stimulation of CBMCs with LPS.  This 
observation was similar to the one of Jansky et al. who reported that LPS stimulated 
human PBMCs released very low levels of IFN-γ and IL-12 compared to significant 
increases of cytokines IL1-β , TNF-α and IL-6 (180), proving that monocytes, 
macrophages and B cells are the main cell types activated by LPS (174). PHA as non-
specific mitogenic stimulus was used to study the production of cytokine from naïve 
T-cells in cord blood. The concentration of PHA as stimulus was set at 5ug/mL and 
the time point for supernatant harvesting at 48 hours for future experiments was based 
on the PHA titration and kinetic study. A concentration of 5ug/mL of PHA (181) and 
1ug/mL of PHA (102, 106, 170) have been used in previous studies with optimal time 
for harvesting supernatant set at 48hours.  
 
Other studies have used similar doses of LPS (179) and PHA (181) to conduct their 
CBMC studies and harvest their supernatants. However, optimal doses used by other 
studies which differ from this study (89, 102, 170) could due to the difference in cell 
culture media used (102, 181). Furthermore, this study includes a more extensive 
panel of cytokines compared to other studies (102, 106, 170, 181) and the optimal 
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doses were chosen to elicit sufficient cytokine responses of all the cytokines measured 
in this panel. 
 
Studies have shown how supplementing the culture media with serum and pre-
priming the cells with rIFN-gamma will boost the response of cytokine production 
(182). Furthermore, a comparison study between AIM-V serum free medium and 10% 
FCS supplemented RPMI medium in the supplementary data by Heaton et al. has 
shown us how serum supplemented media augments production of cytokine while the 
CBMCs only responds to higher concentration of LPS stimulus in the AIM-V media 
(164). 
 
 Pre-priming of CBMC with recombinant IFN-γ prior to any addition of stimuli such 
as LPS has also been used to augment cytokine production and especially in the 
production of IL-12p70. Upham et al. has shown that bioactive IL-12p70 can be 
produced by the cord blood and peripheral cells and their study has employed the 
method of using pre-primed cells with to augment the cytokine responses (182).  IL-
12p70 could not be detected in our culture of CBMC with LPS (data not shown).  
 
In a serum-free condition, the IL-12p70 production is naturally impaired in neonates 
(183). Furthermore, the secretion of IL-12(p70) in neonatal dendritic cells has been 
reported to be impaired due to a specific defect in the IL-12(p35) subunit transcription 
while the IL-12(p40) subunit transcription is preserved (183). In summary, the 
method of using RPMI supplemented with FCS as a culture medium or rIFN-γ pre-
priming may enhance the production of cytokines and induce the production             
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IL-12p70, but these responses might not reflect the true cytokine producing capability 
of the CBMCs. 
 
Despite the reported unresponsiveness LPS stimulated CBMCs in serum-free AIM-V 
medium (164), the experiments conducted show that the cells responded well albeit to 
a lower magnitude of cytokine concentrations to both LPS and PHA stimulus. The 
cytokine expression profiles of the cord and adult blood are comparable to what other 
studies have reported (176, 177). Furthermore, the abolishment of cytokine responses 
after incubation of cells with TLR4 antibody shows that the TLR4 is still able to 
interact the LPS despite the lack of carriers such as sCD14 or LPS binding protein. 
 
The PHA stimulated PBMC versus CBMC showed different profile’s with T- cell 
cytokines IL-2 , IL-5 , IL-6 and TNF-α being produced at significantly higher levels 
at 48 hours in the PBMC compared to the CBMC when stimulated with 5ug/mL PHA. 
Although  PHA targets T cells as well as monocytes (175), this observation does 
agree with the speculation that neonatal T cells are functionally immature (184) and 
reduced in responses to stimuli. Harris et al. reported that CBMCs appear to have 
minimal responses to stimulation with IL-2 , PHA, or alloantigens in their study (185) 
while Silberer et al. also reported that PHA stimulated cord blood mononuclear cells 
had significantly lower IFN-γ and IL-10 compared to adult peripheral blood 
mononuclear cells (186). Cord blood is known to contain primarily “unprimed’ T 
cells expressing the CD45RA+ phenotype and a low proportion of CD45RO+ 
‘memory’ T cells.  It has been suggested that the reduction of the cytokine secretion in 
cord blood naïve T-cells could be due to a reduced number of CD45RO+  cells or a 
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reduced capacity for cord blood CD45RA+ and CD45RO cells to produce cytokines 
(176).  
 
Experimental results have also shown that at a concentration of 100ng/mL LPS and 
above, CBMCs were able to produce higher levels of cytokines TNF-α and IL-6 
compared to adult PBMC and nearly similar levels of cytokine IL1-β. This 
observation agrees with other studies that reported production of certain cytokines by 
neonatal monocytes and antigen presenting cells (APCs) actually exceed that of adults 
(177, 187) , except that the antigen –presenting cells (APCs) of neonates require a 
higher level of activation to reach a functional status than adult APCs do (184).  
 
In conclusion, cell culture conditions for further experiments using CBMCs were 





Chapter 5: Cytokine profiles of lipopolysaccharide (LPS) and phytohaemagglutinin 
(PHA) stimulated cord blood mononuclear cells (CBMCs) and their correlation with 
clinical outcomes in the first 5 years of life  
 
5.1 Introduction 
Wheezing and eczema in the first years of life are generally not associated with atopy (9, 
188) and may be transient (188). A proportion of non-atopic eczema would progress to 
atopic eczema when IgE sensitization occurs (41). Early life transient wheezing is 
heterogenous in etiology and often non-atopic, and usually triggered by respiratory 
viruses (189). Some, however progress to develop allergic asthma later in life (26) or at 
least persist up to adolescence (39). In light of the heterogeneity phenotypes in childhood 
allergic disorders, cord blood cytokines may be associated to specific atopic clinical 
phenotypes. The birth cohort described in Chapter 3 shows that there is a low percentage 
of overlaps (<9%) between the allergic phenotypes in this cohort.  This provides the 
advantage of studying the distinct immune dysregulation in association with each clinical 
phenotype outcome separately.  
 
Immune dysregulation in cord blood mononuclear cells have been previously studied to 
evaluate its association to the development of atopic disorders (Section 1.3, page10). 
However, a major drawback of some studies was that cytokine profiles from CBMCs 
were assessed in relation to clinical outcomes of eczema, asthma, allergen sensitization 
and even allergic rhinitis  that  were grouped together as allergic outcomes (98, 102) or 
atopic disease (97)  instead as their distinct clinical phenotypes. In order to determine 
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whether distinct profile of  innate immune responses including the T-cell cytokine 
production is an inherent feature of infants with eczema and wheezing disorders and 
allergen sensitization, this study set out to evaluate the immunophenotypes of cord blood 
mononuclear cell (CBMC) immune responses in a clinically well-defined birth cohort of 
at risk infants (first degree relative with allergic disease) (130). Intracellular staining will 
be used to identify cell-types of cytokine producing cells. Subjects were grouped 
according to their clinical outcomes at 2 years and 5 years of age: wheeze, eczema as the 
main clinical outcomes, allergen sensitization and healthy subjects as controls. Cytokine 
responses of CBMCs to Toll- Like- Receptor 4 (TLR4) agonist lipopolysaccharide (LPS) 
were assessed to target innate antigen presenting cells (62) and a non-specific mitogen 
phytohaemagglutinin (PHA) was used to target cytokine producing T-cells (190). 
 
5.2 Materials and methods 
5.2.1 Subject recruitment criteria 
Between May 2004 and June 2006, 253 families with a 1st degree relative with allergic 
disease were recruited from the antenatal clinics at the National University Hospital to 
this study. Subjects from this cohort were originally participants of a probiotic 
intervention clinical trial (ClinicalTrials.gov Identifier: NCT00318695). Details of the 
inclusion /exclusion criteria and characteristics of the cohorts have been described in 
section 2.2, page33. Written informed consents were obtained from all families. The 






5.2.2 Follow up examination  
Details of clinical assessments were described in section 2.5,page 36 skin prick tests and 
IgE measurements from serum were described in section 2.6,page 37  
 
5.2.3 Cord blood collection and clinical outcome assessment  
Of the 253 subjects at risk of allergy recruited, a total of 195 cord blood samples were 
collected for the study. The 58 cord blood samples not collected were due to insufficient 
blood for collection, subjects being recruited only after the child had been born or the 
medical staff failing to make the collection. Out of 195 cord blood samples collected, 17 
subjects dropped out by 2 years before the clinical assessments could be made, and by 5 
years a total of 29 subjects had dropped out. At 2 years of age, 178 samples had sufficient 
cells for evaluation but 18 were excluded from the study. The subjects that were excluded 
included those with eczema/wheeze clinical phenotype overlaps ( n=7) and 11 subjects 
developed transient eczema that were not part of our clinical outcomes of interest. Based 
on their clinical outcome, 160 subjects were divided into 4 groups (Figure 5-1). Group 1: 
healthy control infants (n=65) with no clinical manifestations of eczema, wheeze or any 
atopic disorder, and were not allergen sensitized to dietary or inhalant allergens; Group 2: 
infants with wheeze (n=34); and Group 3: infants who developed eczema (n=29) were the 
main outcomes of interest, Group 4: Infants with no clinical manifestation of eczema, 





These same subjects were followed up to 5 years of age (Figure 5-1). Eczema and wheeze 
overlaps, transient eczema, wheeze and allergen sensitization phenotypes which remit by 
3 years of age and late onset eczema, wheeze and allergen sensitization phenotypes were 
excluded from the analysis. The 166 subjects at year 5 were divided into 4 groups based 
on their clinical outcome, Group 1: healthy control infants (n=41) with no clinical 
manifestations of eczema, wheeze or any atopic disorder, and were not allergen sensitized 
to dietary or inhalant allergens; Group 2: infants with wheeze (n=10); and Group 3: 
infants who developed eczema (n=8) were the main outcomes of interest, Group 4: 
Infants with no clinical manifestation of eczema, wheeze or any atopic disorders but were 
sensitized to any dietary or inhalant allergens (n=9). The reason for this method of 
selection was to only include true healthy subjects, and subjects with clinical phenotypes 


























Figure 5-1: Flow chart of study shows the collection of the cord blood samples and 
clinical phenotype outcomes at 2 years and 5 years of age.  
Clinical outcomes at 2 years 
Clinical outcomes at 5 years 
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5.2.4 Subjects selected for cord blood responses 
The subjects were categorized according to clinical outcome as described in Table 5-
1.The main interest was to study the clinical outcomes of eczema and wheeze at 24 
months of age including subjects who developed no clinical manifestations of allergic 
disorders but were allergen sensitized by 2 years of age. The same cytokine profile will 
then be compared with clinical outcomes at 5 years of age. Table 5-1 summarizes the 
definition of the clinical outcomes selected for the study. The eczema and wheeze 
subjects was selected based on subjects who were diagnosed with any eczema/wheeze at 
24 months, and those diagnosed as eczema/wheeze at  age 12 months and continue to 
have eczema/wheeze at age 24 months. The subjects who were ever allergen sensitized 
by 24 months of age were selected based on positive skin prick tests to dietary and 
inhalant allergens.  
 








Clinical phenotype Endpoint of clinical diagnosis 
12months 24 months 60 months
Eczema  +  +  +
-  +  +
Wheeze  +  +  +
-  +  +
Allergen sensitization  + -  +
-  +  +
 +  +  +
Healthy - - - 




5.2.5 Preparation of cord blood mononuclear cells (CBMCs) 
Umbilical cord blood was collected into blood bags (Terumo, Somerset, USA) containing 
heparin and RPMI medium (Gibco Life Technology, Grand Island, NY, USA) and 
processed within 12 hours. CBMCs were isolated by Ficoll–Hypaque (GE Healthcare , 
Uppsala, Sweden) gradient centrifugation and cryopreserved in 7.5% dimethyl sulfoxide 
(Sigma, Munich ,Germany) in fetal calf serum and stored in liquid nitrogen (-150°C) 
until analysis (Methods previously described in section 4.2.1, page 69) 
 
5.2.6 Stimulation of cord blood cells with lipopolysaccharide (LPS) and 
phytohaemaglutinin (PHA)  
After thawing, CBMCs were plated in 96-well round- bottom cell-culture plates in 
duplicates at 2 × 105 viable cells/well in 200 μl medium with AIM-V medium (Gibco 
Life Technology). At the time of thawing, the viability of the cells was median 70% 
(range 67.5%-72.5%) as determined by Trypan blue staining with a median of 50% in 
terms of cell recovery (range 50%- 60%).  The viability of the cells were comparable to 
cell viabilities in studies by Chen et al. (65-85% viability) (191) and Hayakawa et al. 
(75% ± 11% viability) (192). Cells were cultured with or without of LPS at 1µg/mL 
(Escherichia coli LPS 0111:B4, Sigma) for 24 hours or PHA (Sigma) at 5ug/mL for 48 
hours at 37°C in 5% CO2, the culture supernatants were harvested and stored at -80˚C. 
The cytokines in the supernatants were detected using the Cytometric Bead Array (CBA) 
human cytokine Flex Sets and measured by the BD FACSArray™ Bioanalyzer (BD 
Biosciences, San Jose, CA, USA) and the data was analyzed with the BD FCAP Array 
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software (BD Biosciences). Optimal concentration of stimulants used and time-points of 
co-culture with CBMCs were evaluated based on initial experiments (Data shown in 
section 4.3.1 and 4.3.2, page 73 and 76). 
 
5.2.7 Cytokine protein detection by the Fluorescence activated cell sorter (FACS) –
Array (Becton Dickinson) 
Cytokines measured were IL-10 , IL-1β , IL-6, IL-8, IL-12p70, TNF-α , IFN-γ , IL-2 , IL-
5, IL-12/IL-23p40 and IL-13 using the Cytometric Bead Array (CBA) human cytokine 
Flex Sets and measured by the BD FACSArray™ Bioanalyzer (BD Biosciences) with a 
detection limit of 10pg/mL for all cytokines. The responses presented are those evoked 
by the LPS or PHA stimulus after subtraction by responses from unstimulated cultures 
which produced cytokines below the detection limit of 10pg/mL (Methods previously 
described in 4.2.3, page 70). 
 
5.2.8 Cytokines measured from cord blood mononuclear cells (CBMCs) and clinical 
phenotypes of interest 
Figure 5-2 shows the flow chart of cytokines that were measured from supernatant 
CBMC co-cultured with LPS or PHA, and its correlation to clinical phenotypes of 
interest in this study. Cytokines IL-6, IL-8, TNF-α, IL-12/23p40 and IL1-β were grouped 
together as innate pro-inflammatory cytokines while IL-10,IL-2, IL-5,IL-13 and IFN-γ  
were grouped in a category of other cytokines. The main outcomes of interest were 
clinical manifestations of eczema and wheeze phenotypes at 2 and 5 years of age. 
Subjects with allergen sensitization but with no clinical manifestations of allergic 
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disorders were also evaluated in relation to the cytokine profiles at 2 years and 5 years of 
age. All clinical outcomes were compared to the healthy control group of subjects with 












Figure 5-2: Flow chart of cord blood mononuclear cell cytokine response study and 
its correlation to the clinical phenotypes at 2 years and 5 years of age. 
 
5.2.9 Intracellular staining and flow cytometry 
Intracellular staining was carried out to identify the cell types expressing cytokines using 
a drug monensin which disrupts intracellular Golgi-mediated transport and allows 
cytokines to accumulate, yielding an enhanced cytokine signal that can be detected via 
flow cytometry (193). A total of 5 wells containing 2 x 105 cells/mL per well per sample 
of CBMCs from subjects with wheeze (n=3) were cultured with 1µg/mL LPS for 24 
hours or 2.5µg/mL PHA for 24 hours, and monensin (2μM) (Sigma) was added for the 
last 16 hours. The subjects with wheeze were chosen for this experiment due to the higher 
amounts of cytokine IL-6 and IL-8 secreted, cytokines secreted at low amounts are 
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difficult to detect by intracellular staining. After the cells were collected and washed with 
staining buffer (1%BSA in PBS), the cells were stained with cell surface markers anti-
CD3+PerCP (Clone SK7), anti-CD14+ FITC (Clone MФP9), anti-CD19+APC (Clone 
4G7) according to the manufacturer’s instructions (BD Biosciences) for 30 minutes on 
ice. Intracellular cytokine staining was then performed using an intracellular staining kit 
(BD Biosciences). First, the cells were washed twice with staining buffer and were then 
centrifuged to pellet the cells. The cells were then thoroughly resuspended, 100µL of BD 
Cytofix/Cytoperm was then added to the cells and the cells were incubated for 20 minutes 
on ice. The cells were then washed twice with the BD Perm/Wash solution and 
resuspended in 250µL BD Perm/Wash. Specific monoclonal antibodies (mAb) against 
the human cytokines IL-6 ( Clone AS12) and IL-8 ( Clone AS14) (BD Biosciences) were 
added and the cells were incubated for 30 minutes on ice. The fluorescence-labeled cells 
were again washed twice with the BD Perm/Wash solution and resuspended in staining 
buffer prior ( 1% BSA in PBS) to flow cytometric analysis by the FACS Calibur (BD 
Biosciences). 
 
5.2.10 Statistical analysis  
Statistical analysis was performed using SPSS software version 17.0 for windows (SPSS, 
Inc. Chicago III, and USA) and figures were drawn using GraphPad Prism 5 (GraphPad 
Software, Inc. CA, USA) and Sigma Plot (Systat Software, Inc., Chicago, IL).  
 
Due to the non-normality of the data, Mann Whitney U test was performed to assess the 
differences between the cytokine profiles of the 3 groups, wheeze, eczema and healthy 
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controls. Mann Whitney U test is the non-parametric equivalent of the Student’s T test 
and therefore compares medians instead of means, and normal distribution of data is not 
necessary for use of the Mann Whitney U test (141). The p value was adjusted based on 
the Bonferroni correction to account for multiple comparisons when several statistical 
tests are being performed simultaneously; p values are multiplied by the number of 
comparisons.  
 
 Differences in the demographic data were evaluated, the Mann-Whitney U was used for 
numerical data, and the χ2 tests for categorical data. Comparison between two clinical 
outcomes groups (i.e. Eczema versus healthy) were made using Pearson Chi-square (χ2) 
test or Fisher’s Exact test to determine if there were statistically significant relationships 
between the categorical variables (142). Significant differences between groups in the 
univariate analysis (p value <0.05) were included into the logistic regression to adjust for 
potential confounders affecting the cytokine analyses, and due to the non-normal 
distribution of the cytokines; a log transformation was performed before logistic 
regression. The logistic regression analysis was also used to examine the association of 
each outcome ( eg: eczema or wheeze) with the all covariates ( cytokines and clinical 
variables) entered simultaneously into the model. The Binary logistic regression which is 
a generalized linear model which is used when the dependents (i.e. atopic disorders) are 
dichotomous and the independents (i.e. covariates) are continuous or categorical 
variables. Logistic regression determines the odds ratio (OR), the associated 95% 
confidence interval (CI) and adjusts for relevant covariates of the categorical 
dichotomous outcomes (i.e. Eczema versus healthy). The 95% confidence interval for the 
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odds ratio is obtained as 1.96 standard errors on either side of the estimate. The change in 
value of the independent variable is not associated in change in the odds of the dependent 
variable if the 95% confidence interval around the odds ratio includes the value of 1.0 
(143). Values of p ≤ 0.05 were considered statistically significant.  
 
Factor analysis was used to determine predictors of cytokines that were associated with 
wheeze and eczema. This analysis is a data reduction technique which enables a large set 
of variables (cytokines) to be grouped into intercorrelated sets of variables (cytokines) 
using statistical software SPSS. Factors with an eigenvalue greater than 1 were formed 
using only the healthy controls to describe cytokine profile of the healthy children. 
Factor-specific loading was calculated for each original variable which indicates the 
degree of correlation between the specific factor formed and the variable. Factor loadings 
are the weights and correlations between each variable and the factor, the higher the load 
the more relevant in defining the factor’s dimensionality. A negative value indicates an 
inverse impact on the factor. To perform additional analysis by using factors as variables, 
factor scores were generated by the statistical software SPSS. Factor scores are a linear 
combination of all the variables weighted by the corresponding factor loadings. These 
factor scores were then compared between groups by Mann-Whitney test. Logistic 
regression was used to determine factor scores as possible predictors of wheeze and 




5.3.1 Cytokine responses in lipopolysaccharide (LPS) and phytohaemagglutinin 
(PHA) - stimulated cord blood mononuclear cells (CBMCs) assessed in relation to 
the clinical outcomes of eczema and wheeze at 2 years of age 
The cytokine profiles shown in Figure 5-3 and Figure 5-4 are expressed as medians and 
interquartile ranges with p values adjusted for multiple comparisons using the Bonferroni 
method. To further refine the clinical phenotypes evaluated, the data was also analyzed 
for the group with non-atopic eczema (n = 20/29) and non-atopic wheeze (n = 31/34) 
(that is absence of allergen sensitization at 24 months).  
 
5.3.1.2 LPS and PHA stimulated IL-6, IL-8 and TNF-α 
The cytokine profiles of IL-6, IL-8 and TNF-α were measured in both the LPS and PHA 
stimulated conditions (Figure 5-3 A-C and F-H). Both the wheeze 47.4 (17.0 - 85.1) 
ng/mL and eczema 23.1 (17.6 -33.7) ng/mL groups produced higher levels of LPS 
stimulated IL-6 compared to healthy controls 15.9 (7.90 – 25.5) ng/mL, (p=0.003 and 
p=0.036, respectively) with the wheeze group producing the highest levels (wheeze vs 
eczema, p=0.024). Likewise LPS stimulated IL-8 responses in wheeze 182.4 (80.4 -
252.7) ng/mL subjects were also significantly higher compared to both healthy controls 
94.5 (12.6 – 156.6) ng/mL and eczema subjects 12.1 (2.80 – 76.7) ng/mL (p=0.003, 
respectively). In contrast, the eczema subjects had significantly attenuated LPS 
stimulated IL-8 production compared to both the healthy controls and wheeze subjects 




A similar profile was seen in the PHA stimulated IL-6 and IL-8 cytokine profile with 
PHA stimulated IL-8 in the eczema group 6.6 ng/mL (0.01 - 53.33)  also found to be 
significantly attenuated compared to healthy controls 80.70 ng/mL (7.90 - 139.84) (p = 
0.003). A hyper- responsive cytokine profile was seen in the wheeze subjects compared 
to healthy controls (Figure 5-3 A-C and F-H), with increased PHA stimulated IL-6; 2.56 
ng/mL (1.27 - 9.69) vs 0.86 ng/mL (0.34 - 2.35), p = 0.015 and IL-8; 153.81 ng/mL 
(99.08 - 251.20) vs 80.70 ng/mL (7.90 - 139.84), respectively, p = 0.003.  
 
It was noted that the lower quartile and upper quartile wheeze subjects secreting LPS 
stimulated cytokines IL-6 and IL-8 are not discerning factors for the development of 
wheeze phenotypes at 5 years of age. At least 60% of these subjects from both the lower 
and upper quartile responders outgrew their wheeze symptoms by 5 years of age (Data 
not shown). It was noted however that the subjects with persistent wheeze at 5 years were 
only n=10 subjects.  
 
There were no significant differences between groups for the production of LPS 
stimulated TNF-α , but the PHA stimulated TNF-α  did show an increased response in the 
wheeze group compared to the healthy controls (6.49 ng/mL (4.31 - 11.64) vs 4.02 ng/mL 
(3.25 - 5.36), p = 0.003)  
 
5.3.1.3. LPS stimulated IL-12/IL-23p40 and IL-1β 
LPS stimulated IL-12/IL-23p40 production was also significantly higher in the subjects 
with wheeze compared to the healthy controls 0.10 (0.04 – 0.17) vs 0.04 (0.01 -0.08) 
112 
 
ng/mL, p=0.003. Notably, the readout for the related cytokine IL-12 (shared p40 subunit), 
IL-12p70, was undetectable in all groups (Data not shown). There were no significant 
differences between groups for the production of cytokine IL-1β (Figure 5-3 D-E). 
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  Non allergen sensitized subjects  



















Figure 5-3: A-H, CBMC innate pro-inflammatory cytokine profile of healthy 
(n=65), eczema (n=29) and wheeze (n=34) subjects at 2 years of age in response to 
1µg/mL LPS ( A-E) and 5ug/mL PHA ( F-H) measured using the BD CBA Human 
Soluble Protein Flex Set assay. Closed circles represent non- allergen sensitized 
subjects, while the pink circles represent allergen sensitized subjects. The band in the 
middle of the boxplot represents the median value, and the ends of the whiskers represent 
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5.3.1.4 LPS and PHA stimulated cytokine IL-10  
 
There were no significant differences between LPS or PHA stimulated IL-10 responses in 
the eczema or wheeze subjects if compared to the healthy subjects (Figure 5-4 A-B). 
 
5.3.1.5 PHA stimulated T-cell cytokines IL-5, IL-2, IL-3 and IFN γ 
A hyper- responsive cytokine profile was seen in the wheeze subjects compared to 
healthy controls in the production of T-cell cytokines such as IL-2 ; 3.38 ng/mL      (1.78 
- 4.91) vs 1.23 ng/mL (0.29 - 2.40), respectively, p = 0.003, IL-5 ; 0.03 ( 0.02 - 0.05) vs 
0.01 ng/mL (0.01 - 0.03), respectively, p = 0.003, and IFN-γ 2.71 (0.96 - 4.28) vs 0.75 
ng/mL (0.33 - 1.86), respectively, p = 0.003.  
 
Overall, the eczema and wheeze subjects showed distinctly different and divergent 
CBMC cytokine profiles. Only LPS stimulated IL-6 was significantly higher in the 
eczema subjects while the IL-8 response was hypo-responsive in the eczema subjects. 
The wheeze subjects had a more hyper-responsive cytokine profile [innate (IL-6, IL-8, 
TNF-α), and T-cell cytokines (IL-2, IL-5, and IFN-γ), p < 0.05]. This evidence points to 
immune dysregulation in the innate immune system from birth that has skewed the 
wheeze subjects to a more hyper-responsive cytokine profile. 
 
Descriptive data on cytokine concentrations from the LPS and PHA stimulated CBMC 





  Non allergen sensitized subjects  
















Figure 5-4( A-F):CBMC cytokine profile of 1ug/mL LPS and 5ug/mL PHA 
stimulated IL-10 (A-B) and PHA stimulated IL-2, IL-5, IL-13 (C-F) and IFN-γ in 
healthy (n=65), eczema (n=29) and wheeze (n=34) subjects at 2 years of age 
measured using the BD CBA Human Soluble Protein Flex Set assay. Closed circles 
represent non- allergen sensitized subjects, while the pink circles represent allergen 
sensitized subjects. The band in the middle of the boxplot represents the median value, 
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5.3.2 Cytokine profiles of subjects who are healthy with allergen sensitization at 
 2 years of age. 
The cytokine profiles of subjects who were sensitized to any inhalant and dietary 
allergens but without any clinical manifestations of allergic disorders by 2 years of age 
were compared to subjects who were healthy without any allergen sensitization. 
Although, this group was not the main clinical outcome of interest in the study, it would 
still be an important group to include for evaluating the cytokine profiles of subjects who 
are healthy with or without allergen sensitization. Furthermore, it was important to ensure 
that the cytokine profiles seen earlier in Figure 5- 3 and Figure 5-4 were specific for the 
clinical outcomes of eczema and wheeze and not similar to the profiles from subjects who 
were allergen sensitized.  
 
The allergen sensitized group had significantly lower PHA stimulated TNF-α ( p =0.002) 
and LPS stimulated IL-10 ( p = 0.04) but significantly higher production of LPS 
stimulated IL1-β ( p =0.006). T-cell cytokines IL-5 and IL-13 were also found to be 
significantly lower in the allergen sensitized subjects with p value= 0.003 and                   
p value = 0.001 respectively (Figure 5-5, Figure 5-6 and Figure 5-7). 
 
No statistically significant differences were seen between groups in LPS and PHA 
stimulated IL-6 and IL-8, LPS stimulated TNF-α and IL-10 and PHA stimulated IFN-γ 





















Figure 5-5 (A-F): CBMC IL-6, IL-8 and TNF- α cytokine profiles of healthy subjects 
with no allergen sensitization (NAS) (n=65), healthy subjects with allergen 
sensitization (AS) (n=32) subjects at 2 years of age in response to 1ug/mL LPS (A-C) 
and 5ug/mL of PHA (D-F) measured using the BD CBA Human Soluble Protein 
Flex Set assay. The band in the middle of the boxplot represents the median value, and 
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Figure 5-6 (A-B): CBMC IL1-β and IL-12/23p40 cytokine profile of healthy subjects 
with no allergen sensitization (NAS) n=65, healthy subjects with allergen 
sensitization AS n=32 subjects at 2 years of age in response to 1ug/mL LPS 
measured using the BD CBA Human Soluble Protein Flex Set assay. The band in the 
middle of the boxplot represents the median value, and the ends of the whiskers represent 
the 5th and 95th percentile value of the data. 
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Figure 5-7 (A-F): CBMC cytokine profile of  1ug/mL LPS and 5ug/mL PHA 
stimulated IL-10 ( A-B) and PHA stimulated IL-2, IL-5, IL-13 (C-F) and IFN-γ in 
healthy CBMC cytokine profile of healthy subjects with no allergen sensitization 
(NAS) n=65, healthy subjects with allergen sensitization AS n=32 subjects at 2 years 
of age measured using the BD CBA Human Soluble Protein Flex Set assay. The band 
in the middle of the boxplot represents the median value, and the ends of the whiskers 
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5.3.3 Logistic regression analysis of LPS and PHA stimulated CBMC cytokine 
profiles of eczema and wheeze subjects. 
5.3.3.1 Logistic regression adjusting for factors confounding cytokine profiles 
To adjust for analyses accounting for imbalance in demographic and clinical factors 
affecting the cytokine analyses, univariate analysis of the variables was evaluated 
(Appendix F). Based on factors that were statistically different between groups with a p 
value of less than 0.05, the comparison of cytokine profiles were adjusted for the 
following variables: gestational age and paternal eczema for eczema and control groups; 
and mode of delivery, maternal asthma, birth order and birth weight and birth height for 
the wheeze and control groups. Logistic regression analysis including these variables did 
not affect the differences in individual cytokine profiles between the healthy and eczema 
or the healthy and wheeze groups (Appendix E) except the association with IFN-γ which 
was no longer significant ( p=0.059). 
 
5.3.3.2 Logistic regression to determine main risk factors  
Logistic regression was also used to determine separately the main predictors of infant 
eczema and wheeze (i.e. with eczema or wheeze outcome as the dependent variable). All 
clinical variables and cytokine profiles from the LPS or PHA stimulated CBMC that were 
statistically different between eczema and wheeze groups in the univariate analysis were 
entered into logistic regression models (Figure 5-3, Figure 5-4 and Appendix F). Due to 
moderate correlation (r > 0.6) between LPS stimulated IL-8 and PHA stimulated IL-8 
which indicates multicolinearity, these 2 variables could not be included into the same 








Figure 5-8(A-B) show meta analysis plots of LPS stimulated cytokines and clinical 
variables. Subjects with lower production of LPS stimulated IL-8 were more at risk of 
developing eczema (Adjusted OR, 0.7; 95% CI, 0.5 – 0.7); furthermore, a higher 
proportion of eczema subjects had a family history of paternal eczema compared to the 
healthy controls (24/29 vs 8/65, p = 0.027) and a history of paternal eczema was a 
predictor of eczema (Adjusted OR, 7.5; 95% CI, 1.6 – 34.0) p < 0.05, respectively 
(Figure 5-8 A). With regards to wheeze, logistic regression analysis determined that 
higher levels of both LPS stimulated IL-12/23p40 (Adjusted OR, 5.7; 95% CI, 1.2 – 
26.6); and IL-8 responses Adjusted (Adjusted OR, 3.2; 95% CI, 1.0 - 10.2), and an 
increased birth height (Adjusted OR, 1.6; 95% CI, 1.2 – 2.2) (Figure 5-8B) to be factors 
associated increased risk for wheeze with p < 0.05 respectively.  
 
Similar to the LPS stimulated IL-8 subjects with lower production of PHA stimulated IL-
8 were more at risk of developing eczema ( Adjusted OR, 0.6; 95% CI, 0.4 – 0.8); and a 
history of paternal eczema was a predictor of eczema (Adjusted OR, 4.7; 95% CI, 1.1 - 
19.5) p < 0.05 (Figure 5-8 C). With regards to wheeze, logistic regression analysis 
determined that higher levels of both IL-5 ( Adjusted OR, 14.5; 95% CI, 2.2 - 92.9); and 
PHA stimulated IL-8 responses (Adjusted OR, 3.7; 95% CI, 1.4 - 10.2), plus a child 
being the second born and beyond in the family (Adjusted OR, 3.8; 95% CI, 1.1 - 13.6) 
and an increased birth height (Adjusted OR, 1.5 ; 95% CI, 1.2 - 1.9) (Figure 5-8 D) to be 




These data have shown us that eczema and wheeze are indeed multi-factorial disorders, 
because other than an influence of family history (paternal eczema) or clinical 
demographics (birth order and birth height), the evidence emphasizes the importance of 
innate immune responses in early life in determining the outcomes of children from a 
high-risk atopic background. Notably, pro-inflammatory cytokine IL-8 play an important 
role in both the outcomes of eczema and wheeze but have interestingly shown very 




















Figure 5-8 (A-D): Relationship between the outcome of eczema and wheeze at 2 
years of age with LPS and PHA stimulated cord blood cytokine profiles as well as 
clinical characteristics. Closed squares represent statistical significance when all clinical 
variables, LPS (A-B) and PHA (C-D) stimulated cytokine profiles that were statistically 
different between groups in the univariate analysis were adjusted for in the logistic 
regression models. Clinical variables included into the logistic regression: gestational age 
and paternal eczema for eczema and control groups; and mode of delivery, maternal 
asthma, birth order and birth weight and birth height for the wheeze and control groups. 



























5.3.4 Factor Analysis of cytokine profiles  
5.3.4.1 Factor analysis of LPS stimulated cytokine profiles  
Next, the use of factor analysis was employed as an additional statistical tool to 
analyze the LPS stimulated cytokine data. Factor analysis of LPS stimulated cytokine 
responses showed that infants with wheeze have higher factor scores with combined 
IL-1β , IL-6 and IL-12/IL-23p40 responses compared to healthy control subjects and 
eczema subjects (p=0.003) (Table 5-2). Factor 1 indicates that IL-1β, IL-6 and IL-
12/IL-23p40 are correlated variables. These 3 cytokines in combination are also 
significantly enhanced in the wheeze group (Table 5-1), even though as individual 
cytokines, only IL-6 and IL-12/IL-23p40, but not IL-1β, are significantly higher in the 
wheeze group. Logistic regression analysis showed that the combined cytokine 
responses (IL-1β, IL-6 and IL-12/IL-23p40) could predict wheeze relative to the 
scores for the healthy control subjects (adjusted OR, 2.45; 95% 1.50 – 3.93, 
p=0.001).When the 3 variables selected by the factor analysis were presented using a 
3D plot, the wheeze group showed a positive correlation between these cytokines 
(Figure 5-9). Whereas, combined responses from TNF-α, IL-10 and IL-8 had lower 
factor scores (lower production) in the eczema group compared to the healthy control 







Table 5-2: Summary of factor analysis, including factor loadings from a model of 





SPSS extracts all factors with eigenvalue above 1. Eigenvalues associated with each 
factor generated represent the variance explained by that particular linear component 
and SPSS also displays the eigenvalue in terms of percentage of variance explained. 
Values in parentheses are the factor loading scores, factor loadings are the correlation 
coefficients between the variables and factors. Standardized factor-score variables 
derived from the loadings were used in the Mann – Whitney U and logistic regression 
analyses.  
 
Cytokine responses in LPS stimulated CBMC  
Factor 1  Factor 2  
IL-1β (0.776)  TNF- α (0.701) 
IL-6 (0.644) IL-10 (0.642) 
IL-12/IL-23p40 (0.691) IL-8   (0.769) 

















Figure 5-9: 3D Scatter plot of the healthy control and wheeze group at 2 years of 
age in respect to their correlation to the variables from the factor analysis.  
Factor analysis of LPS stimulated CBMC showed that infant wheeze has higher 
combined responses from cytokines IL-6, IL-12/ 23p40 and IL-1β compared to 








































5.3.4.2 Factor analysis on PHA stimulated cytokine profile 
The factor analysis for PHA stimulated CBMC cytokines showed that the wheeze 
group had a significantly enhanced combined PHA stimulated IL-6, IFN-γ, IL-2 and 
IL-8 (factor 1) compared to the healthy controls ( p=0.001). Furthermore, a 
combination of pro-inflammatory cytokines TNF-α and IL-13 in factor 2 was also 
positively associated with the outcome of wheeze ( p=0.006).The logistic regression 
analysis showed that factor 1 cytokines were significantly associated with the 
outcome of wheeze after adjustment for all other confounding factors ( adjusted OR, 
2.08; 95% 1.32 – 3.28, p=0.002) ( Table 5-3). 
 
Table 5-3: Summary of factor analysis, including factor loadings from a model of 







SPSS extracts all factors with eigenvalue above 1. Eigenvalues associated with each 
factor generated represent the variance explained by that particular linear component 
and SPSS also displays the eigenvalue in terms of percentage of variance explained. 
Values in parentheses are the factor loading scores, factor loadings are the correlation 
coefficients between the variables and factors. Standardized factor-score variables 
derived from the loadings were used in the Mann – Whitney U and logistic regression 
analyses. 
 
Cytokine responses in PHA stimulated CBMC 
Factor 1 Factor 2
IL-6 ( 0.857) TNF-α ( 0.757)
IFN-γ   ( 0.772) IL-13 ( 0.768)
IL-2 ( 0.702) 
IL-8 ( 0.725)
Total variance explained (%) 30.94 22.19
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5.3.5 Monocytes are main producers for LPS stimulated IL-6 and both LPS and 
PHA IL-8 in LPS stimulated CBMCs.  
The results have shown that innate pro-inflammatory cytokines such as IL-6 and IL-8 
(Figure 5-3) are also expressed via PHA stimulation. The aberrations in the 
production of both LPS and PHA pro-inflammatory cytokine IL-8 was found to be a 
risk factor  involved in both the development eczema and wheeze at 2 years (Figure 5-
8) which led us to postulate the importance of IL-8 in the innate immune system.  
 
Using the BD CellQuest software (BD Biosciences), the first acquisition gates were 
set at lymphocytes and monocytes respectively based on the forward versus side 
scatter of the live cells. Intracellular cytokine staining analysis identified monocytes 
(CD14+ cells) as the main cell type that produces IL-6 and IL-8 (~2 fold higher post 
LPS stimulation) but not CD19+ B cells (Figure 5-10 A-B) or CD3+ T cells (data not 
shown).  
 
PHA is commonly used as a T cell mitogen in most cord blood studies (101, 195, 196) 
to stimulate the production of naïve T-cell cytokines. For the PHA stimulated IL-8, 
second acquisition gates within the lymphocyte gating where CD3+ T cells were 
identified based on their positive staining were set, and similarly the CD14+ stained 
cells were identified within the monocytes gated. As seen in Figure 5-10 C, the 
CD14+ monocytes are the main producers of cytokine IL-8 (16.1 ± 2.00) % compared 
to CD3+ T cells (3.10 ± 0.63) % after PHA stimulation (Figure 5-10 C). In the 
experiments, the IL-8 producing CD19+ cells could not be analyzed due to a 
significant reduction in the population of CD19+ cells after PHA stimulation which 
was speculated to be due to cell death. The intracellular staining of IL-6 was more 
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difficult to perform with PHA as stimuli as the levels of IL-6 produced are much 
lower than with LPS stimulation, thus results were not shown. This evidence further 
supports this study’s hypothesis that the innate immune system in early life plays a 






















Figure 5-10: CBMCs were cultured with 1 µg/mL LPS or 1ug/mL PHA for 24 
hours and stained for surface markers CD3, CD19, and CD14 followed by 
intracellular cytokine staining of IL-6 and IL-8. The IL-6 and IL-8 cytokine 
production from CD19+ ,CD3+ and CD14+ gated cells shown in the figures are 
from a single representative subject. Intracellular staining was performed to analyze 
the production of (A) LPS stimulated IL-6 and (B) LPS stimulated IL-8 cytokines by 
B – lymphocytes (CD19+) and monocytes (CD14+) (C) PHA stimulated IL-8 by T-
lymphocytes ( CD3+) and monocytes ( CD14+). Mononuclear cells were first gated 
according to the forward and sideward scatter. The numbers in the upper-right 
quadrant indicate percentages of IL-6 or the IL-8 positive cells expressed as mean 
percentage ± standard deviation of three subjects. 
 














5.45 + 1.20 10.31 + 2.20 
0.56 + 0.08 0.77 + 0.06 
4.97 + 1.45 12.15 + 2.65 














0.08 ± 0.006 3.10 ± 0.63 





5.3.6 Association of LPS and PHA stimulated cytokine profiles with eczema and 
wheeze outcomes at 5 years of age. 
The same panel of cytokines were also associated with the eczema and wheeze 
phenotypes followed up to 5 years of age as indicated in flow chart Figure 5-1.  
 
In this study most of the subjects were non-atopic at 2 years of age ( Figure 5-1), but 
at 5 years of age there were more atopic eczema subjects (87.5%) and atopic wheeze 
subjects (70%).  
 
Figures 5-11, 5-12, 5-13 and 5-14 shows that there are no statistical significant 
differences between the groups when the cytokine profiles were assessed in relation to 



















Figure 5-11: CBMC cytokine profile of healthy non-allergen sensitized (H) n=41, 
(E) n=8, wheeze (W) n=10 subjects at 5 years of age in response to 1ug/mL LPS 
measured using the BD CBA Human Soluble Protein Flex Set assay. The band in 
the middle of the boxplot represents the median value, and the ends of the whiskers 
represent the 5th and 95th percentile value of the data. 
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Figure 5-12: A-H, CBMC cytokine profile of healthy (n=65), eczema (n=29) and 
wheeze (n=34) subjects at 5 years of age in response to 5ug/mL PHA measured 
using the BD CBA Human Soluble Protein Flex Set assay. Black circles represent 
non- allergen sensitized subjects, while the pink circles represent allergen sensitized 
subjects. The band in the middle of the boxplot represents the median value, and the 
ends of the whiskers represent the 5th and 95th percentile value of the data. 
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Figure 5-13: CBMC cytokine profile of healthy subjects with no allergen 
sensitization (NAS) n=41, healthy subjects with allergen sensitization AS n=9 
subjects at 5 years of age in response to 1ug/mL LPS measured using the BD 
CBA Human Soluble Protein Flex Set assay. The band in the middle of the boxplot 
represents the median value, and the ends of the whiskers represent the 5th and 95th 
percentile value of the data. 
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Figure 5-14: CBMC cytokine profile of healthy subjects with no allergen 
sensitization (NAS) n=41, healthy subjects with allergen sensitization AS n=9 
subjects at 5 years of age in response to 5ug/mL PHA measured using the BD 
CBA Human Soluble Protein Flex Set assay. The band in the middle of the boxplot 
represents the median value, and the ends of the whiskers represent the 5th and 95th 
percentile value of the data. 
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Functional alterations of the neonatal antigen presenting cells (APCs) such as 
monocytes/macrophages and dendritic cells (DCs) could lead to secondary effects 
such as hyper-responsiveness of the adaptive T cell immunity and therefore 
susceptibility to disease (197, 198). In this at-risk for atopy birth cohort (130) the 
relationship of the immunophenotypes in CBMCs and the subsequent development of 
wheeze and eczema in their first 2 years of life were assessed prospectively. Using 
factor analysis, a novel observation was made that infants with early onset wheeze 
correlated with enhanced combined factor of LPS induced IL-1β, IL-6 and IL12/IL-
23p40.  Additionally, this factor was highly associated with the increased risk for 
early onset wheeze (Table 5-2 and Figure 5-9). The increased combined cytokine 
production capacity by LPS-stimulated APCs (macrophages/monocytes/DCs) is of 
particular interest as this combination of cytokines is an important determining factor 
for the differentiation of IL-17–producing Th17 cells in humans (87, 199, 200). 
 
 IL-23 is a member of IL-12 cytokine family. It is a heterodimeric cytokine produced 
by antigen presenting cells (monocytes and DCs) comprising of p19 subunit specific 
for IL-23 and a p40 subunit shared with IL-12 (201) . The secretion of IL-12(p70) in 
neonatal dendritic cells is impaired due to a specific defect in the IL-12(p35) subunit 
transcription, while the IL-12(p40) subunit transcription is preserved (183). Hence, 
neonatal monocytes are biased in the production of IL-23 (183, 202). It was therefore 
reasoned that it is likely the IL-12/IL-23p40 measured in this study could be from IL-
23. The combination of IL-23 plus IL-1β is crucial for the differentiation of CD161+ 
precursor T cells from cord blood and newborn thymus into IL-17A producing Th17 
cells, and for polarizing neonatal CD4+ and CD8+ T cells into IL-17 producing cells 
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(199, 200, 202, 203). In addition, pro-inflammatory cytokines IL-6 and IL-1β, through 
(STAT3), results in the up regulation of the Th17 specific transcription factor, retinoic 
acid –related orphan receptor C (RORC2), which ultimately drives Th17 
differentiation (87) . Furthermore, it has been shown that cytokines IL-6 and IL-1β 
but not transforming growth factor are crucial for the differentiation of human Th17 
cells. In addition, LPS activated monocytes, but not the monocyte-derived dendritic 
cells, efficiently primed the differentiation of human Th17 via production of IL-6 and 
IL-1β (87). Moreover, a recent animal study using a viral PAMP double-stranded 
RNA also suggested that IL-6 plays a crucial role in the development of the Th17 cell 
response in the airways associated with viral respiratory infection (204). The 
importance of the innate immune regulation in immunopathology following viral 
infection has been highlighted in a study involving respiratory syncytial virus (RSV) 
infected (STAT-1)–knock-out mice. The attenuated type I interferon (IFN) (α/β) 
production was associated with increased mucus production and airway hyper-
responsiveness along with increased pro-inflammatory cytokines IL-17 and IL-23 
(201).  
 
This study suggests that the IL-23/IL-17 cytokine axis plays a role in the pathogenesis 
of viral induced airway inflammation. Together, this line of evidence raises the 
possibility that the enhanced combination of responses of cytokines IL-12/23p40, IL-
1β and IL-6 in LPS stimulated CBMC of infants with early life wheezing, may be 
indicative of an inherent feature of the innate system of these infants. The limitation 
in this current study is that the IL-12/IL-23p40 measured could be from cytokines IL-
12/IL-23p40 homodimer, IL-12, or IL-23. Of these, IL-12 is unlikely, as IL-12p70 
was also measured in supernatants of LPS stimulated CBMC using the FACs Array 
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and was found to be below the detection limit. The possibility of detecting IL-12/IL-
23p40 homodimer cannot be ruled out.  
 
Most of the subjects who developed wheeze at 2 years were non-atopic (91%) and an 
increase in IL-6 and IL-8 production was observed from the LPS and PHA stimulated 
CBMCs in the wheeze group (Figure 5-3). These are consistent with previous studies 
showing higher CBMC production of IL-6 and IL-8 in response to stimulation with 
RSV (205, 206) or LPS (207) . In the physiological condition, IL-8 is a primary 
neutrophil chemokine attractant molecule secreted by epithelial cells upon viral 
infection (208), and is thought to play a role in viral-induced wheezing. For example, 
a study of the promoter region of IL-8 identified a common single-nucleotide 
polymorphism (SNP) at position-251 to be associated  with RSV induced wheezing 
(209) and it has also been identified that whole blood from individuals carrying the (-) 
251A allele produce greater IL-8 response when stimulated with LPS in vitro (210).   
 
The hypo-responsiveness of IL-8 production was seen in both the LPS and PHA 
stimulated CBMCs and was significantly associated with the outcome of eczema 
(Figure 5-3). Recent published data suggested that defects in the innate immune 
system might link to the development and severity of eczema (70). The suppression of 
pro-inflammatory cytokine IL-8 was highlighted in a few eczema studies. For 
example, suppression of IL-8 has been observed in highly inflamed areas of chronic 
inflammatory disorders such as eczema and psoriasis, where epidermal IL-8 
immunoreactivity was reduced compared to healthy skin (211). Lesional skin of 
patients with eczema is known to be more frequently colonized with Staphylococcus 
aureus than was nonlesional skin (212). This could point to the reduction of IL-8 
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might playing a role in the bacterial colonization because of the lack of neutrophil 
recruitment to the skin which is involved in the phagocytosis of bacteria (211). 
Furthermore, it has been demonstrated that monocytes from eczema patients 
heterozygous for a mutation in the TLR2 have significantly decreased IL-8 production 
compared to wild type eczema patients and the healthy controls (213). This evidence 
coincides with the hypo-responsiveness of IL-8 from CBMCs and similar IL-8 hypo-
responses in the inflamed skin in later life. Additionally, a recent cord blood study by 
Woods et al. has found an association between reduced CBMC IL-8 and IL-13 
cytokine responses to a variety of innate, adaptive and mitogenic stimuli and have 
reported hyporresponsiveness of CBMCs stimulated with either LPS or peptidoglycan 
with lower IL-12, IFN-γ, IL-10 and TNF-α associated to the development of eczema 
(214). This study’s findings are consistent with the findings by Wood et al. and 
provide additional supporting evidence that attenuated IL-8 responses of CBMCs to 
stimuli increases the risk of eczema.  
 
A few other studies have also reported reduced IFN- γ, (10, 15) enhanced IL-4 (215)  
and IL-13 (101) to be associated with atopic dermatitis. The discrepancies in the 
eczema cytokine profiles compared to the ones previously published could be due to 
the inclusion of all eczema outcomes into their analyses regardless of the sensitization 
status and their selection criteria for subjects to be included into the analyses, which 
might affect the cytokine production. For example, Woods et al. only included 
subjects with an eczema diagnoses with an EASI score greater than or equal to 1.0 at 
either the 3 or 12 month exam into their analyses (214). Furthermore, Prescott et al. 
has reported decreased levels of PHA stimulated IFN-γ  and increased responses from 
lipopolysaccharide stimulated IL-6 and TNF-α in subjects who developed allergic 
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manifestations (including food allergy or allergen sensitization) with the main 
outcome being eczema (102). However, in the latter report, infants with concomitant 
wheeze were also included in the analysis and the data included both wheeze and 
eczema outcomes (102), this may at least in part explain the hyper-responsive rather 
than hypo-responsive innate cytokine responses seen in their study. 
 
Additionally this study’s data have identified monocytes from the CBMC to be the 
main cell type that produces IL-6 and IL-8 upon LPS and PHA stimulation (Figure 5-
10). Intracellular staining has shown that CD14+ monocytes are the main producers of 
PHA stimulated IL-8 cytokines but not CD3+ T cells or CD19+ B cells. Despite the 
notion that mitogen PHA mainly activates T cells, it has been shown that PHA is also 
able to activate purified monocytes to release chemokines such as IL-8 as well as 
monocyte chemotactic peptide-1 (MCP-1) (190). It has been shown that LPS activated 
monocytes produced significant levels of IL-6 and IL-1β (87). Furthermore, purified 
human CD14+ monocytes produced high levels of IL-23 in response to LPS (216). In 
recent years, there have been a number of studies reporting phenotypically and 
functionally distinct subsets of human monocytes that play a key role in polarizing the 
innate and the adaptive immune system and act by regulating the adaptive responses 
in a type I or and type II direction (217, 218). On the basis of this emerging evidence, 
this study proposes a notion that monocytes could be the major cell type involved in 
the intrinsic immune dysregulation in predisposing neonates to the development of 
early childhood disease.  
 
The cord blood cytokine profiles associated with wheeze in the PHA stimulated 
CBMC also showed a profile of hyper-responsive T-cell cytokines TNF-α, IFN-γ, IL-
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2, IL-5 and IL-13 compared to healthy subjects  (p < 0.05) (Figure 5-3 and Figure 5-
4). IL-10 cytokine has been implicated to play an immunoregulatory role by 
exhibiting potent suppressive functions on T-cell activation which may contribute to 
its protective attributes (170, 219, 220). Although the IL-10 induced by LPS and PHA 
stimulation in this study was lower in the wheeze subjects compared to the healthy 
subjects the difference did not reach statistical significance (Figure 5-4). 
 
The wheeze outcome was also associated with increase T cell cytokine IL-5 responses 
(Figure 5-4). Zhang et al. studying a high risk cohort reported that the high production 
of IL-5 and low production of IL-10 was a predictor of respiratory infections that 
causes wheeze in children (195). The release of IL-5 has been shown to be 
responsible for airway inflammation, bronchial hyper-responsiveness, IgE production 
and eosinophil recruitment in subjects with viral-induced wheezing (195, 221). 
 
Early-life IFN-γ production has been reported to be inversely related to the outcome 
of early wheezing. Guerra et al. has showed that impaired production of  IFN-γ at 3 
months of life is related to the outcome of  recurrent wheezing in the first year of life 
(222) and similarly, Stern et al. reported that low IFN-γ production from 9-month olds 
was associated to the increased risk for wheeze at 6 years of age independent from 
sensitization (223). Additionally, phytohaemagglutinin (PHA) stimulated of cord 
blood in a study by Gern et al. showed that children at first year of life with > 2 
episodes of wheeze had a lower production of  IFN-γ (224). In contrast however, were 
two studies that overall found no association between cord blood IFN-γ production 
and wheezing at 1 (222) and 2 years of life (225). This study will be the first to report 
the association between increased IFN-γ levels and the outcome of wheeze by 2 years 
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of age (Figure 5-4). These observations are consistent with studies on the role of IFN-
γ in the development of airway hyper-responsiveness in murine models (226, 227) 
.Furthermore bronchial hyper-responsiveness in children has also been associated 
with increased IFN-γ particularly from CD8+ T cells(228). 
 
The increased production of Th2 cytokine IL-13 in cord blood cells of wheeze infants 
indicates that this cytokine may be important in the pathogenesis of wheeze (Figure 5-
4). In agreement with these findings was a study by Spinozzi et al. as have they 
reported a significant correlation between the development of wheeze at 1 year of age 
with higher percentages of CD4+T IL-13 + cells at birth (225). Whereas, Gern et al. 
reports a reduction in the phytohemagglutinin (PHA) induced IL-13 responses in 
relation to the outcome of wheeze in the first year of life (224). 
 
In this study, the LPS and PHA stimulated CBMC cytokine profile was only seen to 
be associated with the development of allergic phenotypes at 2 years of age but not at 
5 years of age. The lack of association to cytokine profiles at 5 years of age could be 
due to the decrease in the subject numbers, especially for the clinical outcomes of 
eczema ( n=8) and wheeze ( n=10) and because of this we do not have enough power 
to detect any significant differences in the analysis at 5 years of age. 
 
Aside the role of the immune system, paternal eczema history was also strongly 
associated with the outcome of eczema in this study (Figure 5-8). This observation 
supports previous reports showing a positive association between early childhood 
eczema and maternal and paternal eczema (229, 230), with a stronger association with 




For the wheeze subjects, this study also suggests that the second born child and 
beyond is more prone to the development of wheeze (Figure 5-8), and it has been 
reported by Perzanowski et al. that increasing birth order was associated with 
increasing prevalence of respiratory symptoms including wheeze (231). Additionally, 
birth height of infants was found to be an independent risk factor associated with 
wheeze (Figure 5-8). This is despite previous observations that later-borns tend to be 
longer, and are heavier (232). A study in New Zealand found that the development of 
asthma was associated with increased birth length (233). In contrast, a study in 
Stockholm found birth length to be inversely associated with any wheeze at age 4 
years and late onset wheeze (234). The association of birth weight and length with the 
outcome of wheeze is therefore not conclusive. 
 
This study suggests distinct inherent immunological predisposition influences the 
development of wheeze and eczema in early life. Furthermore, the immunophenotype 
of the clinical outcomes do not overlap with subjects who were healthy with allergen 
sensitization (Figure 5-5, Figure 5-6 and Figure -7). Previous studies which have 
grouped together different clinical outcomes of allergic disorders (Section 1.3, Table 
1-3 and 1.4,page 20 and 24) might have missed out on distinct cytokine profiles 
related to each of these clinical phenotypes. To address the limitations of the study I 
do understand that the use of frozen cord blood cells might not be ideal due to the cell 
death that occurs in the process of thawing. This might lead to cell death of specific 
cell types that might lead to the alteration of the cell compositions in each subject and 




In summary, the hypo-responsiveness of chemokine IL-8 which is mainly produced 
by monocytes might be a possible predictive factor for the development of eczema. In 
contrast, the hyper-responsiveness of wheeze subjects involves increased PHA 
stimulated IL-8 as well as cytokine IL-5. This study also provides the impetus to 
further define the functional aberrations of the innate immunity and the possible role 
of the IL-23/IL-17 axis associated with early onset wheezing. While other studies 
have only focused on high- and low-risk neonates without follow-up on subsequent 
outcome of atopy/allergic diseases or examined the atopic phenotypes in isolation(92, 
93, 235, 236),  this study has clearly evaluated the 2 year clinical outcome of this 





Chapter 6: Chemokine and other soluble mediator profiles in association to eczema, 
wheeze and allergen sensitization. 
 
6.1 Introduction  
Chemokines are a superfamily of proteins involved in the immune cell chemotaxis by  
regulating leukocyte traffic under homeostatic and inflammatory conditions, (103) their 
release plays an important role in the pathogenesis of allergic disorders (108, 237) and 
are easily detected in the plasma or serum in cord blood (238). The chemokine receptors 
are expressed on the surface of several cell types involved in allergic inflammation such 
as CCR1 on eosinophils, basophils and monocytes. CCR2 is expressed on the Th1 
lymphocytes and CCR3 on Th2 lymphocytes (239). 
 
To date studies have focused on the association of  chemokines and soluble mediators in 
the serum or plasma from cord blood of subjects with atopy, characterized by Th2 
immune responses which is normally related to cytokines , IL-5 and IL-13 and the 
induction of IgE synthesis (9). Elevated levels of cord blood CCL17, CCL17/ CXCL10 
ratios and CCL22/ CXCL10 ratios at birth were associated with  children who 
subsequently developed allergic symptoms (116, 238), while allergic sensitization was 
preceded by elevated levels of CCL22 and reduced levels of CXCL11(116, 240).  
 
Aside from soluble receptor sCD14, soluble cytokine and immunoglublulin receptors like 
sCD30, sCD23 and sIL4-receptor have been measured in cord blood before but were not 
found to be associated with the development of atopic disorders. Moreover, CD30 and 
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CD23 level in serum of cord blood were not associated to subjects who subsequently 
developed allergic sensitization and atopic dermatitis before the age of 3 (119). 
 
Studies have focused on a narrow panel of chemokines and soluble receptors measured in 
cord blood serum or plasma. Furthermore, neither chemokines/cytokines nor soluble 
cytokine receptors studies in cord blood had any significant impact in predicting atopic 
disorders so far. This section of the thesis aims to include a wider panel of chemokines as 
well as cytokines, soluble receptors, growth factors and soluble MMPs/TIMPs from in 
vitro cultures using cord blood mononuclear cells stimulated with LPS. We aim to 
associate these soluble mediator profiles with subjects who subsequently develop 
eczema, wheeze or allergen sensitization by 2 years of age and at 5 years of age. 
 
6.2 Materials and Methods  
6.2.1 Subjects selected for study 
This section of the study used the same cord blood mononuclear cells (CBMCs) from the 
group of subjects described in Chapter 5 (Figure 5.2, page 97). Figure 6-1 summarizes 
the soluble mediators of interest that will be associated to the clinical outcomes at year 2 
and year 5. The outcomes of eczema, wheeze and allergen sensitization (without clinical 
outcomes) will be compared to a control group of subjects who are healthy (no clinical 
outcomes and no allergen sensitization). Details of the subject’s selected were previously 
described in section 5.2.4, page 93 However, in this part of the study there are only n=62 
subjects who are healthy without allergen sensitization and n=31 wheeze subjects, the 
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difference in the number of subjects in this part of the study from Chapter 5 is due to 










Figure 6-1: Flow chart of cord blood mononuclear cell soluble mediator response study 
and its correlation to the clinical phenotypes at 2 years and 5 years of age. 
 
6.2.2. Multiplex assays 
6.2.2.1. Selection of soluble mediators of interest using the RayBio cytokine antibody 
array. 
To identify chemokines and other soluble mediators associated with our clinical 
outcomes, preliminary screening was carried out using the RayBio Custom cytokine 
antibody array. Cytokine protein membranes coated with 174 cytokine, chemokine, and 
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soluble receptor antibodies were probed with supernatant samples according to the 
manufacturer’s instructions using RayBio Human Cytokine Antibody G Series 2000 
(RayBiotech, Inc., Norcross, USA).  The supernatant used were from 3 random samples 
pooled together from each group: the healthy group, the eczema group and the wheeze 
group from cord blood mononuclear cells cultured with 1ug/mL LPS and 5ug/ml PHA 
using cell culture methods as described previously in Chapter 5.  
 
By comparing the signal intensities, relative expression levels of the analytes measured 
were made (Data not shown). From this preliminary semi-quantitative analysis, cord 
blood cells stimulated with LPS had more soluble mediators showing differential profiles 
amongst the 3 groups studied compared to cells stimulated with PHA. Thus, further 
quantification was carried out using only LPS stimulated cord blood mononuclear cells.  
 
6.2.2.2. Quantification of soluble mediators  
Measured analytes which showed differential profiles amongst the 3  groups were then 
selected for quantification using the human milliplex kit (Millipore, Massachusetts, USA) 
with supernatant cultured from n=154 LPS stimulated and unstimulated cord blood 
samples with methods previously described in Section 5.2.6, page 94 . The analytes of 
interest were chosen from several multiplex panels: the Milliplex Map human 
cytokine/chemokine (panel I, II and III), the Milliplex map human TIMP panel II and 
Milliplex map human soluble cytokine receptor panel. The assays were performed 
according to the instructions of the manufacturer (Millipore). Data was acquired by a 
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Bio-Plex 200 instrument (BioRad, USA) and was analyzed by the Bio-Plex Manager 
software (version 4.1, BioRad).  
 
6.2.3 Statistical analysis 
Statistical analysis was performed using SPSS software version 19.0 for windows (SPSS, 
Inc. Chicago III, and USA). The Mann-Whitney U test was used to analyze the 
differences between the groups of the soluble mediator profiles and comparisons were 
made between the eczema group versus the healthy group, between wheeze versus the 
healthy group and between healthy subjects with no clinical manifestations of allergic 
disorders with allergen sensitization and without allergen sensitization (Figure 6-1). 
Bonferonni adjustments were made for multiple comparisons. The logistic regression was 
also used to adjust for potential confounding factors in the association of the soluble 
mediators’ profiles and the outcome of allergic disorders by 2 years of age. Values of p ≤ 
0.05 were considered statistically significant.  
 
6.3 Results  
6.3.1 Association of cord blood mononuclear cell (CBMC) production of 
chemokines, cytokines, soluble receptors, MMP-TIMP and growth factors in 
relation to allergen sensitization, eczema and wheeze at 2 years of age.  
By measuring the levels of soluble mediators detected at birth in cord blood, we 
evaluated the association of specific soluble mediators with the outcome of allergen 
sensitization, eczema and wheeze by 2 years of age as potential risk factors preceding the 




Figure 6-2 to 6-5 presents the scatter plots of chemokines, cytokines, soluble receptors, 
soluble growth factors, soluble tissue inhibitors of metalloproteinases (TIMP) and matrix 
metalloproteinases (MMP) between allergen sensitized, eczema, wheeze and healthy 
control groups. The p values for Figure 6-4 and Figure 6-5 have been adjusted for the 
multiple comparisons between the healthy, eczema and wheeze group using the 
Bonferroni correction.  
 
Both the profiles from the unistimulated as well as LPS stimulated CBMC have been 
presented in this part of the study as most of the soluble mediators in the unstimulated 
conditions produced significant amounts of protein within the detection limits. 
 
6.3.1.1. Allergen sensitization profile at 2 years of age. 
Results in section 5.3.2, page 107 show that distinct immunophenotypes exist between 
subjects that were non allergen sensitized and allergen sensitized without the 
development of clinical allergic disorders. 
 
Thus, in addition to the clinical outcomes of eczema and wheeze, this section of the study 
sought to evaluate the possible inherent differences in the chemokine and other soluble 
mediators responses from cord blood cells of healthy subjects who did not develop any 
clinical manifestations of allergic disease by 2 years of age. The comparison was made 
between those who developed allergen sensitization and those who did not develop 
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allergen sensitization (healthy control group) when assessed by skin prick test to inhalant 
or dietary allergens. 
 
Figure 6-2 and Figure 6-3 are scatter plots of the chemokine and soluble mediator’s 
profiles between the healthy and the allergen sensitized group. Overall, subjects who 
were sensitized had increased production of several chemokines from unstimulated 
CBMCs compared to the healthy group such as CCL1 [0.006 (0.001-6.21) vs 
0.001(0.00002- 0.006)ng/mL ], CCL8 [0.02 (0.01- 0.22) vs 0.01 (0.01-0.02)ng/mL], 
CCL22 [0.44 (0.17-0.94) vs  0.18 (0.07-0.51)]ng/mL , CCL24 [6.84 (2.17-8.94) vs  
4.85(2.54-6.74)ng/mL] and CXCL5 [0.35 (0.19- 6.47) vs 0.042(0.010-0.239)ng/mL] 
with  p < 0.05 respectively. Interestingly, only chemokine CCL7 was suppressed in the 
allergen sensitized group 0.04(0.02-0.06)ng/mL compared to the healthy group 0.06(0.04 
– 0.08)ng/mL ( Figure 6-2). 
 
LPS stimulated chemokine CCL3 (monocyte inflammatory protein-1 alpha), CXCL6 
(granulocyte chemotactic protein-2), cytokine IL-16, soluble receptors sEGFR, sIL-2Rα, 
sIL-6R, sTNF-αRI along with sTIMP-2, MMP-9 and M-CSF were all significantly 
upregulated in the allergen sensitized group compared to the healthy group. Unstimulated 
CBMC showed profiles of significantly higher sEGFR, sIL-6R, sTNF-αRI and sTNF-
αRII  in the sensitized group compared to the group with no sensitization [1.16 (0.75-
1.32) vs 0.67 (0.51-0.87)ng/mL], [0.08 (0.05-0.19) vs 0.04 (0.02-0.07) ng/mL] ,[0.05 
(0.03- 0.08)ng/mL vs 0.02(0.01-0.04)ng/mL], [0.14 (0.10-0.34) vs 0.08 (0.06-0.13) 
ng/mL] with p =0.001 respectively. In addition to soluble receptors, TIMP-1 and TIMP-2 
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as well as PDGF-BB were significantly elevated in the allergen sensitized group 
compared to the non-sensitized group [4.43(1.25-8.22) vs 1.40 (0.74-2.24)ng/mL, 
p=0.001] , [0.94 (0.47-1.47) vs 0.36(0.26- 0.48)ng/mL, p=0.001] and [0.08(0.04- 0.13) vs 
0.03(0.02-0.10)ng/mL, p=0.012] ( Figure 6-3).Descriptive data of LPS stimulated 
chemokine and soluble mediator levels in median and interquartile range values are 
available in Appendix G. Table 6-1 shows a summary of all the chemokine and soluble 
mediator profiles that were statistically significant ( p < 0.05) based on the Mann-
Whitney U test.  
 
Table 6-1: Summary of both unistimulated and LPS stimulated chemokine and other 
soluble mediator profiles between the subjects with allergen sensitization and the healthy 
control group based on the Mann-Whitney U test. 
Chemokines and soluble mediators listed in table are those with statistical significant differences 
(after Bonferonni adjustment). Arrows indicate increased or decreased production in the outcome 























Figure 6-2: Chemokine profile of healthy non allergen sensitized (AS) (n=62) and healthy 
allergen sensitized (AS) (n=32) subjects from unstimulated (M) cord blood mononuclear 
cells (CBMCs) and in response to 1ug/mL lipopolysaccharide (LPS). The band in the middle 
of the scatter plot represents the median value, and the ends of the whiskers represent the 25th 
and 75th percentile value of the data. NS indicates no statistical significant differences. 
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Figure 6-3: Soluble receptor, cytokine, growth factor, TIMP/MMP   profile of 
healthy non- allergen sensitized (AS) (n=62) and healthy allergen sensitized (AS) 
(n=32) subjects from unstimulated (M) cord blood mononuclear cells (CBMCs) and 
in response to 1ug/mL lipopolysaccharide(LPS). The band in the middle of the scatter 
plot represents the median value, and the ends of the whiskers represent the 25th and 75th 
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6.3.1.2 Eczema and wheeze profile at 2 years of age  
Figure 6-4 and 6-5 shows the chemokine and other soluble mediator profiles between the 
healthy, eczema and wheeze groups.  
 
In contrast to the profile of the allergen sensitized subjects, eczema at 2 years was 
significantly associated with mainly reduced levels of  LPS stimulated CCL1( I-309), 
CCL2 (monocyte chemotactic protein-1, MCP-1), CCL7 (monocyte chemotactic protein-
3 ,MCP-3), CCL8 (monocyte chemotactic protein-2 ,MCP-2), CCL22 (Macrophage-
derived chemokine ,MDC), CCL24 (Eotaxin-2) at birth  compared to healthy subjects, 
including CXC chemokines such as CXCL1/2/3 (GRO), CXCL5 (Epithelial cell-derived 
neutrophil-activating protein-78 ) and CXCL6 (Granulocyte chemotactic protein 2)           
( Figure 6-4). 
 
 A similar profiles of reduced CCL22 was seen between the unstimulated cord blood cells 
in the healthy group compared to the eczema group [0.165(0.05-0.72) vs 0.823(0.25-
1.55) ng/mL, p=0.02] (Figure 6-4). Eczema development at 2 years was also associated 
with a reduction of LPS stimulated soluble IL-6 receptor (sIL-6R), including TIMP-1, 
MMP-1 and MMP-9 plus growth factors Macrophage colony-stimulating factor (M-CSF) 
(Figure 6-5).  
 
The wheeze group similar to eczema presented with reduced productions of LPS 
stimulated chemokines CCL1, CCL20 (macrophage inflammatory protein -3α, MIP-3α) 
and soluble MMP-1(Figure 6-4 and Figure 6-5). Table 6-2 and 6-3 shows a summary of 
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all the chemokine and soluble mediator profiles that were statistically significant (p < 
0.05) based on the Mann-Whitney U test. 
 
Table 6-2: Summary of both unistimulated and LPS stimulated chemokine and other 
soluble mediator profiles between the subjects with eczema and the healthy control group 









Table 6-3: Summary of both unistimulated and LPS stimulated chemokine and other 
soluble mediator profiles between the subjects with wheeze and the healthy control group 










Chemokines and soluble mediators listed in table are those with statistical significant differences (after 
Bonferonni adjustment). Arrows indicate increased or decreased production in the outcome group 
(eczema) compared to the control group (healthy) 
Chemokines and soluble mediators listed in table are those 
with statistical significant differences (after Bonferonni 
adjustment). Arrows indicate increased or decreased 
production in the outcome group (eczema) compared to the 
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Figure 6-4: Chemokine profile of healthy (n=62), eczema (n=29) and wheeze (n=31) 
subjects from unstimulated (M) cord blood mononuclear cells (CBMCs) and in 
response to 1ug/mL lipopolysaccharide (LPS). The band in the middle of the scatter 
plot represents the median value, and the ends of the whiskers represent the 25th and 75th 
percentile value of the data. The pink circles represent the subjects who are allergen 
sensitized and the black circles are the subjects who are non-sensitized. NS indicates no 
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Figure 6-5: Soluble receptor, cytokine, growth factor, TIMP/MMP profile of healthy 
(n=62), eczema (n=29) and wheeze (n=31) subjects from unstimulated (M) cord 
blood mononuclear cells (CBMCs) and in response to 1ug/mL lipopolysaccharide 
(LPS). The band in the middle of the scatter plot represents the median value, and the 
ends of the whiskers represent the 25th and 75th percentile value of the data. The pink 
circles represent the subjects who are allergen sensitized and the black circles are the 
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6.3.1.3 Logistic regression of eczema, wheeze and allergen sensitization profiles  
Logistic regression models were used to account for the imbalance in demographic and 
clinical factors affecting the association of the chemokine, cytokine, and soluble receptor 
and growth factor profiles to their respective outcomes (allergen sensitization, eczema 
and wheeze). 
 
For the subjects who were allergen sensitized by the age of 2 years, cord blood soluble 
mediators were mainly positively associated with this outcome, but this relation was no 
longer statistically significant for LPS stimulated MMP-9, including CCL22, CCL24 and 
PDGF-BB from unstimulated cord blood cells after the adjustment for confounding 
factors (Appendix H). All other soluble mediators remained statistically significant in 
both unadjusted and adjusted models  
 
All the chemokines and soluble mediators associated to eczema as listed in Table 6-2 
remained statistically significant after the adjustment in the logistic regression model 
(Appendix I). For the outcome of wheeze, the association of CCL1 and MMP-1 with 
wheeze was no longer significant. Only CCL20 remained statistically significant with the 






 6.3.2 Association of cord blood mononuclear cell (CBMC) production of 
chemokines, cytokines, soluble receptors, MMP-TIMP and growth factors in 
relation to later eczema, wheeze or allergen sensitization at 5 years of age.  
The CBMC production of the soluble mediators measured were found not to be 
associated with the clinical outcomes at 5 years of age when similar analyses were 
applied (Figure 6-6, Figure 6-7, Figure 6-8 and Figure 6-9). However, it was noted that 
the number of subjects who developed persistent clinical outcomes up till 5 years of age 
very small, thus it there was insufficient power to make conclusive statement about the 



















Figure 6-6: Chemokine profile of healthy (n=41), eczema (n=8) and wheeze 
(n=10) subjects from unstimulated (M) cord blood mononuclear cells (CBMCs) 
and in response to 1ug/mL lipopolysaccharide(LPS). The band in the middle of the 
scatter plot represents the median value, and the ends of the whiskers represent the 
25th and 75th percentile value of the data. 
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Figure 6-7: Soluble receptor, cytokine, growth factor, TIMP/MMP   profile of 
healthy (n=41), eczema (n=8) and wheeze (n=10) subjects from unstimulated (M) 
cord blood mononuclear cells (CBMCs) and in response to 1ug/mL 
lipopolysaccharide (LPS). The band in the middle of the scatter plot represents the 
median value, and the ends of the whiskers represent the 25th and 75th percentile 
value of the data. 
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Figure 6-8: Chemokine profile of healthy non allergen sensitized (AS) (n=41) and 
healthy allergen sensitized (AS) (n=9) subjects from unstimulated (M) cord blood 
mononuclear cells (CBMCs) and in response to 1ug/mL lipopolysaccharide 
(LPS). The band in the middle of the scatter plot represents the median value, and the 
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Figure 6-9: Soluble receptor, cytokine, growth factor, TIMP/MMP   profile of 
healthy non- allergen sensitized (AS) (n=41) and healthy allergen sensitized (AS) 
(n=9) subjects from unstimulated (M) cord blood mononuclear cells (CBMCs) 
and in response to 1ug/mL lipopolysaccharide (LPS). The band in the middle of 
the scatter plot represents the median value, and the ends of the whiskers represent the 
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6.4 Discussion  
In our study, we have identified several soluble mediators measured from 
unstimulated and LPS stimulated CBMC to be potential risk factors associated with 
early eczema, wheeze and allergen sensitization (Chapter 5). Aside the conventional 
cytokines measured, this exploratory study of soluble mediators may be useful in the 
identification of newborns at birth that are at risk for the development of these allergic 
disorders at 2 years of age and may further provide novel information on the 
aberrations of the innate immune system that leads to the development of eczema, 
wheeze or allergen sensitization in early childhood.  
 
6.4.1 Allergen sensitization  
Interestingly, a substantial number of elevated chemokines and soluble receptors were 
associated with allergen sensitization as seen from this study. This profile is 
contrasting to the earlier study described in section 5.3.2, page 107 which showed 
profiles of diminished production of LPS stimulated TNF-α, IL-10  and PHA IL-5 and 
IL-13 associated with allergen sensitization. From the cytokine profile and current 
chemokine and other soluble mediator profile observed, this study can conclude that 
differential immunophenotypes are present between subjects without clinical 
manifestation of allergic disorders with positive skin prick test to any dietary or 
inhalant allergens by 2 years of age and without allergen sensitization. The cytokine, 
chemokine and soluble mediators profiles further justify the need to analyse each 
allergic phenotype as a separate outcome (ie: allergen sensitization, eczema and 
wheeze versus healthy controls) to enable the evaluation of the distinct 




Evidence suggests that Th1 and Th2 cells selectively migrate in response to the 
corresponding chemokines (241), and the secretion of particular cytokines by Th2 
cells is thought to be responsible for promoting and maintaining allergic reactions, 
upregulating IgE production and contributing to the differentiation and activation of 
eosinophils (242). The group of subjects who subsequently developed allergen 
sensitization characterized by 2 years of age showed differential responses in their 
chemokine profile. CCL22 (macrophage-derived chemokine) was found to be 
significantly higher at birth in infants who subsequently develop allergic sensitization, 
and our observation was similar to a study where high CCL22 levels at birth was 
associated with sensitization (circulating IgE to food allergens and/or positive SPT) at 
24 months of age (240). Furthermore, CCL22 is known to act specifically on Th2 
lymphocytes and Th2 cytokines IL-4 and IL-13 are able to stimulate the production of 
CCL22 by monocytes while IL-10 inhibits its production (243). It was noted that 
subjects with allergen sensitization was also associated with a profile of reduced LPS 
stimulated IL-10 production as reported in section 5.3.2, page 107. 
 
Chemokine CCL3 (Macrophage inflammatory protein-1α) was significantly elevated 
in the group of subjects with allergen sensitization, and is a chemokine which induces 
the migration of specifically eosinophils in a concentration dependent manner in vitro 
. Eosinophils are one of the principal effector cell types activated at the sites of 
allergic inflammation and accumulation is partially dependent on the local generation 
of soluble chemoattactant chemical signals (244). Furthermore, eosinophils are able to 
synthesize and secrete PGD2, a key mediator of allergic inflammatory which 
functions as an autocrine signal for eosinophil activation (245).  In the in vitro 
condition, CCL3 is able to enhanced IgE and IgG4 production by surface IgE+ and 
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surface IgG4+ B cells when induced by IL-4 plus anti-CD40 mAb in a dose-dependent 
manner (246).  
 
Chemokine CCL24 (Eotaxin-2) that was found to be significantly elevated in the 
allergen sensitized group is also a potent chemoattractant for eosinophils, and a study 
by Menzies-Gow et al. has reported a significant infiltration of eosinophils and 
basophils in human volunteers following intradermal injection of eotaxin-2 (247).  
 
CCL1( I-309) was another chemokine upregulated in the cord blood of infants with 
allergen sensitization that has been shown to play a role in recruiting eosinophils in 
the lung of mice following allergen challenge which was directly affected by 
neutralization of CCL1, but had no effect on the recruitment of Th2 cells (248).  
 
CCL8 (monocyte chemoattractant protein 2), an agonist for the chemokine receptor 
CCR8 was found to be significantly higher in production at birth in subjects who 
developed allergen sensitization. CCL8 has been shown to induce the migration of 
highly differentiated Th2 cells enriched in IL-5 and the IL-23 receptor. Additionally, 
it has been reported that CCR8 and CCL8 deficient mice had markedly less 
eosinophilic inflammation than wild-type, highlighting the importance of the 
CCR8/CCL8 complex in eosinophil recruitment (249).  
 
Interestingly, another monocyte chemotactic protein like CCL8 which is the CCL7 
(Monocyte Chemotactic Protein-3) was found to have a contrasting profile of 
significantly reduced levels in the allergen sensitized group compared to the group 
that was healthy. The under-expression of this chemokine was observed in a study by 
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Chehimi et al. who has reported that subjects with the hyper-IgE syndrome 
characterized by markedly increased levels of IgE had underexpressed CCL7 genes 
compared to other chemokine genes measured like CCL8, CCL22, CCL1 and CCL3 
where the gene expression level reached up to 200% compared to the controls (250).  
 
Finally, CXCL5 (epithelial-derived neutrophil-activating peptide 78) which was 
discussed earlier as neutrophil-specific chemoattractant was also upregulated in the 
cord blood of subjects who were allergen sensitized. This chemokine has been shown 
to mediate specifically the infiltration of neutrophils and not eosinophils (251). 
However, mast cells and basophils are classical FcεRI expressing cells but Gounni et 
al. has reported that human neutrophils express FcεRI with high affinity for IgE 
which might explain the susceptibility to allergen sensitization when the CBMC of 
neonates are inherently more capable of secreting CXCL5. 
 
In our study we have also observed higher IL-16 levels at birth in subjects with 
allergen sensitization, a cytokine which is able to play a role in amplifying 
inflammatory processes. Nagy et al. reported that in subjects grouped based on 
specific IgE, serum IL-16 levels were significantly elevated in subjects who were 
sensitized compared to the non-sensitized subgroup (252). Furthermore, IL-16 seems 
to be significantly correlated with total IgE  in OVA challenged mice where  repeated 
inhalation of OVA induced a marked-upregulation of the OVA-specific IgE in serum 
and treatment of mice with antibodies to IL-16 significantly suppressed this 




Soluble receptors sEGFR, sIL2-rα, sIL-6R, sTNF-αRI and TNF-αRII were all 
significantly elevated in subjects who were allergen sensitized. The IL-2- receptor α  
(CD25)  was found to be upregulated in the group with allergen sensitization where it 
was reported to play a role in allergic inflammation especially in the recruitment of 
eosinophils (254). Similarly with soluble TNF-α receptors I and II which were also 
significantly upregulated in the allergen sensitized group are reported to be associated 
with allergic inflammation (255). 
 
sIL-6R has been shown to  induce the secretion of CCL2  suggesting that the IL-6/IL-
6R complex might contribute to the recruitment of  monocytes and T lymphoctyes 
during inflammation (256). In the allergen sensitized subjects we see the increase in 
sIL-6R along with the increase of sTIMP1, sTIMP2 and MMP9. Aida et al. has 
reported that IL-6 and sIL-6R to be able to stimulate the production of  MMPs and 
their inhibitors suggesting that the  IL-6R may be  responsible for modulating the 
production of MMPs (257). 
 
6.4.2 Eczema  
In contrast to the allergen sensitized subjects, the CBMC chemokine and other soluble 
mediator secretion levels of the eczema and wheeze were reduced compared to their 
healthy controls.  
  
CXCL5 production was found to be reduced in the eczema subjects. It is well-known 
that the expression of innate immune marker CXCL5 is inducible by a variety of 
inflammation mediators including lipopolysaccharide (LPS) , and it is essential as a 
chemo-attractant for the recruitment and activation of neutrophils via protease-
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activated receptor (PAR) (258). Microbes and/or their components can penetrate and 
destroy the epithelium to release proteases that can potentially activate PARs. PARs, 
especially the expression of PAR-2 on the human skin as well as innate immune cells 
(monoctyes, neutrophils and eosinophils) is an integral component of the host 
antimicrobial innate immunity that functions by enhancing phagocytic activity against 
Gram-positive (S. aureus) bacteria by human leukocytes (259). It’s also been 
associated with several inflammatory skin disorders involving barrier abnormalities 
including atopic dermatitis (260).  
 
Interestingly, Rohani et al. has reported an inhibition in the induction of CXCL5 
when activation of PAR-2 was inhibited by siRNA for PAR-2(258). Furthermore, 
CXCL5 has been reported to be a regulator of the IL-17 axis and neutrophil 
homeostasis in mice (261). Neutrophils, important for host defense against bacterial 
and fungal infections are largely absent in eczema skin biopsies (70), while IL-17 
which is necessary for protective immunity against extracellular pathogens were also 
found to be expressed in low levels in human eczema skin lesion (262). This 
observation relates well to the earlier finding reported in section 5.3.1.2,page 101 
where IL-8 which is also important for neutrophil recruitment (211) was also found to 
be reduced in eczema subjects. 
 
Another chemokine which was reported to exert higher antibacterial activity in an in 
vito condition compared to chemokine CXCL5 against several gram-positive and 
gram-negative aerobic bacteria which are relevant in dermal infections is CXCL6 
(263). The production of chemokine CXCL6 was also reduced at birth in subjects 




 In this study, monocyte chemotactic proteins (CCL2/MCP-1, CCL8/MCP-2, 
CCL7/MCP-3) which were found to be suppressed in production at birth in the 
eczema subjects play a critical role in the innate immunity by directing the migration 
of monocytes to the site of inflammation and as chemoattractants for  T lymphocytes 
and natural killer cells (264, 265), hence the impairment of production might indicate 
a defective innate immune response. The reduced production of CCL2 in the eczema 
subjects are agreeable with a study by Sugiyama et al. that has found a negative 
relationships between cord blood CCL2/MCP-1 in relation to the risk of atopic 
dermatitis in the first year of life (266). Furthermore, CCL2/MCP-1 secretion by 
human neutrophils and monocytes help resolve acute inflammation by facilitating 
monocyte recruitment to the site of bacterial infection (259).  
 
 Interestingly, we have also found that subjects with eczema by 2 years had 
diminished production of CCL22 and CXCL6; both chemokines regulate trafficking 
of cutaneous CD4+CD25+ regulatory T cells that express CCR4 and CCR8 into skin. 
The role for CD4+CD25+  regulatory T cells in atopic dermatitis was suggested when 
CD4+CD25+FoxP3+ T-regulatory cells were not found in lesional atopic dermatitis 
skin, and an impaired infiltration of CD4+CD25+FoxP3+ T-cells causes a 
dysregulation of effector T cells (267). In addition to this, loss-of-function mutations 
in the gene encoding FoxP3 has been reported to be associated with increased hyper 
IgE levels and eosinophilia which are prominent features in eczema (268).  
 
Eotaxin-2/ CCL24 which signals exclusively via the CCR3 receptor with eosinophil-
selective chemoattractant activity was found to have lower levels of expression at 
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birth in subjects with eczema by 2 years of age. Reported elevated  gene expression of 
eotaxin-3/CCL26 and eotaxin-1/CCL11 but lower expression levels of  eotaxin-
2/CCL24 in skin lesions of atopic dermatitis patients compared to skin of healthy 
controls indicate an important role of CCL24 in atopic dermatitis (269) . 
 
The sIL-6r has the potential to act as an antagonistic molecule. It was shown that sIL-
6R in the assay setup enhanced the antagonistic properties of sgp130 by promoting 
formation of an [IL-6-sIL-6R-sgp130] tertiary complex, hence preventing IL-6 
signalling through the cognate receptor (270). Diminished levels of soluble IL-6 
receptor (sIL-6r) was associated to the outcome of eczema, and in section 5.3.1.2,page 
101 we reported an increased LPS stimulated IL-6 to be associated with the outcome 
of eczema by the age of 2 years. 
 
As mentioned earlier, the IL-6r was reported to be responsible for modulating the 
production of MMPs and their inhibitors. In the allergen sensitized subjects, the 
increased sIL-6r was seen along with increased soluble TIMP-1, MMP-1 and MMP-9, 
while the reduction of sIL-6r was accompanied by reduced levels of TIMP-1, MMP-1 
and MMP-9 in the eczema subjects. 
 
6.4.3 Wheeze 
 CCL20 (Macrophage Inflammatory Protein-3) is a peptide with both chemotactic and 
antimicrobial/antimicrobial activity. Its secretion by innate immune cells can be via 
pathogen-associated molecular patterns (PAMPs), for example lipopolysaccharide 
(LPS), lipoteichoic acid (LTA), and Pam (3)Cys (271). This chemokine production is 




 CCL20 is released by epithelial cells of the airway as part of the airway host defense, 
and in the in vitro condition has been shown to exhibit anti-microbial activity similar 
to α-defensins by bacterial cell membrane permeabilization, especially against Gram-
negative organisms that are lung pathogens (272). Furthermore, the role of CCL20 
having anti-viral properties has been demonstrated in an in vitro study when pre-
incubation of Vaccinia virus with CCL20 resulted in a concentration-dependent 
reduction in virus plaque formation (273). Aside its anti-microbial and anti-viral 
properties, CCL20 chemokine released by epithelial airway cells (274) function in the 
recruitment of a distinct population of CCR6-expressing immature DCs for 
subsequent antigen presentation (275). Immature DC’s are part of the innate response 
capable of antigen capture and antigen presentation that determines a specific T-cell 
response which makes them important in the development and perpetuation of airway 
immune responses (274).  
 
In summary, the subjects with allergen sensitization were associated to a chemokine 
profile of elevated eosinophil chemoattactants and Th2-specific chemokines. The 
outcome eczema and wheeze were associated with diminished productions of 
antibacterial and antiviral chemokines. Furthermore, neutrophil chemoattractants 
CXCL5 and CXCl6 were specifically associated to the eczema subjects along with IL-




 Table 6-4: Summary of chemokines associated with the outcome of allergic disorders 






In conclusion, our study reports that the variations in immunologic responses at birth 
seen from the chemokine, cytokine, and soluble receptor and growth factor profiles in 
cord blood mononuclear cells with the outcome of early childhood eczema, wheeze 
and allergen sensitization by 24 months suggests that differential innate immune 










Chapter 7: Conclusions and future directions 
The first objective of this dissertation involved a 5 year follow up which have yielded 
valuable information on the progression of eczema and wheeze disorders from the 
first 2 years of life. In this cohort, 85% of those who ever had eczema and 63% of 
those who ever had wheeze developed symptoms in the first 2 years of life. The 
prevalence of allergen sensitization in eczema and wheeze subjects at 2 years was low 
at 32%. At year 5, this percentage increased to 73%, 79% and 89% for eczema, 
wheeze and rhinitis respectively.  At 2 years of age, only eczema was significantly 
associated with allergen sensitization and at 5 years of age, only wheeze and rhinitis 
were significantly associated with allergen sensitization. Despite the association of 
allergen sensitization with wheeze and rhinitis at 5 years of age, after adjustment for 
confounders in the logistic regression, early allergen sensitization alone at 2 years was 
not a risk factor for the subsequent development for these allergic disorders. Instead, 
we have concluded that the early phenotypes of eczema and wheeze at 2 years are 
important determinants of subsequent development of allergic disorders at 5 years. 
Early allergen sensitization without these early phenotypes as co-factors constituted 
no increased risk subsequent eczema or wheeze.  
 
The second objective of this dissertation was to utilize frozen cord blood mononuclear 
cells (CBMCs) collected from the infants at birth to conduct immunological assays, to 
determine the association of CBMC immune responses with the development of 
eczema, wheeze and allergen sensitization in subjects without any clinical 
manifestation of allergic disorders by year 2 and year 5. The results showed that a 
distinctly inherent immunological predisposition influences the development of 
wheeze and eczema by 2 years. The hypo-responsiveness of cytokine IL-8 is a 
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possible risk factor for the development of eczema. In contrast, the hyper-responsive 
cytokine profile of increased lipopolysaccharide (LPS) stimulated IL-8 and IL-
12/23p40 as well as phytohaemagglutinin (PHA) stimulated IL-8 and IL-5 were 
significantly associated to the subsequent development of wheeze at 2 years.   
Furthermore we have made a novel observation of the enhanced combined IL-6, IL-
12/23p40 and IL-1β and its significant association to the risk for wheeze at 2 years 
(adjusted OR=2.45; 95% CI =1.50–3.93, p=0.001). This novel observation points to 
the possible role of the IL-23/IL-17 axis associated with early onset wheezing in the 
first 2 years of life as this combination of cytokines are an important determining 
factor for the differentiation of naïve T cells into IL-17–producing Th17 cells in 
humans.  
 
A part of the study has shown us that the main producers of both cytokine IL-8 and 
IL-6 from LPS as well as PHA stimulated CBMCs are CD14+ monocytes, and further 
classification of these cells would be very interesting. Certain inherent immunological 
factors, especially in the innate compartment involving mainly antigen presenting 
cells such as monocytes predisposes the allergic phenotypes in early life and 
furthermore the impaired functionality of monocytes at birth could be associated with 
these allergic disorders. The involvement of monocytes in the outcome of childhood 
allergic disorders will be further explored using a gene microarray approach to 
elucidate the molecular mechanisms associated with the differential 
immunophenotypes . The CD14+ monocytes from CBMCs will be purified and 
activated by stimulating the cells with LPS to study the differential gene profiles of 




Furthermore, this cohort has cryo-preserved peripheral blood mononuclear cells 
(PBMC) from subjects aged 1 year. Future work involving study of the cytokine 
profile responses of the 1 year old PBMC using similar culture conditions to detect 
progression of the cytokine profiles would be compared to that of CBMCs. In 
addition, given the combination of cytokines (IL-6, IL1-β and IL-12/23p40) that were 
produced in the wheeze subjects in response to LPS, the production of cytokine IL-17 
will be studied in the 1 year PBMC.  
 
We have also extended our panel of soluble mediators to chemokines, additional 
cytokines, soluble receptors and soluble growth factors in LPS stimulated CBMC in 
the effort to potentially identify unreported soluble mediators associated with allergic 
disorders in early childhood. In summary, chemokines involved in anti-microbial and 
anti-viral activities were found to be reduced in the subjects who developed 
subsequent eczema (CXCL5 and CXCL6) or wheeze (CCL20) at 2 years of age. 
Furthermore, CXCL5 and CXCL6 which also function as neutrophil chemoattractants 
found to be reduced in eczema subjects tallies with earlier findings of reduced pro-
inflammatory IL-8 productions in eczema subjects which is also involved in 
neutrophil recruitment and activation. 
 
 Interestingly, the subjects classified as allergen sensitized without any clinical 
manifestations of allergic disorders showed a contrasting profile from that of the 
eczema and wheeze subjects. Chemokines that were chemoaattractant for eosinophils 
(CCL3 and CCL22) were found to be elevated in these subjects, including 
significantly elevated levels of soluble receptors reported to be associated with 




The findings from this study has shown that aside from cord blood cytokine 
production, immunological dysregulations seen from chemokine or soluble cytokine 
receptor production points to other potential soluble mediators from cord blood which 
play an important role in the development of early childhood disorders. 
 
 In conclusion, the findings in this dissertation first point to the fact the clinical 
phenotypes of eczema and wheeze at 2 years are important risk factors for the 
development of allergic disorders at 5 years of life. From here, this thesis went on the 
answer the question about the ability to associate the development of these clinical 
phenotypes at 2 years to distinct cytokine profile from cord blood mononuclear cells. 
To results from the work managed to prove that distinct immune dysregulation 
detected by the cytokine profile secretion of cord blood mononuclear cells (CBMCs) 
were involved in the risk of the subsequent manifestation of the clinical phenotypes of 
eczema and wheeze at 2 years of age. The finding of this thesis allows us to generate a 
hypothesis for future studies that several immune cells are involved in the 
inflammatory airway hypoer-responsive which causes wheezeing in early childhood. 
First would be the important role of T-cells, especially IL-5 in the recruitment of 
eosinophils (276). However, it is also known that in human patients with 
asthma/wheeze levels of IFN-γ which are Th1 cytokines are increased as well (277). 
From the increased production of T-cell cytokines IL-2, IFN-γ and IL-5 that was 
shown in Chapter 5 of this dissertation, both Th1 and Th2 cytokines play a role in the 
development of wheeze. A contrasting hypo-responsive phenotype seen from the IL-8 
production was associated with eczema, which points out that different underlying 
innate immune responses are associated to the development of eczema and wheeze. 
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Furthermore, it is possible to hypothesize that the suppression of IL-8 expression may 
be involved in significantly impair host defense against various infectious agents in 
eczema skin.  
 
The results of this study have furthered our understanding of the pathogenesis and 
development of wheeze and eczema in young children. These results could also 
translate to the development of diagnostics that could more accurately predict wheeze 
and eczema. More importantly, this information would provide the impetus to 
designing novel preventive and therapeutic strategies. Future studies of this cohort 
could aim to validate these with a new multi-center birth cohort and come up with a 
prediction model to move on to developing protein array diagnostic kits for predictive 
markers of wheeze and eczema . 
 
It was r noted that the limitation of a study like this is the selection bias by selecting 
only subjects from a “high-risk” background, and the fact that the results from this 
study cannot be generalized to the entire population. There is a need if possible to 
validate the current results with a larger cohort from the general population. By 
comparing the allergic disorder outcomes to a group of truly healthy subjects from 
non-allergic families more significant differences in the cytokines measured might be 
revealed. However, based on previously published studies (Chapter 1), differential 
cytokine responses were reported just by comparing cytokine production from 
subjects in the high-risk and low-risk for atopy background. By comparing the CBMC 
cytokine responses of allergic outcomes (eczema and wheeze) in this study to subjects 
who were asymptomatic (healthy) from the same high-risk background, we do 
eliminate a possible confounding factor from the genetic background that could affect 
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the cytokine profile.  A high-risk cohort study such as this one also points out that 
despite similar genetic background of these subjects , the intrinsic differences in the 
CBMCs capability of producing cytokines are very distinct in the subjects who 
develop allergic disorders from the subjects who are healthy  (asymptomatic). The 
subjects who manifested symptoms probably have a stronger genetic predisposition to 
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Appendix B- Follow-up form  




























Appendix B- Skin prick test form  











Appendix B- Atopic disease form  













Appendix E  
 
Cytokine responses to lipopolysaccharide (LPS) in infants with eczema and wheeze at 2 years of age. P values have been adjusted for 
risk factors gestational age, paternal eczema using logistic regression analysis with eczema as the outcome and for risk factors birth 












*      Significant differences were found between groups with P value < 0.05  
**    Significant differences were found between groups with P value < 0.01 





Cytokine responses to phytohaemagglutinin (PHA) in infants with eczema and wheeze at 2 years of age. P values have been adjusted 
for risk factors gestational age, paternal eczema using logistic regression analysis with eczema as the outcome and for risk factors 









*      Significant differences were found between groups with P value < 0.05  
**    Significant differences were found between groups with P value < 0.01 
233 
 
ND  Not detectable  
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Appendix F  
Demographic characteristics of the children with eczema and wheeze and the healthy control 
















Values were presented as median with interquartile range and numbers with percentages for        
                             categorical data. Mann – Whitney tests; otherwise χ2 tests were used. 
Healthy Eczema Wheeze Healthy vs. Eczema Healthy vs. Wheeze
(n=65) ( n= 29) (n=34) P value P value 
Gestational age in weeks median (IQR)¶ 38.7 (1.6) 39.6 (1.7) 39.3 (1.9) 0.021 0.088
Infant sex , no (%)
Male 30(46) 18(62) 19(56) 0.154 0.358
Ethnicity ( %) 0.946 0.873
Chinese 30(46) 14(48) 13(38)
Malay 27(42) 12(41) 16(47)
Indian 7(10) 3(10) 4(12)
Others 1(2) 0(0) 1(3)
Mode of delivery , no.(%)
Lower segment caesarean section¶ 20(31) 6(21) 4(12) 0.313 0.036
Family history 1st degree relative (%) 
Maternal asthma ¶ 8(12) 5(17) 12(35) 0.522 0.007
Maternal eczema 12(18) 4(14) 4(12) 0.578 0.39
Maternal allergic rhinitis 23(38) 16(36) 16(47) 0.072 0.357
Paternal asthma 12(18) 4(14) 5(15) 0.578 0.638
Paternal  eczema¶ 5(8) 7(24) 2(6) 0.027 0.739
Paternal allergic rhinitis 19(32) 9(31) 8(24) 0.86 0.545
Sibling asthma 6(8) 5(17) 8(24) 0.264 0.053
Sibling eczema 7(12) 5(17) 6(18) 0.385 0.336
Sibling allergic rhinitis 7(11) 4(14) 6(18) 0.674 0.336
Birth order ¶ 0.771 0.038
1 27(42) 14(45) 7(23)
2 13(20) 6(20) 14(45)
>3 25(38) 9(35) 13(32)
Birth Height in median (IQR)¶ 49 (3) 50 ( 2.0) 50 ( 4) 0.076 0.003
Birth weight in  median (IQR)¶ 3.0 ( 0.5) 3.1 ( 0.5) 3.3 ( 0.5) 0.147 0.01
Weaning age in months mean ( SD) 6 (1) 6(0.0) 6 ( 2.0) 0.055 0.378
Prenatal maternal smoking 4(6) 2(7) 2(6) 1.000 1.000
Passive smoke exposure in household 19(29) 9(31) 14(41) 0.86 0.231
Keep pets ( %) 18(28) 5(17) 6(18) 0.276 0.268
Type of housing (%) 0.626 0.306
Public housing 56(86) 26(90) 26(76)
Private housing ( Condominium) 5(8) 2(7) 8(24)
Landed property 4(6) 1(3) 0(0)
Feeding history – birth to month 6 (%) 0.187 0.761
Near total breastfeeding with at least 60mL of 
   
1(2) 2(7) 0(0)
Any breastfeeding 47(72) 19(66) 25(74)
Total formula 17(26) 8(28) 9(26)
Probiotic supplementation 30(46) 9(31) 14(41) 0.169 0.636
*SCORAD index  Mean ± SD ( Range) 0 16.3 ± 8.1 (3.7-35.9) 0
Frequency of wheeze 
1 0 0 16
2 to 3 0 0 14
> 3 0 0 4
* SCORAD was not recorded for 13 subjects in the eczema group 




 Eczema  Wheeze Allergen sensitization in 
healthy subjects 







































































































The levels [median (25th-75th percentiles)] of lipopolysachharide (LPS) stimulated cord blood 
mononuclear cell (CBMC) chemokines, cytokines, soluble receptors, soluble TIMP/MMP and 
soluble growth factors in infants who developed eczema, wheeze and those who are healthy at 2 












































































































       































































































































0.561) 0.864) 0.547) 0.864) (0.291-1.58) (0.193-0.864) 






































































































*p value <0.05 in the Mann-Whitney U comparison between groups 
            **p value< 0.01 in the Mann-Whitney U comparison between groups. 




Chemokines Unstimulated Lipopolysaccharide ( LPS) 
Unadjusted Adjusted Unadjusted Adjusted 
OR p value  AdjOR Adj p 
value 
OR p value  AdjOR Adj p 
value 
CCL1 2.315 0.001 2.249 0.001 0.438 0.051 0.413 0.057 
CCL2 1.495 0.353 1.587 0.302 0.713 0.318 0.636 0.205 
CCL3 0.486 0.199 0.330 0.075 24.203 0.011 38.00 0.007 
CCL4 0.902 0.833 0.751 0.574 2.840 0.060 2.815 0.068 
CCL7 0.079 0.001 0.043 0.001 0.466 0.149 0.379 0.088 
CCL8 11.655 0.001 9.853 0.001 0.726 0.373 0.634 0.226 
CCL20 1.525 0.498 1.898 0.310 1.562 0.334 1.545 0.368 
CCL22 2.592 0.020 2.141 0.065 2.360 0.066 2.153 0.095 
CCL24 1.438 0.407 1.294 0.580 1.448 0.533 1.25 0.702 
CXCL1/2/3 1.257 0.563 0.974 0.950 .1.475 0.490 1.737 0.340 
CXCL5 2.171 0.001 2.002 0.004 1.344 0.500 1.160 0.736 
CXCL6 2.300 0.210 2.082 0.278 3.120 0.024 2.904 0.039 
Cytokines         
IL-1α 0.243 0.166 0.223 0.193 1.600 0.124 1.612 0.125 
IL-16 1.362 0.612 1.077 0.908 11.989 0.003 10.564 0.005 
Soluble 
receptors 
        
EGFR 15.38 0.001 42.09 0.001 17.653 0.037 18.541 0.037 
IL-6R 17.777 0.001 16.31 0.001 5.861 0.014 5.509 0.020 
IL-2rα 242.77 0.050 108.37 0.096 10.422 0.001 11.910 0.001 
Appendix H 
Univariate analysis and multivariate analysis of the association of unstimulated and LPS 
stimulated chemokines, cytokines, soluble receptors, and soluble TIMP/MMP and growth 
receptors with the outcome of allergen sensitization in subjects without any clinical manifestation 




Boldfacing indicates P values of less than 0.05 in the adjusted and unadjusted models , 












TNF-αRI 27.770 0.001 23.951 0.001 254.490 0.000 269.282 0.001 
TNF-αRII 9.580 0.002 7.805 0.006 2.333 0.074 2.195 0.100 
MMP/TIMP         





0.001 4.803 0.020 4.041 0.044 
MMP-1 0.657 0.326 0.742 0.496 1.486 0.186 1.322 0.352 
MMP-9 1.480 0.396 1.186 0.726 4.090 0.038 3.230 0.083 
Growth 
factor  
        
M-CSF 0.950 0.936 0.653 0.562 6.205 0.008 5.287 0.015 
PDGF-AA 1.1800 0.598 1.067 0.828 2.116 0.193 1.925 0.267 




Univariate and multivariate analysis of the association of unstimulated and LPS 
stimulated chemokines, cytokines, soluble receptors, soluble TIMP/MMP and growth 
receptors with the outcome of eczema at 2 years of age after adjustment for paternal 
eczema and gestational age. 
Chemokines 
 
Unstimulated Lipopolysaccharide ( LPS) 













CCL1 1.604 0.050 1.042 0.746 0.288 0.001 0.326 0.006 
CCL2 2.297 0.076 1.801 0.145 0.423 0.010 0.456 0.022 
CCL3 1.339 0.361 0.914 0.826 0.429 0.144 0.343 0.068 
CCL4 5.87 0.077 0.226 0.116 0.388 0.060 0.379 0.056 
CCL7 0.771 0.526 0.581 0.269 0.106 0.001 0.115 0.001 
CCL8 2.284 0.304 0.417 0.172 0.454 0.030 0.472 0.05 
CCL20 1.064 0.914 1.285 0.683 0.779 0.548 0.716 0.404 
CCL22 0.655 0.116 0.661 0.142 0.197 0.001 0.215 0.001 
CCL24 1.015 0.946 0.535 0.053 0.088 0.001 0.100 0.001 
CXCL1/2/3 0.877 0.298 0.653 0.111 0.304 0.019 0.217 0.016 
CXCL5 1.290 0.287 0.853 0.461 0.240 0.001 0.249 0.001 
CXCL6 0.817 0.778 0.509 0.356 0.143 0.001 0.127 0.001 
Cytokines         
IL-1α 1.553 0.221 1.604 0.213 0.556 0.042 0.582 0.076 
IL-16 2.539 0.086 2.195 0.237 2.143 0.296 0.984 0.982 
Soluble 
receptors 




















Boldfacing indicates P values of less than 0.05 in the unadjusted and adjusted models . 







EGFR 20.96 0.077 1.644 0.670 0.205 0.326 0.301 0.203 
IL-6R 1.399 0.426 0.351 0.035 0.128 0.004 0.117 0.004 
IL-2rα 7.609 0.276 0.065 0.300 1.153 0.754 0.647 0.352 




1.643 0.269 0.228 0.035 0.249 0.099 0.252 0.102 
MMP/TIMP         
TIMP-1 1.508 0.248 0.341 0.039 0.399 0.023 0.335 0.013 
TIMP-2 1.620 0.260 0.282 0.025 0.630 0.257 0.356 0.017 
MMP-1 1.184 0.651 0.801 0.606 0.314 0.001 0.349 0.004 
MMP-9 1.400 0.263 0.681 0.283 0.133 0.001 0.168 0.002 
Growth 
factor  
        
M-CSF 1.647 0.271 0.939 0.921 0.128 0.007 0.149 0.013 
PDGF-AA 1.162 0.650 0.915 0.762 0.412 0.116 0.330 0.047 





Chemokines Unstimulated Lipopolysaccharide ( LPS) 







OR p value  AdjOR Adj p 
value 
CCL1 0.880 0.296 0.807 0.138 0.543 0.116 0.553 0.225 
CCL2 1.852 0.126 1.658 0.251 0.637 0.110 0.694 0.250 
CCL3 0.891 0.763 0.995 0.990 0.508 0.243 0.275 0.046 
CCL4 0.532 0.185 0.588 0.297 0.328 0.084 0.266 0.756 
CCL7 2.579 0.116 1.946 0.290 0.864  0.753 0.821 0.688 
CCL8 0.322 0.111 0.209 0.083 0.685 0.267 0.620 0.205 
CCL20 0.628 0.598 0.469 0.534 0.252 0.009 0.305 0.044 
CCL22 0.448 0.018 0.502 0.059 0.547 0.122 0.550 0.142 
CCL24 1.820 0.225 1.443 0.496 0.648 0.410 0.629 0.414 
CXCL1/2/3 1.118 0.759 1.039 0.920 0.357 0.253 0.296 0.125 
CXCL5 0.484 0.526 0.407 0.241 0.491 0.036 0.516 0.090 
CXCL6 0.082 0.760 0.031 0.856 0.286 0.014 0.239 0.010 
Cytokines         
IL-1α 1.245 0.609 1.318 0.561 0.363 0.251 0.326 0.169 
IL-16 0.506 0.231 0.775 0.669 0.305 0.107 0.324 0.172 
Soluble 
receptors 
        
EGFR 0.762 0.803 0.878 0.914 0.334 0.245 0.194 0.096 
IL-6R 0.755 0.573 0.927 0.885 0.485 0.162 0.422 0.118 
Univariate analysis and multivariate analysis of the association of  unstimulated and LPS 
stimulated chemokines, cytokines, soluble receptors, soluble TIMP/MMP and growth 
receptors with the outcome of wheeze after adjustment for maternal asthma, birth height, 




Boldfacing indicates P values of less than 0.05 in the adjusted and unadjusted models , 
OR, Odds ratio 
 
 
IL-2rα 0.038 0.217 0.016 0.163 0.338 0.125 0.190 0.119 
TNF-αRI 0.680 0.458 0.739 0.588 0.076 0.772 0.051 0.087 
TNF-αRII 0.560 0.366 0.632 0.518 0.506 0.119 0.462 0.098 
MMP/TIMP 
 
        
TIMP-1 0.608 0.318 0.557 0.269 0.690 0.316 0.592 0.198 
TIMP-2 0.762 0.644 0.696 0.555 0.695 0.449 0.558 0.292 
MMP-1 0.799 0.605 0.935 0.890 0.503 0.041 0.531 0.092 





      
M-CSF 
 
0.233 0.049 0.246 0.079 0.759 0.616 0.658 0.491 
PDGF-AA 0.813 0.399 0.845 0.505 0.549 0.257 0.483 0.196 
PDGF-BB 0.997 0.994 0.928 0.845 0.592 0.143 0.562 0.127 
